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1. Summary / Zusammenfassung 
1.1. Summary 
 
Especially for local treatment of lung diseases the respiratory tract is the target for inhalation 
medicines. In the future the lungs could also be entrance for inhalation therapies for systemic 
diseases. 
Besides a tendency in development of active pharmaceutical ingredients (API) to poorly sol-
uble substances, there is also interest in producing controlled released inhalation dosage 
forms. Thus, for quality control or decision support in development in vitro dissolution meas-
urement would become mandatory. Therefore, appropriate dissolution techniques need to be 
established. 
Aim of this thesis was the evaluation of different dissolution techniques and the determination 
of impact factors on the dissolution process. For the experiments different poor and one good 
soluble API as model substances were used. 
It could be shown that the membrane material for dose collection of the fine particles has to 
be chosen carefully. For achieving a mono layer and homogenous particle distribution on the 
membrane different dose collection systems were tested. The most suitable is a modified 
Andersen cascade impactor with a stage extension allowing particle sedimentation. 
Each of the tested dissolution techniques showed individual advantages and disadvantages. 
In summary the modified flow through cell was not appropriate, the µDiss and the modified 
Franz cell showed only a limited usability. As most suitable techniques a modified 
Transwell® system and the paddle apparatus with membrane holder were identified. 
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1.2. Zusammenfassung 
 
Die Lunge dient vor allem bei Erkrankungen der unteren Atemwege als lokaler Applikations-
ort inhalativer Wirkstoffe. In Zukunft kann die Lunge auch als Eintrittspforte für inhaltive Arz-
neiformen mit systemischer Wirkung in den Fokus rücken. 
Schlecht lösliche Arzneistoffe, aber auch Formulierungen mit verzögerter Wirkstofffreiset-
zung werden den Einsatz von in vitro Dissolution Techniken zur Qualitätskontrolle, aber auch 
während der Entwicklung erforderlich machen. Dafür ist jedoch die Etablierung geeigneter 
Techniken erforderlich. 
Ziel dieser Arbeit war die Bewertung verschiedener Dissolutionmethoden und die Untersu-
chung möglicher Einflussfaktoren auf den Auflöseprozess. Mit Hilfe schlechtlöslicher und 
einem gut löslichen Wirkstoff sollten die Techniken untersucht und die Stärken und Schwä-
chen analysiert werden. 
Es konnte gezeigt werden, dass das Membranmaterial, auf dem der Feinanteil abgeschieden 
wird, sorgfältig ausgewählt werden muss. Zum Erreichen einer gleichmäßigen einschichtigen 
Partikelbelegung wurden verschiedene Systeme untersucht. Es wurde ein modifizierter An-
dersen Kaskaden Impaktor mit einer Stageverlängerung, die das Sedimentieren der Partikel 
ermöglicht, als am geeignetsten identifiziert. 
Jede der getesteten Dissolutionmethoden wies Vor- und Nachteile auf. Zusammenfassend 
ist festzuhalten, dass die modifizierte Durchflusszelle ungeeignet ist und µDiss und modifi-
zierte Franz Zelle nur bedingt einsetzbar sind. Das Transwell® System und die Paddleappa-
ratur mit Membranhalter haben sich als sehr gut geeignet erwiesen. 
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2. Introduction 
2.1. Introduction 
 
In the past inhalation medicine has focused on the treatment of lung diseases, like chronic 
obstructive pulmonary disease (COPD) or asthma as the only target [1]. The systemic effect 
of inhalation medicine has been reserved for anaesthetic gases [2] over years. A few years 
ago a paradigm shift to inhalation therapy for systemic diseases has been started [3]. The 
first break through for treatment of a chronic systemic disease due to oral inhalation was the 
inhaled insulin (Exubera®, Pfizer, New York, USA) [2] which was available on the US - mar-
ket from 2006 to 2007 [4]. 
The respiratory tract offers optimum conditions for systemic delivery of medicine due to a 
large surface area with a good epithelial permeability, optimum blood perfusion, low concen-
tration of drug metabolizing enzymes and the avoidance of the first pass effect [2,5,6]. Fur-
thermore, the lung as systemic entry to the human body is useful if the API is not bioavailable 
after e.g. oral dosing or due to rapid onset of action [7]. 
Over the years development of inhaler and powder technology has been advanced and a 
reproducible pulmonary deposition, also in the deeper lungs is possible [4,8]. Consequently, 
in vitro tests for inhaled formulations focused on the aerodynamic size of inhaled particulate 
formulations containing active pharmaceutical ingredient and excipients so far [9,10]. How-
ever, the fate of substance particles after deposition is still unclear [11]. It is evident, that 
small hydrophobic molecules are absorbed very fast and the solute is transported across the 
epithelium with usually good bioavailability [11,12]. But very low water soluble substances 
may have decreased absorption [11] due to delayed dissolution. However, for bioavailability 
of active pharmaceutical ingredients (API), either local or systemic, it is necessary that the 
particles are dissolved in the small volume of aqueous fluid (10 - 20 ml/100 m2) in the res-
piratory tract [13,14]. Furthermore, the development of new pharmaceutical actives tends to 
poorly soluble substances [15]. In addition, the idea of local treatment of lung diseases like 
tuberculosis, pulmonary aspergillosis or cancer with controlled released drugs, requires 
knowledge about the dissolution processes [3,4,16,17]. Therefore, in vitro dissolution testing 
of inhalation powders could be used as meaningful selection tool in inhalation substance de-
velopment and for quality control. Thus, despite other factors, dissolution of particles in the 
lung might be different from those of the bulk material during a dissolution test [11]. Never-
theless, the in vitro dissolution test might help to understand how the substance might dis-
solve following deposition in the respiratory tract [18].  
In all pharmacopeias in vitro dissolution testing of solid and semi-solid dosage forms are 
standardized test methods [19]. It is well established for quality control testing as well as for 
prediction of in vivo drug release [20]. In some special cases even a correlation between in 
vitro dissolution profiles and in vivo pharmacokinetic data [21] and an abbreviated new drug 
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approval is possible [21,22]. Presently, no pharmacopoeia or other regulatory requirements 
for dissolution test method for powder for inhalation exist [20]. An evaluation of in vitro disso-
lution tests for inhalation dosage forms was performed by the Ad Hoc Advisory Panel of the 
USP in 2008. They concluded that there is no evidence that dissolution was “kinetically 
and/or clinically crucial for currently approved” inhalation dosage forms [13]. Nevertheless, in 
recent years there has been an academic as well as an industrial interest in the development 
of a suitable in vitro dissolution test for determining dissolution of powders for inhalation 
[20,23]. 
If local or systemic treatment with low water soluble substances should be also successful in 
the future, it is necessary to know not only about the aerodynamic particle behavior but also 
about their dissolution in vitro as well as in vivo. 
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2.2. Background and Significance 
 
2.2.1. The respiratory tract and the deposition of particles 
2.2.1.1. Anatomy 
The respiratory tract’s main function is exchange of oxygen from the alveolar gas into the 
pulmonary capillary blood and carbon dioxid exchange vice versa [24].  
The respiratory tract could be separated into two main parts, the upper and lower lung. All 
together the lung could be splitted into 23 generations from the trachea to the alveoli. The 
upper part is divided into the head airway region with nose, mouth, pharynx and larynx, and 
the tracheobronchial region from the trachea to the terminal bronchiols. Its main functions are 
warming and humidifying of air, and to retain foreign material to protect the lower lung. The 
lower lung is the pulmonary or alveolar region where the gas exchange takes place. [24-26]. 
The respiratory tract is characterized by a thin epithelium, large surface area (> 100 m2), low 
enzymatic activity, and a rich blood supply [27]. In the respiratory tract numerous cell types 
are existent. The airway epithelium is pseudostratified and mainly contains ciliated cells, gob-
let cells and Clara cells [28]. The alveolar epithelium in contrast shows a different morpholo-
gy. It consists of pneumocyte cells type I and II [26,28]. The type II cells produce lung surfac-
tant. The type I cells create due to their structure the large surface area of the respiratory 
region [26]. The pH of the respiratory tract depends on the health conditions of the human 
lungs and a link between pH and airway function and disease was found. In healthy humans 
the pH of the airway surface liquid is described to be between 6.6 [29] and 7.1 [30]. Humans 
who are suffering on chronic bronchitis or other diseases have an increased average trache-
obronchial pH of 7.7 [29]. 
 
2.2.1.2. Particle deposition 
Fate of particles after inhalation either as medicine or as environmental aerosol depends on 
the particle properties [6,26,31], airway geometry, and inhalation velocity [6,31]. More than 
90% of particles with an aerodynamic diameter larger than 10 µm are deposited in the oro-
pharynx [32]. The critical aerodynamic diameter for reaching the lungs is supposed to be 
< 5 µm [33]. The most important particle deposition mechanisms are impaction, sedimenta-
tion, and diffusion (Figure 2.1). A minor part plays interception and electrostatic deposition 
[25,31,32].  
Crucial for deposition of aerosol particles > 3 µm is the incapability of following the change of 
direction of the airstream at the crotches. Due to their inertia these particles follow a short 
distance their primary direction and impact on the airway walls. Particles contacting the air-
way walls are trapped and could not reenter the airstream [25,31,32]. For lung disease 
treatment the most desirable deposition mechanism is settling due to gravitation in the bron-
Chapter 2.1 Background and Significance 
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chiols and alveols [31]. The relevant diameter for settling is depending on literature between 
0.5 – 4 µm [25,31,32]. For the smallest particles (< 1 µm) diffusion in all room directions 
takes place due to Brownian molecular motion [34]. 
 
 
Figure 2.1: Schematic drawing of the most important particle deposition mechanisms in the lung modi-
fied from [35]. Impaction takes place for particles > 3 µm, sedimentation for particles with a diameter of 
0.5-4 µm, and diffusion for particles < 1 µm. 
 
 
2.2.1.3. Defense mechanisms of the lungs and consequences for substances 
The human respiratory tract is a highly complex organ with the function of filtering the inhaled 
air [7]. Therefore, the lungs have very effective defense mechanisms against aerosol haz-
ards [25] like medicinal particles, polls, and dusts. These clearance mechanisms are interact-
ing with the deposited particles and reducing the time for drug dissolution. The epithelium 
cells in the upper lung are covered with a thick mucus layer (8-15 µm) [11]. This viscoelastic 
layer is on top of the beating cilia [36,37] which transport the mucus and entrapped particles 
with a continuous flow of 3-35 mm/min out of the lungs. Then, the transported mucus and 
particles are swallowed at the larynx [26,37]. In the human respiratory tract 30-65% of epithe-
lium is covered with ciliated cells [6]. The cilia are hair-like appendages with a central ax-
oneme. This cytosceletal structure consists of a bundle of microtubules, which are moved 
due ATP depletion [6]. The resulting beating or movement of the cilia is coordinated and 
rhythmic [38]. Moreover the mucus layer could be divided into an upper gel layer and lower 
few micrometers thick periciliary layer, with a low viscosity [6,26]. The mucus, a complex fluid 
of 3% mucus glycoprotein in 90-95% water [6,26], is continuously secreted by goblet cells 
and subepithelial adenocytes [24,26]. It acts as chemical and physical barrier to particle dif-
fusion [11] and hinders penetration [39]. Furthermore, the mucus distribution over the res-
piratory tract is heterogeneous especially concerning the thickness and surface coverage 
[6,38]. The time frame for particle dissolution before clearing is quite short in the upper lung. 
The maximum clearance time described in literature for the upper lung is around 24 h [40]. 
Only particles which are deposited at the edge of the mucus layer undergo the elimination 
[6]. 
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In the lower or peripheral lung instead of the mucus coverage an ultra thin film of alveolar 
lining fluid covers the cells. After particle deposition and dislocation a so called lung opsoni-
sation takes place: the particles are coated with lipids and surfactant proteins for enticement 
of macrophages [36,40-42]. The macrophage are very flexible in “site of operation” due to 
amoeboid movement [26]. Hence, in the lower lung phagocytosis by macrophages is the 
predominant clearance mechanism [11,26]. The clearance time in the peripheral lungs takes 
place in between days, weeks or even month [40].  
However, in literature are also descriptions of the failure of the lung defense mechanisms. 
For a sufficient amount of inert ultra fine charcoal particles inflammation of interstitium and 
bronchial epithel is described, due to the low water solubility of the charcoal [32]. Further-
more, the shape plays an important role for phagocytoces by macrophages. A very popular 
example are asbestos fibers which could reach the alveoli but due to the long fibers macro-
phages can not phagocytose them [32]. Hence, the fiber stays in the alveoli resulting in 
chronic lung diseases or lung cancer [43]. 
 
2.2.2. What is dissolution? 
There are several possible formulations to define dissolution. In the most simple one „Disso-
lution is the process by which a solid substance enters the solvent phase to yield a solution” 
[44]. More detailed, dissolution is a minimum two step process with heterogeneous interac-
tions between the phases. In the first step molecules from the solid phase are removed and 
form solvated (in the case of water hydrated) molecules at the solvent-solid phase. In a sec-
ond diffusion / convection controlled step, these solvated molecules are transported to the 
bulk solution [44,45]. This mass transfer during the dissolution process is influenced by hy-
drodynamic as well as thermodynamic effects. For poorly soluble substances the mass trans-
fer is mainly controlled by diffusion and / or convection [44]. Several factors influence the 
dissolution process, like the exposed surface and their structure, the wettability of the sub-
stance particles, the temperature, the stirring speed and the surrounding concentration of 
already dissolved substance in the medium [46]. From the more pharmaceutical point of view 
“dissolution is an important factor of drug bioavailabilty” [46]. Therefore, dissolution testing is 
an important tool of quality control for dosage forms, because differences in dissolving prop-
erties could result in large blood level differences [44,46]. 
 
2.2.3. State of the art: Dissolution techniques for powders for inhalation 
Unless now no pharmacopeia in vitro dissolution test for powders for inhalation exists. Never-
theless, in literature dissolution methods for powders for inhalation are described and already 
two reviews are published [1,20] but actually no technique has been adopted [17]. In the fol-
lowing the current state of the art will be described.  
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In 2000, McConville et al. described a modified twin stage impinger for testing their controlled 
release formulations for inhalation. Below stage 1 a 300 ml water reservoir was added. At the 
connection area between the reservoir and stage 1 the glass bottom was removed and a 
brass mesh inserted. On the mesh the deposited particles (6.4 - 10 µm) formed a gel layer 
and dissolution could take place. The dissolved particles diffused through the mesh in the 
acceptor medium. In a closed loop set up the dissolution medium was pumped through the 
reservoir into a spectrophotofluorometer for concentration measurements [18].  
A different approach was from Davies and Feddah, who tested several inhaled corticoster-
oids (ICS) with an adapted flow through cell. With the flow through cell they wanted to differ-
entiate between different formulations and provide information about the rate of release in 
quality control and development. For this purpose, first the substance powder was deag-
glomerated on a fiber glass membrane using an Andersen cascade impactor (ACI). The 
glass fiber membrane was covered with a cellulose acetate membrane filter with a pore size 
of 0.45 µm. The membrane sandwich was then placed into a stainless steel filter holder with 
a small inlet and outlet tubing [19]. In literature this flow through cell set up is also described 
with the use of the next generation impactor (NGI) as dose collection method [47]. 
An approach between Franz cell and flow through cell is the horizontal diffusion cell. Thereby 
a nylon membrane with substance particles on top was clamped between two acrylic sheets. 
In the acceptor compartment a magnetic flea stirred the dissolution medium [48]. 
Further approaches used the paddle apparatus (USP apparatus 2) [3,49] or the USP appa-
ratus 1 (basket apparatus) and weighed the powder directly into the vessel or basket, without 
deagglomeration step [50,51]. In a further test, the powder was filled into gelatin capsules. 
Afterwards the capsule was placed with a sinker on the vessels bottom and dissolution test 
was started [52]. 
Salama et al. compared dissolution of controlled release particles with USP apparatus 2 
(paddle), adapted apparatus 4 (flow through cell), and Franz cell. The substance was directly 
weighed into the vessel or on a nitrocellulose membrane (0.45 µm), without any aerodynamic 
classification. The comparison of the dissolution profiles was performed with similarity and 
difference factor. Further the release kinetics were determined. It was found, that Weibull 
function best describes the release profiles. Regarding the Franz Cell Higuchi release kinetic 
was well fitting, suggesting a wetting and diffusion mechanism [3]. However, the usage of 
Higuchi model beside ointments is critically [53].  
A different approach was described by Son et al.. They use the paddle apparatus and a spe-
cial membrane holder. First the particles were aerodynamically classified on a polycarbonate 
membrane (pore size 0.05 µm and 1 µm) with a NGI. The particles on the membrane were 
covered with a second pre soaked membrane and placed into a modified histology cassette 
[54]. In a second publication the whole set up was more sophisticated. In the NGI a remova-
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ble dissolution cup was inserted. After dose collection the dissolution cup was removed, cov-
ered with a membrane, clamped into a cassette and placed into the paddle apparatus [55]. 
Due to the commercial availability of the NGI dissolution cup and to its apparently simple 
practicality this approach is also used in different other publications [17,56,57]. 
Mees et al. also used the combination of NGI and paddle apparatus for their dissolution test 
of powders for inhalation. In contrast to the study of Son et al., a stainless steel filter was 
placed directly above the nozzles in the NGI [58]. 
The above described techniques used all large amounts of dissolution medium, from 150 ml 
[54] up to 300 ml [17,18,55-57,59] or even 1000 ml [3]. The 1000 ml approach is orientated 
on dissolution tests for solid and semi solid dosage forms [60], 150 ml and 300 ml are cho-
sen more or less randomly, for example Son et al. used a mini dissolution apparatus [54] or 
because it was described in a pioneering publication [59]. 
A quite different approach with a very low amount of dissolution medium was first described 
by Arora et al.. Instead of the “classical” dissolution techniques like paddle apparatus, flow 
through cell, or Franz cell, in their publication the usage of a Transwell® system for determin-
ing dissolution properties of different inhaled corticosteroids was described. The particles 
were collected on polyvinylidene fluoride filters on the impaction plates of the ACI. After dose 
collection the filters were placed face down on the polyester Transwell® membrane [61]. 
More sophisticated approaches are the usage of a stirred acceptor medium [62] and dose 
collection directly on the Transwell® membrane [63,64]. Furthermore, the combination of a 
Transwell® insert with the larger acceptor compartment of the Franz Cell is described [64]. 
Commonly, concentration measurements for determining the dissolution profiles were per-
formed by HPLC analysis of sampled fractions or online UV / Vis detection. By using a mem-
brane the remaining particles were rinsed after the dissolution test for determining the 100% 
amount [20] of applied particles. 
As described above several different membrane materials (e.g. polycarbonate, cellulose ace-
tate) with a pore size from 0.05 µm up to 1 µm were used. The most common pore sizes 
were 0.4 µm and 0.45 µm, respectively [20].  
The used dissolution media vary strongly and are used with or without the addition of surfac-
tants. For overcoming the problem of non sink conditions [57], due to low solubility of sub-
stances and a limited amount of dissolution media, in a couple of publications surfactants 
above the critical micelle concentrations were used. Beside the artificial polysorbate 
(Tween®) 80 [52,55] and sodium dodecyl sulfate (SDS) [57,58,62] also dipalmytoylphospha-
tidylcholine (DPPC) [19,47,55,59] was used. As dissolution medium with low or even no buff-
ering capacity water [18,19] or simulated lung fluid [17,19,47,55,59] were used. A higher 
buffer capacity have phosphate buffers [3,55,56,61] or physiological buffered solution as de-
scribed in the European Pharmacopoeia 7.2 [57]. The pH of dissolution media ranged be-
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tween 6.8 - 7.4 [20] and thus is in the physiological range as described above. The described 
dissolution experiments were performed at 37°C, to mimic human body temperature [20]. 
Mechanistically the techniques are based on dissolution – diffusion processes when a mem-
brane is used or only dissolution in set ups were API formulation or powder is directly placed 
into the dissolution medium.  
In literature most publications in the field of inhalation dissolution required sink conditions, as 
it is claimed for solid and semi – solid dosage forms [1], for the testing of powders for inhala-
tion without further explanation. Sink conditions ensure no “significant modifying effect” of the 
already dissolved substance on the dissolution rate of the remaining API [10]. In literature 
several definitions of sink conditions could be found. For dissolution testing of solid and semi 
– solid dosage forms the United States Pharmacopeia (USP) defines a three fold greater 
amount of dissolution medium as it is required to form a saturated solution of the substance 
[65]. In the European Pharmacopeia sink conditions “normally occur in a volume of dissolu-
tion medium that is at least 3 - 10 times the saturation volume” [10]. In a further definition the 
API concentration in the dissolution medium should not exceed 20% of the saturation solu-
bility [61]. In the strictest definition found in literature the border of API concentration in the 
medium is 10% of saturation solubility [31] for having sink conditions. In the thesis poor solu-
ble but not extreme poorly water soluble substances were used, hence the strictest sink con-
dition limit is useable. 
In conclusion for the development of a suitable dissolution technique for powders for inhala-
tion first the powder has to be classified aerodynamically for example on a membrane. With-
out a deagglomeration step the micronized powder is agglomerated and the particle diameter 
is larger than the inhalable fraction (< 5 µm). The membranes pore size should be small 
enough that substance particles could not leave the membrane without dissolving, but large 
enough that solved molecules could pass the membrane. Additionally, the membrane should 
not hinder diffusion, because dissolution of substance is under investigation. Furthermore, 
the dissolution medium should have a sufficient buffer capacity, temperature should be set to 
37°C and the pH should be in the physiologically range. In addition, amount of substance or 
amount of dissolution medium should be chosen in the way, that sink conditions are provid-
ed. In this thesis the strictest definition of sink conditions (10% of saturation solubility) is uti-
lized. Moreover, the use of surfactants in dissolution medium could be useful. Because sev-
eral different dissolution techniques are described an overall comparison might be meaning-
ful. 
. 
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2.3. Aim of the thesis 
 
The main motivation of this thesis was the fact that there is still no standard dissolution tech-
nique for dissolution testing of powders for inhalation. Whereas other research groups in this 
field focus either on comparison of different dissolution techniques without aerodynamic 
classified powders or uses aerodynamic classified substances but only one dissolution test 
set up, it was decided to combine the two different approaches. To date, no study has been 
performed to investigate this topic for powders for inhalation. Therefore, the major aims of 
this thesis were: 
 
1) To evaluate the most suitable dissolution techniques for powders for inhalation using 
model substances.  
 
2) To identify important impact factors on the dissolution process, for example mem-
brane material, dose collection method and use of surfactants in the dissolution me-
dium. 
 
3) To evaluate a theoretical model to predict dissolution profiles of powders for inhala-
tion and compare the model with experimental data. 
 
4) To compare the used experimental techniques to each other. 
 
 
 
Out of focus were the following aspects: 
 
 To test or use simulated lung fluid, because of its low buffer capacity. For developing 
a new in vitro dissolution technique a higher buffer capacity of dissolution medium is 
much easier to handle. Usage of simulated lung fluid will be the next step. 
 
 To perform an in vitro in vivo correlation. Therefore, a dissolution method needs to be 
established and in vivo data are necessary. 
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3. Material and Methods 
3.1. Substances and surfactants 
3.1.1. Budesonide 
Budesonide is a glucocorticoid steroid which is used in the rhinology or for local treatment 
(inhalative) of asthma [66]. Like cortisol or other cortisol derivates Budesonide is a strong 
antiphlogistic medicine and reduces the inflammatory changes of the mucous membranes. 
Furthermore, Budesonide reduces the mucus production and the corrosion of epithelia cells, 
increases the mucociliar clearance, stabilizes the mast cells and shows an enforced effect of 
beta sympathomimetica, due to an enlarged expression of beta receptors. Due to the small 
absorption of swallowed Budesonide and a large first pass effect, only small systemic ad-
verse effects are possible if Budesonide is used inhalative [67,68]. In the asthma treatment 
guidelines Budesonide among others is the treatment of choice for long term control [69]. 
Budesonide was chosen as model substance because of its low water solubility. The litera-
ture solubility in an aqueous medium is 23 µg/ml [19]. The substance used for experiments in 
the PhD thesis was purchased from Cipla, India and micronized via jet milling. 
 
 
Figure 3.1: Chemical structure of Budesonide [70] 
 
3.1.2. Substances A 
Substances A, current active pharmaceutical ingredients (API) in the research pipeline, were 
obtained from Boehringer Ingelheim (Ingelheim, Germany). Substance A dibromide and crys-
talline base were micronized via jet milling. For producing the amorphous base, the free base 
of Substance A was spray dried. The substances were chosen due to different modifications 
of the same substance with supposed different solubility.  
 
3.1.3. Fenoterol HBr 
Fenoterol Hydrobromide (Fenoterol) is a short acting beta sympathomimetic agent for inhala-
tion. In asthma treatment the bronchodilator is used as quick relief medication [69]. As a re-
sult of the fast onset of action, Fenoterol HBr is inhaled in case of an acute asthma attack. 
Due to stimulation of beta 2 receptor, the concentration of  cAMP in the respiratory muscle 
cells is increased [66], resulting in a decreasing Ca2+ concentration in the airways’ smooth 
musculature and a relaxing of the airways [67,68]. Furthermore, the mucociliary clearance is 
increased because of increased beating frequency of the cilia. 
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Fenoterol HBr has a high aqueous solubility [66] and was chosen as counterpart for the sub-
stances with low solubility and as a positive control. The substance was obtained from Boeh-
ringer Ingelheim and micronized via jet milling. 
 
Figure 3.2: Chemical structure of Fenoterol [70] 
 
Table 3.1: Physicochemical characteristics of substances 
 
 
Budesonide 
Fenoterol 
HBr 
Substance A 
free base dibromide 
chemical  
formula 
C25H34O6 C17H21NO4 HBr - - 
molecular 
weight [g/mol] 
430.53 384.3 683.8 - 
log D 3.2 [71] -0.9 [72] 2.4 - 
soluble in ACN buffer ACN buffer 
 
3.1.4. Alveofact® 
Alveofact® (dry powder ampoule) consists of 50.76 - 60.00 mg of a phospholipid (66 µmol) 
fraction from bovine lungs. The medicine, only available by prescription, is used as preven-
tive medicine at prematurely born children with a high risk of a respiratory distress syndrome. 
Alveofact® was obtained from Boehringer Ingelheim. 
 
3.1.5. Dipalmytoylphosphatidylcholine  
Dipalmytoylphosphatidylcholine (DPPC) is a native phospholipid and with approximate 40% 
the main component of lung surfactant. Furthermore, DPPC is able to reduce the surface 
tension near zero [73]. The substance was purchased from Lipoid (Ludwigshafen, Germany). 
 
 
Figure 3.3: Chemical structure of DPPC [74] 
 
3.1.6. Tween®  
Tween® is the trade name of mixtures of esters from polyoxyethylen sorbitan and higher fatty 
acids (C12 to C18). They belong to the class of non ionogenic o/w emulsifying agents and act 
for example as solubiliser for slightly aqueous soluble or non aqueous soluble substances. 
Chapter 3.1 Substances & Surfactants 
 
18 
For pharmaceutical usage the sum of all ethylenoxide groups is usually 20 [31]. The polyox-
yethylen sorbitan esters are well tolerated, almost non irritant and non toxic [66]. They are 
used in food, cosmetics and pharmaceutical products [75]. In the thesis instead of polysorb-
ate always the trade name Tween® is used. 
 Tween® 20 (Acros Organics, Geel, Belgien) 
esterfied with lauric acid 
 Tween® 80 
esterfied with oleic acid 
 
Figure 3.4: Chemical structure of Tween® 20 [74] and Tween® 80 [76] 
 
3.1.7. Sodium dodecyl sulfate 
Sodium dodecyl sulfate (SDS) is an anionic detergent and a very effective surfactant, which 
is used e.g. in ointments and cremes. It is also used for denaturing proteins and nucleic acids 
(SDS – Page) [66]. 
SDS was obtained from Karl Roth (Karlsruhe, Germany). 
 
Figure 3.5: Chemical structure of SDS [74] 
 
Table 3.2: Physicochemical characteristics of surfactants 
 
 DPPC Tween® 20 Tween® 80 SDS 
chemical  
formula 
C40H80NO8P C58H114O26 C64H124O26 C12H25NaO4S 
CMC [%(w/v)] 3.3 10-7[77] 0.0074[76] 0.0016[76] 0.173-0.230[76] 
molecular 
weight [g/mol] 
734 1228 1310 288 
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3.2. Methods 
3.2.1. High performance liquid chromatography 
The high performance liquid chromatography (HPLC) is a technique for separating a mixture 
of compounds for quantitative and qualitative analysis. HPLC depends on different chemical 
and physicochemical interactions of sample, column material (stationary phase) and mobile 
phase. The following mechanisms are often distinguished: adsorption, partition, ion ex-
change, size exclusion and bioaffinity.  
The signal at the end of the chromatographic process can be detected e.g. by UV Vis spec-
troscopy and depends on the concentration of the substance. The mobile phase, e.g. a mix-
ture of organic and non organic solvents, is pumped either isocratic or with a gradient profile 
through the system. The column material or stationary phase has a high surface area, nor-
mally consisting of silica particles or polymers and due to the separation mechanism defines 
the chromatographic system. One parameter for describing the chromatographic process is 
retention time (signal against time), the maximum of the substance peak on the chromato-
gram [31].  
In this PhD thesis reversed phase (RP) chromatography for quantitative measurement of all 
investigated substances was performed using a LiChrosphor 60 RP select B, 60x4 mm col-
umn, purchased from MZ Analysentechnik (Mainz, Germany). The column temperature was 
set to 40°C.  
RP chromatography column material is nonpolar or chemically modified and the mobile 
phase is aqueous and more or less polar. Consequently, substance molecules, which are 
more polar, have a shorter retention time than less polar molecules. More hydrophobic mole-
cules have a higher affinity to the stationary phase and have therefore a higher retention time 
[31]. 
The measurements were performed using Alliance system (Waters, Eschborn, Germany) 
with UV-VIS detector (operating at 240 nm for Budesonide, 225 nm for Substances A and 
280 nm for Fenoterol). The volume of each sample injected was 10 µl. The mobile phase 
consisted of buffer pH 3 and Acetonitrile (ACN).The flow rate was set to 1.7 ml min-1 for 
Budesonide and Substance A and 1 ml min-1 for Fenoterol. Mobile phase degassing was 
performed either with helium or ultrasonic treatment for 15 minutes.  
The mobile phase mixture was adapted starting from an existing HPLC method with the aim 
to shorten the retention time. Mobile phase composition of 60:40 (buffer/ACN) for 
Budesonide, 65:35 (buffer/ACN) for Substance A and 90:10 (buffer/ACN) for Fenoterol 
showed the best balance between retention time and peak form.  
Furthermore, the limit of quantification (LoQ) of substances was determined. LoQ is the 
smallest amount of substance that can be reliably (suitable precision and accuracy) meas-
ured. Two different approaches based on the ICH guidelines [78] were applied: first calcula-
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tion from the signal to noise ratio (10:1) and second basing on the relative standard deviation 
of 6 injections < 10%.  
For all substances multipoint calibration with external standards was performed. 
 
3.2.2. Solubility measurements 
Solubility is defined as the degree, to which a substance dissolves in a solvent to make a 
homogenous solution [79]. The solubility of one substance is the saturation concentration in 
a defined solvent at a defined temperature and standard air pressure. The maximum soluble 
amount of a substance depends on the chemical properties of solute and solvent. The solu-
bility of substances is influenced by particle properties like size or morphology or outer cir-
cumstances like temperature, surfactants, and pH value [31]. The European Pharmacopeia 
differentiates between various states of solubility. Very soluble are substances, when less 
than 1 ml is needed to solve one gram solute. Very slightly soluble are substances when for 
dissolving 1 g of substance 1000 to 10000 ml solvent is needed. If more than 10000 ml sol-
vent is needed, substance is practically insoluble [10]. In pharmaceutics the biopharmaceuti-
cal classification system (BCS) is well known. The BCS, based on the work of Amidon [80], 
classifies substances depending on their aqueous solubility and intestinal permeability into 
four classes. The four classes are: high solubility / high permeability (Class I), low solubility / 
high permeability (Class II), high solubility / low permeability (Class III), and low solubility / 
low permeability (Class IV). The aim of the BSC is the prediction of in vivo intestinal absorp-
tion due to the measurement of in vitro dissolution, solubility and permeability of oral dosage 
forms in aqueous media [81]. For improving the solubility surfactants above the critical mi-
celle concentration (CMC) can be used [82].  
Before performing solubility tests a suitable filter which does not interact with the dissolved 
substance has to be found. For filter determination a solution of API and dissolution medium 
is filtered through a Spartan 13/0.45 RC (Schleicher and Schüll, Dassel, Germany) and Mil-
lex LCR 0.45 µm membrane filter (Millipore, Molsheim, France), respectively. Of each filtered 
milliliter the content of substance is determined with HPLC. Aim is to reach the initial concen-
tration with smallest amount of filtration steps. For solubility measurement the shake-flask 
method was used [83]. 50 fold amount of the supposed solubility of the substance is added 
to the solubility medium (25 - 50 ml). As solvent phosphate buffered saline (PBS) buffer 
pH 7.4 with or without surfactant was used. The amount of drug is sufficient to obtain a satu-
rated solution in equilibrium with the solid phase. The flasks were stored in an overhead 
shaker in a climate cabinet (Espec climate cabinet, Weilburg, Germany) at 22°C and 50%r.h. 
for 24 h protected from light. After this time period the not solved parts are allowed to sedi-
ment. The supernatant is filtered with the previously determined filter, a Spartan filter. 
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3.2.3. Scanning Electron Microscopy (SEM) 
In this PhD thesis SEM was used for visualizing substance particles and membrane material. 
For imaging of particles, membranes and particle distributions, large magnifications are 
needed. Because the resolution in light microscopy is limited due to proportionality of wave-
length and resolution for these requirements scanning electron microscopy was used. In this 
technique at high vacuum an electron beam is emitted by thermionic emission from a wolf-
ram cathode and accelerated due to a high voltage electric field. The electron beam is fo-
cused by condenser lenses and deflected in x and y axis by deflecting (scan) coils. This nar-
row - few nm thick -, focused beam of primary electrons is scanning the surface of the sam-
ple with a raster pattern.  
 
 
Figure 3.6: Schematic drawing of signals in the scanning electron microscopy, modified from [84,85]. 
Due to interaction between primary electron beam and the sample backscattered electrons, secondary 
electrons and characteristic x rays are detected. 
 
The image in scanning electron microscopy is created due to the interaction between sample 
atoms and electron. Therefore, the detected signals contain information about sample’s 
composition and surface topography. Depending on probe material and penetration, the sig-
nals include among others secondary electrons, backscattered electrons and characteristic 
X-rays. The penetration depth of the electron beam depends on the atomic number and the 
used acceleration voltage; the higher the acceleration voltage or the smaller the atomic num-
ber the deeper the penetration [84,85].  
For non electrically conductive probes additional sample preparation is required. Without 
sample preparation the probe tends to charge resulting in image artifacts. For sample prepa-
ration the samples are coated with an ultrathin coating of gold or platinum by sputtering. 
The Scanning Electron Microscope used in this thesis was a Supra 55 vP (Leo, Gemini, 
Zeiss, Oberkochen, Germany). The used acceleration voltage depends on the probe material 
and issue. Membranes were sputter coated with approximately 5 nm platinum with a Preci-
sion Etching Coating System ((PECS), Model 682, Gatan, München).  
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3.2.4. Dynamic light scattering  
In this thesis dynamic light scattering (Zetasizer Nano Range, Malvern Instruments, Herren-
berg, Germany) was used for determining the micelle size of surfactants in PBS buffer.  
Dynamic light scattering or photon correlation spectroscopy (PCS) is a technique for deter-
mining particle size of small particles in suspension in a range between 3 nm to 3 µm. With 
PCS particle size is not directly measured. Strictly speaking, dynamic light scattering is a 
method for measurement of particle velocity and flow rate above a background emission. 
Dynamic light scattering measures a time dependent fluctuation in the scattering intensity. 
Therefore, a monochromatic and coherent laser beam is focused into the suspension. The 
particles, depending on size, scatter the light in all directions and the signals are detected. In 
the medium small particles are moving faster than large particles resulting in a faster fluctua-
tion in the scattering intensity for the small particles [31,86].  
 
 
Figure 3.7: Schematic drawing of the principal of photon correlation spectroscopy modified from [86].  
A laser beam is focused into the suspension, and the light is, depending on particle size, scattered in 
all directions. During a time interval small particles move faster than larger particles, resulting in a 
faster fluctuation of the scattering intensity. Software calculates form the scattering intensity at differ-
ent time points the diffusion coefficient which then allows calculating particle size using Stokes -
Einstein equation. 
 
From the scattering intensity at different time points, the software calculates a correlation 
function (g(τ)). From the decrease of the slope, software calculates the diffusion coefficient 
and depending on the diffusion coefficient the particle size using Stokes - Einstein equation 
[31,86]. 
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3.2.5. Laser diffraction 
Geometric diameter of micronized drug powder was studied using laser diffraction (HELOS, 
Sympatec GmbH, Clausthal-Zellerfeld, Germany).  
Laser diffraction is used for particle size analysis of particles in solid, semi-solid, liquid or 
aerosolized systems with a wide size range between 0.1 µm to 9 mm. Monochromatic paral-
lel laser light is irradiated in a measurement cell and there scattered by the particles. De-
pendent on particle size but independent of particle position scattered light reaches the cor-
responding detector. Small particles scatter the light in large angles, large particles in small 
angles. For spherical particles a ring structure occurs (Figure 3.8, right) 
Because of several particle sizes in a probe, complex interference patterns are detected and 
a complex algorithm calculates the particle size “backwards” [86]. Assuming that the pattern 
and the intensity of all particles are identical to the sum of the individual patterns of all parti-
cles particle size distribution is calculated [87]. Mathematically the diffraction phenomena 
could be described by Fraunhofer or Mie theory [88]. Mie theory is used if particle size is 
smaller or similar to wavelength. Light is reflected or scattered in large angles. For Mie theory 
optical parameters of particles must be considered. A subgroup or special case of Mie theory 
is Fraunhofer theory. Fraunhofer theory is used if particle size is much bigger than wave-
length. It describes the light scattering resulting from diffraction with small diffraction angles 
[89]. 
   
Figure 3.8: Laser diffraction 
A parallel laser beam is focused into the measurement cell and light is scattered from the particles. 
Through a Fourier lens the light reaches the detector. The light diffraction is independent of particle 
position (left) [88]. One spherical particle shows a typical ring structure, depending on particle size 
(right) [86]. 
 
Particles were dispersed with a dry powder unit (RODOS, Sympatec GmbH, Clausthal-
Zellerfeld, Germany) at a pressure of 3 bar. The powder was placed on a vibration channel 
and transported to the dispersion unit. As focal distance f = 50 µm (effective range: 0.45 - 
87.5 µm) was chosen. Evaluation was performed using high resolution mode (Fraunhofer 
HRLD, Software Vision, WINDOX 5.4.0.0) under the assumption of a spherical model (shape 
factor = 1). For reporting median value (x50) and x10 and x90, respectively were denoted [34]. 
Diameter reported for x50 means that 50% of particles have a smaller diameter than the de-
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clared one [86]. Also interesting is Q (5.0) the percentage volume of particles with a diameter 
less than 5 µm. 
 
3.2.6. Budesonide-Respitose blend and determination of homogeneity 
For local treatment of lung diseases with dry powder inhalers often API lactose mixtures are 
used. For Budesonide the blend is normally 2% API and 98% lactose. Therefore, a mixture of 
Budesonide and Respitose®, a fine milled lactose, was performed using a Resodyn mixer 
with a frequency intensity of 70% for 15 minutes or 20 minutes, respectively. 
For determination the homogeneity of the mixture 5 samples were taken from different places 
in the powder. The samples were each dissolved in PBS buffer pH 7.4 in a 50 ml graduate 
flask. Concentration measurements were performed using HPLC. 
 
3.3. Dose collection methods 
3.3.1. Andersen Cascade Impactor 
The respiratory tract distribution of particles inhaled depends on the aerodynamic particle 
sizes [33]. For classifying powders for inhalation different methods are described in the 
pharmacopeia [9,10]. One of the techniques for determining the in vitro distribution of aero-
dynamic fine particles is the Andersen cascade impactor (ACI). It consists of eight different 
stages (0-7) with decreasing nozzle size by increasing stage number. Between the stages, 
collection or impaction plates are placed. Depending on the decreasing nozzle size the air-
stream is accelerated. Particles, whose aerodynamic diameter is too large, can not follow the 
almost 90° deviation of the airstream and impact on the collection plate [25,33]. 
 
Figure 3.9: Schematic drawing for the impaction mechanism in the Andersen cascade impactor, the air 
stream is from up to down. With increasing stage number, the airstream speed increases and particles 
are impacted on the collection plates, modified from [9].  
On stage 0 a pre-separator, high top and a sample induction port (SIP) are placed.  
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As device for dose collection a HandiHaler® (HH) (2.6, Boehringer Ingelheim, Germany) with 
polyethylene capsules is used. The micronized or spray dried powders are directly manually 
weighed into the capsules (analytical balance (AX205, Mettler Toledo, Gießen, Germany), 
micro balance (XP6U, Mettler Toledo, Gießen, Germany)). The amount of powder depends 
on ACI set up and the substances used. 
The collection plates and the pre-separator are coated with a coating reagent (3% Brij 35, 
14% Ethanol, 83% Glycerol) for ensuring effective impaction of the particles and avoiding 
bounce off effects. The USP requires for aerodynamic size distribution measurements of 
aerosols a 4kPa pressure drop over the inhaler and a duration that ensures “ a withdrawal of 
4l air from the mouthpiece of the inhaler” [9]. Every inhaler has a device depending re-
sistance, hence flow rate has to be adjusted to achieve the requirements. For the HH the 
flow rate needed is 41.6 ± 0.5 l/min. After setting the flow rate an adapter is placed onto the 
SIP, the capsule is pierced and the HH is placed into the adapter. The valve opening time 
(5.77 sec) is calculated from the adjusted flow rate and the required volume of air. Due to the 
airflow the capsule vibrates and rotates along their long axis and the powder is released and 
is following the airstream into the ACI. During this process the powder is deagglomerated. 
For dose collection the filters of choice are either a regenerated cellulose (RC) membrane 
with a pore size of 0.45 µm (Whatman, Dassel, Germany) or a polycarbonate membrane 
(IPC) with a pore size of 0.4 µm (Isopore™, Millipore, Cork, Ireland). Both membranes are 
cut with a cutter to a diameter of 80 mm. The dose collection is performed in air conditioned 
rooms with a temperature of 22°C ± 2°C and a relative humidity of 50% ± 10 %. 
In the following sub sections special cases of dose collection with the ACI are described. 
 
3.3.1.1. Standard 
For determination of the aerodynamic particle size distribution of the different substances 
“standard” ACI with eight stages (0-7) was used. As filter the regenerated cellulose mem-
brane was used. The collection plates and the membrane were rinsed with 10 ml solvent 
(Table 3.1), pre-separator with 50 ml solvent, adapter, high top and SIP together with 100 ml 
and the opened capsule together with the HH with 50 ml.  
 
3.3.1.2. Abbreviated or short stack 
Particles with an aerodynamic particle diameter < 5 µm (fine particle dose (FPD)) are sup-
posed to reach the lungs [33]. Nichols demonstrated that the theoretical cut off points using 
the ACI depend on flow rate [90]. Based on the pharmacopeia method for the assessment of 
fine particles the flow rate is set to 41.6 l/min as described above. At this flow rate the cut off 
diameter (< 5 µm) of inhalable fraction is at stage 1 [90]. Due to the interest in the whole FPD 
for dissolution tests, the stages 2-7 are removed and the whole FPD is collected on the 
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membrane on the filter stage. The fine particle fraction (FPF) in percent is calculated from the 
amount of substance weigh into the capsule and the FPD on the membrane.  
In the following the abbreviated ACI set up is labeled as aACI. 
For flow through cell dissolution testing a special pattern on the filter stage was used, for fur-
ther details see chapter 3.5.2.2. 
 
3.3.1.3. ACI with stage extension 
To favor and allow sedimentation instead of impaction of fine particles on the collecting 
membrane, a stage extension (SE) between collection plate 1 (stage 1) and the filter stage is 
inserted in the aACI set up. The height of the stage extension was calculated depending on 
the volume of the abbreviated ACI. For achieving the same volume as the aACI the cylindri-
cal stage extension has a height of 5.8 cm. For allowing sedimentation of the particles on the 
membrane the vaccum pump airflow profile was adapted in the way that the main aerosol 
reaches approximately the middle of the stage extension (pump time 0.85 s) 
After the pump stop, an optimum waiting time for sedimentation was determined and the best 
result taken (5 minutes).  
 
 
Figure 3.10: Schematic drawing of a) abbreviated ACI with normal filter stage, b) abbreviated ACI with 
stage extension and c) normal filter stage or d) modified filter stage, respectively. 
 
Aim was a complete sedimentation of particles in the stage extension on the membrane. Be-
sides the normal ACI filter stage a modified filter stage (Figure 3.10 d) was used. The modi-
fied filter stage consists of three small bars and thus changes the flow and deposition pat-
tern. The set up with the modified filter stage is only possible using the regenerated cellulose. 
Due to the very thin and instable consistency of the Isopore™ polycarbonate membrane the 
modified filter stage is not suitable, hence the standard filter stage was used. In the following 
the set up with aACI, stage extension and modified filter stage is labeled mACI, the set up 
with aACI, stage extension and normal filter stage: aACI + SE. 
a b 
c 
d 
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3.3.1.4. ACI for Transwell®s 
Three Transwell® inserts are placed onto the normal filter stage inside the stage extension. 
For avoiding drug deposition into the vacuum pump the three inserts are placed into the 
voids of a pattern. For avoiding drug sedimentation on the inner and outer wall of the insert a 
Polyetherketone (PEEK) cover is placed as cover over the Transwell® insert. This cover is 
very thin and does not hinder sedimentation of particles on the Transwell® insert membrane. 
After dose collection the PEEK cover is removed. The PEEK cover is necessary because 
without the cover the particles deposited on the inner and outer wall and are also rinsed after 
the dissolution tests, resulting in an overestimation of the amount of substance deposited on 
the membrane. The pump regime and waiting time are the same as described above for 
mACI (chapter 3.3.1.3). 
 
Figure 3.11: Transwell® insert with the removable PEEK cover to restrict drug deposition to the mem-
brane. 
 
3.3.2. Airbrush 
A different dose collection approach is the airbrush method. Therefore, 10 mg micronized 
powder of the respective substances is dispersed into 25 ml antisolvent dichloromethane. 
The membrane is stretched onto a collection plate and the whole experiment is performed 
into a fume hood. Afterwards 5 ml antisolvent - substance suspension is sprayed with an 
airbrush onto the membrane. Finally the membrane is shortly dried. 
 
 
Figure 3.12: Schematic drawing of the airbrush dose collection method. 
The suspension is sprayed with the airbrush onto a membrane which is fixated onto an ACI dose col-
lection plate. 
 
3.3.3. Aerosol generator 
Another dose collection method is the aerosol generator, a current Boehringer Ingelheim 
development. Aim is a higher deagglomeration of the particles than by the use of the HH. 
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The substance powder is filled into a cavity and aerosolized into an aerosolisation chamber 
with compressed air. From there the fine dispersed powder is sucked into the mACI for dose 
collection as described in 3.3.1.3. 
 
3.3.4. Important pretests -Fine particle dose on membrane 
Important for comparison of dissolution tests is a similar mass of particles on the membrane. 
Therefore, before starting dissolution tests, the optimum capsule sample fill weight has to be 
determined for every substance and dose collection method (3.3.1.2, 3.3.1.3 and 3.3.1.4).  
In addition, for the stage extension method (3.3.1.3) the optimum waiting time was deter-
mined. Therefore, the same amount of Budesonide was weighed into the capsule and wait-
ing time was varied.  
Additionally, for the flow through cell the impact of the position of the membrane in the dose 
collection pattern during dose collection was determined (3.3.1.2) 
After dose collection the membranes were rinsed in a defined amount of solvent (Table 3.1) 
and concentration was measured with HPLC analysis. 
 
3.4. Membrane classification 
In Table 3.3 the membranes used in this PhD thesis are summarized. 
 
Table 3.3: Membrane material 
 
membrane pore size  
[µm] 
pores / area 
[pores / cm2] 
manufacturer techniques mem-
branes used 
regenerated 
cellulose (RC) 
0.45 - Whatmann,  
Dassel Germany 
Flow through cell 
Franz cell 
Paddle apparatus 
Transwell® 
Isopore™ 
polycarbonate 
(IPC) 
0.4 1.5 x 108 Millipore,  
Cork, Ireland 
Franz cell 
Paddle apparatus 
Transwell® 
polycarbonate 
(PC) 
0.4 1 x 108 Corning Costar,  
Corning, USA 
Transwell® 
polyester 
(PE) 
0.4 4 x 106 Corning Costar,  
Corning, USA 
Transwell® 
     
 
3.4.1. Contact angle measurement 
Wetting, a phenomenon especially at the three phase boundary layer between solid, liquid, 
and vapor phase [91] is the possibility of substances to spread over the surface of the solid 
surface. The wetting and spreading phenomena are based on the cohesive and adhesive 
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forces. If the cohesive forces of the liquid are smaller than the adhesive forces between liquid 
and solid the contact angles is 0° and the surface is fully wettable by the liquid [92]. In partic-
ular, for dissolving of pharmaceutical active ingredients wetting of the particles is important 
[31]. The easiest way of measuring the wettability of surfaces is measurement of the contact 
angle Θ of a droplet on a solid surface. Depending on interaction between the liquid and the 
solid phase, different droplet forms occur. If the contact angle is 0° the surface is fully wetta-
ble with the liquid, for a contact angle smaller than 90° the wettability is good, in the case of 
water as liquid this means the solid is hydrophilic. For contact angles larger than 90° the solid 
has a poor wettability; in the case of water, the solid is hydrophobic. Is the solid not wettable 
the contact angle is 180° [91]. Theoretically, contact angle measurement has to be per-
formed on homogenous surfaces [93]. In practical contact angle measurement problems 
such as microscopic roughness, chemical heterogeneity and contamination of the surface 
[92,94], heterogeneous drop size, molecular orientation and deformation of the surface and 
liquid molecular transport [92] take place. All these effects lead to contact angle hysteresis 
which is the difference between the advancing and the retreating / receding contact angle 
[92,93,95]. Therefore, measurement of a static sessile drop for contact angle measurement 
is defective, with an accuracy of no better than ± 2° [95]. 
In Young’s equation (Equation 3.1) [96] the equilibrium of the tangential forces of the inter-
faces of the three phases in the interception point is shown [91,95]. Where γS/L is the surface 
tension between liquid and solid, σL/G is the liquid vapor interfacial energy, σS/G is the solid 
vapor interfacial energy and Θ the contact angle. 
 
                  
Equation 3.1: Young equation [96] 
 
 
Figure 3.13: Schematic of liquid drop showing the quantities in Young’s equation, where G is the vapor 
phase, L the liquid phase and S the solid phase, modified from [31]. 
 
For determination of the membranes’ surface polarity contact angle measurement was used. 
The measurement was performed with water with / without 0.02% DPPC in the advancing 
sessile drop method at a Drop Shape Analysis (System DSA 10 MK 2, Krüss, Germany). 
Therefore, a drop of 8 µl volume with a flow rate of 16 µl/min was observed. During droplet 
advancing software calculated every second for 15 seconds the advancing contact angle. 
Chapter 3.4 Membrane classification 
 
30 
The illuminated droplet is live pictured to the software by a camera vertically arranged to the 
sample table. For each membrane material 5 drops were performed. 
 
 
Figure 3.14: Schematic drawing of a contact angle measurement apparatus. With a syringe a droplet 
is placed on the sample. The sample area is illuminated. Live images are taken by a camera connect-
ed to software. 
 
For the poorly soluble substances used in the thesis contact angle measurement was per-
formed, too. Therefore, with a KBr press 20 mg of substance were pressed with a pressure 
of 3*104 N to a small pellet. On this pellet advancing contact angle measurement with water 
with / without 0.02% DPPC was performed as described above for the membranes. 
 
3.4.2. Membrane permeation test 
For characterizing the permeability of the membranes for the test substances diluted in PBS 
buffer a membrane permeation test was performed. Low diffusibility of a substance dissolved 
in a buffer solution might influence the dissolution tests results. The tests were performed in 
a small glass Franz cell filled with 7.25 ml PBS buffer. Above the lower cylinder a second 
smaller one is placed. Between the two cylinders the membrane is clamped. The two cylin-
ders are compressed with an external spring. Onto the membrane (permeation area approx-
imately 0.785 mm2) 100 µl of substance-buffer solution with a concentration 10 µg/ml is 
placed. Stirring speed for maintaining a homogeneous mixture is set to 140 rpm. The meas-
urements were done in a climate cabinet (Espec climate cabinet, Weilburg, Germany) at 
37°C and 100% r.h.. For sampling 200 µl of analyte containing solution is manually removed 
with a syringe (100 Sterican® (Braun, Melsungen, Germany) and 1 ml disposable syringe 
(Wicom, Heppenheim, Germany)) through the small side arm and filled into HPLC vials with 
micro inserts according to a defined time schedule (waiting times: 5, 10, 3 x 15, 3 x 60 
minutes). The removed 200 µl are refilled with fresh pre warmed PBS buffer. At the end of 
the diffusion test, the membrane is rinsed with 25 ml of solvent (Table 3.1). The concentra-
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tion of substance was determined by HPLC analysis. Each experiment was performed in 
triplicate.  
 
 
Figure 3.15: Schematic drawing of the Franz cell used for membrane permeation test. 
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3.5. Dissolution techniques 
 
3.5.1. µDiss Profiler™ 
Fiber optic based systems for in situ dissolution concentration monitoring of tablets, for intrin-
sic dissolution rate determination or solubility measurement are well-described in literature 
[81,97-103]. The in situ measurement has several advantages i) real time measurement [98] 
ii) smaller time intervals of data sampling points resulting in a more detailed dissolution pro-
file and hence the possibility of a higher discrimination ability [98,102], iii) a simplification of 
dissolution analysis as HPLC analysis is not necessary and the sample solute is directly ana-
lyzed by UV absorption spectroscopy [99,100,102] and iv) increased precision as improper 
sampling or sampling timing errors can be avoided [100-102]. Besides those advantages, 
several issues especially concerning the excipients and the strict dissolution testing regulato-
ry in the pharmacopeia, especially concerning to the used apparatus, are described in litera-
ture [100,102,103]. One special case of fiber optic dissolution measurements are those with 
a small volume of dissolution medium. These dissolution tests are also useful in early stage 
of development, when only small amounts of API are available,  
Currently, fiber optic systems for dissolution tests for aerodynamic classified powders for 
inhalation are not described in literature. 
In this PhD thesis a small volume dissolution tester (µDiss Profiler™, pION, Billerica, MA, 
USA) with a maximum volume of 20 ml dissolution medium was used. Important difference to 
the other in this thesis investigated dissolution techniques is the online in situ UV detection of 
API. 
The µDiss (Figure 3.16) consists of several parts, which can be divided in three main com-
ponents: diode array UV-spectrometer, fiber optics and probe vessels.  
The vessels are placed in a water bath heated metal block, with a small magnetic stirrer un-
der each vessel. The fiber optics (Figure 3.17) are directly placed into the medium with API. 
For the simultaneous online measurement of six different samples UV light is transferred 
through fiber optics directly into the probe. At the end of each fiber optic a capping piece 
consisting of a lens, a gap (which determines the path length) and a mirror are positioned. In 
the lens the light is focused and sent through the liquid, reflected at the mirror again transit-
ing the probe. In the lens transmitted light is focused and transferred to the diode array spec-
trometer [100]. For the µDiss profiler between different gap sizes could be selected, the more 
cloudy the suspension the smaller the path length should be. For low concentrations a larger 
path length should be used. In the following experiments no excipients were present so a 
gap with 5 mm was chosen  
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Figure 3.16: Schematic drawing of µDiss profiler™ [104]  
Software controlled and according to a defined time schedule a diode array UV spectrometer emitted 
UV light via an optrode into a sample. The sample with stir bar is placed into a water bath heated met-
al block, for temperature control. The sample solution flows through a gap. Due to sample concentra-
tion a reduced amount of light is reflected at the mirror at the end of the gap, and transmitted light is 
measured with UV diode array spectrometer. Simultaneously measurement of six different samples is 
possible 
 
 
Figure 3.17: Schematic drawing of a fiber optic probe, modified from [100] 
The light from the spectrophotometer is focused due to a lens into the gap, where sample solution 
flows through. At the end of the gap at a mirror the light is reflected, again transiting the probe, fo-
cused in the lens and than the transmitted light is transferred to the detector. 
 
The diode array spectrometer measures the concentration of drug substance as a function of 
time for each channel recording the whole spectrum with each measurement. According to a 
defined time schedule (Table 3.4) the shutter is opened and UV light could reach the sample 
for measurement. Before the measurement, a calibration has to be recorded allowing deter-
mination of the concentration of the used substance according to Lambert-Beer’s law. First 
100% transmission and “dark spectra” of media are measured for baseline determination, 
followed by the measurement of the calibration curve with suitable concentrations of API in 
suitable media. Before the samples are measured 100% transmission, and dark spectra of 
the dissolution medium have to be measured again. In contrast to 100 % transmission, the 
“dark spectrum” is an internal calibration with closed shutter – no light should reach the diode 
array spectrometer. According to the calibration curve, blanks have to be created, where the 
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calibration curve could be inserted due to different media for calibration and dissolution tests, 
followed by the dissolution measurement. 
 
3.5.1.1. Dose collection and dissolution method 
The collection of aerosol particles less than 6.4 µm was performed using the twin stage im-
pinger instead of the ACI. As described in the European Pharmacopoeia 7.0 7 ml and 30 ml 
[10] of PBS buffer were introduced in the upper and lower impingement chambers. The air-
flow through the apparatus was adjusted to 60 l/min [10]. For detailed schematic see Figure 
3.18. Micronized powder was weighed into polyethylene capsules and dispersed using the 
HH. The suspension with particles less than 6.4 µm was aliquoted (3 ml) and transferred 
immediately into the vessels of the µDiss. Stir bar speed was set to 700 rpm. For analysis of 
the µDiss spectra the exact content of API in the sample has to be known. Consequently, 
one extra aliquot was diluted with solvent to 50.0 ml and concentration determined using 
HPLC.  
 
 
Figure 3.18: Modified schematic of twin stage impinger, modified from [10] 
The twin stage impinge consists of two stages. In the upper chamber (1. stage) 7 ml medium is placed 
in the large chamber (2.stage) 30 ml is placed. Due to an air stream from up to down, particles are 
placed inside the medium.  
 
Table 3.4: Time schedule for µDiss online UV measurement 
 
number of measured spectra 1 40 30 30 15 
interval between measurements [s] 5 15 30 120 120 
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3.5.2. Flow through cell 
The history of flow through cell dissolution testing started in the late fifties (1957); in 1995 it 
was implemented as apparatus 4 in the USP [60,105] and in 2007 in the Ph.Eur. [10,46]. For 
oral solid dosage forms the pharmacopoeias describe two cells with a diameter of 12 mm 
and 22.6 mm, respectively [10,60]. For further dosage forms like suppositories, powders, 
implants and drug eluting stents different cell types are available [60]. For the standard flow 
through cell the pharmacopoeias usually claim the usage of glass beads in the bottom cone 
for avoiding drug material flowing into the inlet tubing [10,60].  
The dissolution medium is pumped through the cell, from bottom to top, either in an open or 
closed set up [106]. In the closed set up a smaller, but well defined, amount of dissolution 
medium is required and is continuously pumped through the cell. This set up for example is 
used to overcome LoQ of the API [106], due to concentration of dissolved substance. Fur-
thermore, in the closed as well as in the open set up an online UV detection is possible with-
out sampling [82]. The open set up offers advantage of infinite amount of dissolution medi-
um, which is suitable for substances with low solubility [10,82,105-108] and provides sink 
conditions [82,105,106,108]. Sink conditions should imitate the physiological conditions, 
where the dissolved drug is absorbed and the locate drug concentration is low [31]. Further 
advantages are continuous sampling [82], a flow rate change [108] and possible easy disso-
lution medium change during the run [82,108]. Beside the advantages there are also some 
influencing parameters, which should be controlled, e.g. the size of the glass beads, the 
temperature in the cell, the flow rate and the level of deaeration [82,109]. 
The usage of flow through cell for powders is suitable due to the limit of volume and the re-
duced spreading of drug particles to undefined sites of the apparatus [110] compared for 
example to the paddle apparatus. Bhattachar et al. tested several mixing and layer set ups 
for powder and glass beads to achieve maximum dissolution and reproducibility. The best 
results could be shown for a homogenous mixture of powder and beads. But for micronized 
powders, especially for those with a poor solubility and wettability, the substances are floated 
and adsorbed at the filter, resulting in incomplete dissolution [105,110].  
In this PhD thesis not only poor soluble micronized powders were used. The focus lies on the 
fine particle dose, so the classical flow through cell set up as described above, has to be 
adapted. Davies et al. used an custom made flow through cell were a membrane with FPD 
could be used in [19]. In this set up the dissolution medium enters the cell and thus the 
membrane on one place only without further distribution. Consequently, it is questionable if 
the membrane is wetted completely, or if the dissolution medium goes straight through. 
Boehringer Ingelheim developed a new flow through cell (build by Zentrale Mechaniker 
Werkstatt, Boehringer Ingelheim, Ingelheim, Germany) (Figure 3.19) [104], which was used 
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in this PhD thesis. This new cell should ensure a homogenous wetting of the whole mem-
brane simultaneously. 
This cell consists of several parts. The two outer holders are connected either to the HPLC 
pump (AXP, Dionex, Idstein, Germany) or to the sampling unit. The pump provides a con-
stant flow rate and reduces the in literature described difficulty of adjusting the flow rate [82]. 
Between the holders on the upper and the bottom side two parts remembering on quench 
heads (Figure 3.20) are placed. The two quench heads are the important improvement com-
pared to the flow through cell of Davies and Feddah [19]. Between the two “quench heads” 
on the bottom side a metal sieve, the membrane with powder and a covering membrane are 
clamped. As membrane material regenerated cellulose (RC) with a diameter of 24 mm was 
used exclusively. The whole cell is closed and bolted together avoiding leakage. The upper 
“quench head” ensures a uniform dissolution medium distribution on and wetting of the 
membrane. Without the fluid distribution, the dissolution medium jet goes straight through the 
membrane resulting in an uneven wetting. The metal sieve avoids rupturing and sliding of the 
membrane into the lower “quench head”, which concentrates the medium with analyt to one 
fluid jet. The pump pumps the dissolution medium with a constant flow rate of 1 ml/min 
through the apparatus in an open method set up. As dissolution medium PBS buffer pH 7.4 
was used. The probe sampling procedure depends on method set up. It was either per-
formed as “all in one” sampling over a defined time period or according to on a defined time 
schedule (sampling type “all” or “partial”) automated by a Gilson sample injector (Gilson, 
Middleton, United Kingdom) into HPLC vials.  
The whole flow through cell with pump and sampling unit is placed into a climate chamber 
and the temperature is set to 37°C. The climate cabinet allows to control the temperature, 
which is often seen as problem [82]. 
At the end of each experiment the membrane and the remaining cell parts together are 
rinsed each with 50 ml of solvent (Table 3.1). Concentration measurement is performed with 
HPLC. 
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Figure 3.19: Schematic drawing of the flow through cell [104] 
A HPLC pump pumps the dissolution medium through the flow through cell. The powder is entrapped 
between two membranes. On the sampling side an additional metal sieve is inserted. With a “quench 
head” the dissolution medium is uniformly distributed on the membrane, after passing membrane and 
metal sieve, the dissolution medium with substances is recollected with a second “quench head” and 
according to set up sampled. 
 
 
 
Figure 3.20: Schematic drawing of one “quench head” 
The “quench heads” ensure uniform dissolution medium distribution on the membrane. 
 
3.5.2.1. Diffusion pre-tests 
The pre-tests were performed with Budesonide in triplicate. 
For measuring the diffusion capability through the flow through cell, the following set up was 
used. Therefore, 0.5 mg of Budesonide is solved in PBS buffer in a 250 ml graduated flask. 
The substance – buffer - solution is directly pumped through the assembled cell with the two 
membranes and is collected in a 50 ml graduated flask. For determining the influence of 
pump and tube (background noise) between each probe, 5 ml substance – buffer - solution is 
directly collected behind the pump without use of the cell. As described above the cell is 
rinsed after each experiment.  
hole 
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For determining the validity of the flow through cell each 100 µg of Budesonide are directly 
weighed onto the membrane and two different sampling methods (sampling type “all” or “all 
in one”) are preformed. 
 
3.5.2.2. Dose collection and dissolution testing 
As dose collection method aACI (Chapter 3.3.1.2) with a special PEEK pattern (diameter 
80 mm) with four voids inserted on the filter stage was used (Figure 3.21). Use of the pattern 
was required due to the small flow through cell size and therefore small membrane size 
(ø 24 mm) and for avoiding substance load into the vacuum pump. The use of an additional 
larger filter beneath the small membrane instead of the pattern is not possible because of an 
influence on the air flow in the aACI. Into the pattern voids simultaneously four membranes 
are allocated. Three of the membranes are used for dissolution experiments with the flow 
through cell, the fourth is used as reference membrane and rinsed with 50 ml of solvent 
(Table 3.1). 
 
 
Figure 3.21: Schematic drawing of pattern with membranes for dose collection  
 
 After dose collection the influence of the sampling was determined for Budesonide. Sam-
pling until “4 minutes” in the first two minutes every 0.25 minutes and from 2 to 4 minutes 
every 0.5 minutes was performed. After sample “4 minutes” on the one side every minute 
one milliliter was collected (label: “all”), on the other side to defined time points one millili-
ter was collected and the rest was abolished (label: “partial”).  
 In addition, for Budesonide different flow rates (0.5 ml/min, 1 ml/min and 5 ml/min) in the 
“all” sample set up were tested  
 Furthermore, with a flow rate of 1 ml/min and the sampling type “partial” for the different 
modifications of Substance A and Fenoterol HBr the influence of different fine particle 
doses on membrane was determined. Furthermore, the aim was to compare a FPD of 
20 µg, 60 µg and 100 µg, respectively. 
 
Table 3.5: Time schedule for sampling 
 
interval [min]  0.25 0.5 1 5 15 
samples 
partial 
8 4 
1 5 2 
all 57 - - 
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With the “partial” sample type data treatment is more complex, because discarded amount 
has to be calculated. The data treatment is described on the example of sample 15, the time 
interval between sample 14 and sample 15 is 5 minutes. As often used in flow through cell 
set ups the mass is accumulated. 
Therefore, the accumulated mass of sample 15 is the sum of the mass of the concentration 
of sample 14 calculated of 5 ml, the mass of the mean of concentration of sample 14 and 15 
calculated of 5 ml and the accumulated mass of sample 14. 
 
Macc15
  
= c14 [µg/ml] * 5 [ml] + Mean (c14, c15 [µg/ml]) * 5 [ml] + Macc14 [µg ] 
 
Equation 3.2: Calculation of accumulated amount of dissolved substance 
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3.5.3. Franz Cell 
The Franz diffusion cell is named after its first descriptor T.J. Franz, who described in 1975 
the use of a diffusion cell for absorption studies of organic compounds in human skin [111]. 
Although the Franz diffusion cell is still not a pharmacopeia method, the FDA recommends 
the use of a diffusion cell for in vitro release testing of topical dosage forms in the SUPAC –
SS guideline [112]. Up to now, the Franz Cell has become the “gold standard” for transder-
mal drug delivery studies [113-115]. In the classic set up real skin, or a synthetic or artificial 
membrane [114], is clamped between an acceptor chamber and a glass top. The dissolution 
medium in the acceptor chamber can be heated, due to temperature jacket. The sampling 
over a side arm or sampling port is performed with a syringe [111]. One major problem de-
scribed in literature are air bubbles at the membrane liquid interface and the difficulty or even 
failure of removing them [114,116]. Due to air bubbles the precision of data can be lower and 
outliers are possible. Hence, the problem of air bubbles is also taken into account in the 
SUPAC - SS guideline [112].  
In dissolution testing for inhalation powders the Franz diffusion cell, as described above, is 
used by the working group of Paul Young [3,64,117,118]. More details are already described 
in chapter 2.2.3. 
For the dissolution studies in this PhD thesis Franz diffusion cell was chosen to mimic the air 
liquid interface of the lung. The traditional set up [111] as used for example for the mem-
brane permeation test (3.4.2) and the manual modified Franz cell described in the 
NanoInhale project [119] was modified by Boehringer Ingelheim (built by Zentrale Elektronik 
Werkstatt and Glasbläserei, Boehringer Ingelheim, Ingelheim). The dissolution medium res-
ervoir is enlarged from a few milliliters in the traditional set up to 1 l to allow sink conditions 
for poorly soluble substances. The dissolution medium (PBS buffer pH 7.4) temperature is 
set to 37°C and stirred with a magnetic stir bar at 100 rpm to maintain a homogenous solu-
tion. A higher stirring speed is due to the formation of a vortex not recommended, because 
the vortex hinders homogenous wetting of the membrane. For temperature control during 
dissolution testing a thermometer is placed inside the acceptor chamber.  
After dose collection the membrane is placed into the membrane holder with particles faced 
up and clamped. During the dissolution test the holder is heated from above to avoid con-
densation and thus droplets. The condensed droplets can fall on the membrane and influ-
ence the dissolution process. For the used modified Franz Cell the sampling procedure is 
automated with a Gilson Liquid Handler 215 (Gilson, Middleton, United Kingdom). According 
to a defined time schedule (Table 3.8) a needle immerges through a septum into the accep-
tor chamber and samples 1 ml which is transferred into an HPLC vial. 
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Table 3.6: Time schedule for sampling 
 
interval [min] 3 5 15 60 
samples 21 11 10 18 
interval [min] 
for Fenoterol 
1.5 5 15 60 
 
After sampling the needle is cleaned automatically and the removed solvent is refilled with 
fresh pre-warmed PBS buffer (37°C) to maintain a constant dissolution medium volume. After 
stopping the dissolution test, the membrane is removed and rinsed with 50 ml solvent for 
dissolving the remaining particles (Table 3.1). Concentration measurement is performed with 
HPLC. All tests were performed in triplicate. 
 
 
Figure 3.22: Schematic drawing of modified Franz Cell adapted from [104] 
Franz cell with fine particles collected on a membrane. According to a defined time schedule sampling 
of one ml is automated with a Gilson robot. The sampled milliliter is refilled with fresh pre warmed PBS 
buffer. Typically for the Franz Cell is an air liquid interface.  
 
3.5.3.1. Diffusion test 
In addition to the general membrane permeation test, described in chapter 3.4.2 with the tra-
ditional Franz cell for the modified Franz cell set up a diffusion test was performed. This test 
allows a direct comparison between diffused and dissolved (dissolution + diffusion) amount 
of substance whereas the general test provides information if a membrane is suitable or not. 
The diffusion tests in the modified Franz Cell were performed with the regenerated cellulose 
and the Isopore™ polycarbonate membrane. Therefore, 10 ml of substance - buffer solution 
with a concentration between 10 µg/ml to 21 mg/ml and 40 mg/ml for Fenoterol, respectively 
were placed onto the membrane. Sampling was performed as described above. 
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3.5.3.2. Dose collection and dissolution testing 
As dose collection method aACI with an additional “delrin” ring on the membrane (outer di-
ameter: 80 mm, inner diameter 60 mm) was used (Figure 3.23). The ring is needed for guar-
anteeing a substance free outer area, where the membrane is clamped onto the membrane 
holder. For dose collection substances were weighed into polyethylene capsules (Table 3.7). 
The particles were collected either on a regenerated cellulose membrane (RC) or an Iso-
pore™ polycarbonate (IPC) membrane.  
 
 
Figure 3.23: Schematic drawing of filter stage (ACI) with membrane and delrin ring for Franz Cell 
 
 
Table 3.7: Substances-weights into polyethylene capsule for dose collection 
 
substance weight [mg] 
Budesonide 
1 
10 
Fenoterol 
1 
10 
Substance A amorphous base 1 
Substance A crystalline base 1 
Substance A bromide 1 
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3.5.4. Transwell® Dissolution System 
The Transwell® permeable supports are a commonly used device for cell culture issues. In 
2010 the static Transwell® system was introduced as new approach for dissolution testing of 
powders for inhalation [61]. In a more sophisticated approach the acceptor medium was 
stirred [62]. 
The modified Transwell® (Corning Costar, Corning, USA) as well as the Franz Cell [111] has 
an air liquid interface at the membrane but with the small amount of dissolution medium it 
mimics more the limited capacity of lung fluid in vivo [61,63].  
In this PhD thesis the release profiles of aerodynamically classified particles of Substance A 
in its different forms and Budesonide were investigated using an adapted Transwell®. For 
the commercially available Transwell® with 6 wells (insert membrane diameter 24 mm) a 
spacer plate (2 mm) was constructed, leaving the inserts open lifting the inserts and hence, 
adding space to use stir bars in the receptor chamber. Stirring speed was set to 140 rpm. For 
sampling small holes for each well were drilled into the lid.  
 
Figure 3.24: Schematic drawing of Transwell® dissolution apparatus. 
 
The Transwells® are available with polyester (PE), polycarbonate (PC) or collagen coated 
polytetrafluoroethylene membranes with different pore sizes. For dissolution testing so far 
polyester membranes were used [61]. As for the other dissolution techniques regenerated 
cellulose (RC) and Isopore™ polycarbonate (IPC) membranes were used, hence these 
membranes were also tested. Furthermore, the membrane permeation test showed a sub-
stance retraining effect for the PE membrane (chapter 4.1.4) and in literature for the 
Transwell® polycarbonate also a delayed diffusion was described [62].  
For using RC and IPC membrane a commercially available Transwell® insert was modified. 
The membrane was cut out, and a small thermoformed plastic edge was created. On this 
edge a small metal sieve was placed as support for the membranes. The modified inserts 
were reusable in contrast to the standard Transwell® insert.  
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Dissolution tests were performed at 37°C and 100% r.H. in a climate cabinet (Espec climate 
cabinet, Weilburg, Germany) using degassed PBS buffer pH 7.4 as dissolution medium. The 
use of a climate cabinet was necessary for avoiding evaporation of the small amount of dis-
solution medium. The membranes with particles facing up were touching the dissolution me-
dium, ensuring an air liquid interface with no hydrostatic pressure on the system (Figure 
3.24). Therefore, for the commercially available inserts 2.6 ml and for the adapted inserts 
3.85 ml dissolution medium was placed into the acceptor compartment. According to a de-
fined time schedule (Table 3.8) probe sampling was manually done with a syringe (needle: 
100 Sterican® (Braun, Melsungen, Germany) and 1 ml disposable syringe (Wicom, Heppen-
heim, Germany)). The solvent removed during sampling (0.2 ml) was refilled with fresh pre-
warmed PBS buffer (37°C) to maintain a constant dissolution medium volume. At the end of 
the experiment each insert was rinsed with 25 ml of solvent according to the used substance 
(Table 3.1) to determine the total recovery.  
All experiments (Table 3.9) were done in triplicate and concentrations were determined with 
HPLC. The total amount of drug initially loaded on the membranes was measured using the 
maximum of the cumulatively released amounts plus the remaining quantity of particles on 
the membrane (determined at the end of each experiment). The amount of drug released 
was calculated with Equation 3.3. Percentages of drug released were calculated by dividing 
the amount of drug released by the drug mass which was loaded on the membrane after 
aerosolization and separation with the ACI.  
 
Table 3.8: time schedule for sampling 
 
interval [min] 5 10 15 60 
samples 1 1 3 3 
 
 
mt=I = ct=I * Vdissolutionmedium – (ct=i-1*(VDissolutionmedium - Vsampling)) + mt=i-1 
 
Equation 3.3: Calculation of amount of released substance m: amount of drug released, V: volume, c: 
concentration 
 
3.5.4.1. Dose collection 
Dose collection basics are already described in Chapter 3.3.1.4, but some additional infor-
mation are required. For the Transwell® insert membranes (PE and PC) set up with aACI + 
SE and special PEEK covers, for the RC membrane mACI and for the IPC membrane aACI + 
SE are used. After dose collection RC and IPC filter are cut out on the Transwell® insert size 
(ø 24 mm) and used with the modified insert as described above. After removing the PEEK 
cover the PE and PC membrane are directly usable for the experiment. 
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3.5.4.2. Addition of a dissolution layer on the membrane 
Adding a dissolution layer as used by Arora [61] is thought to improve drug dissolution by 
providing a higher volume on the powder side and hence diffusion across the membrane. 
After dose collecting the inserts were placed into the Transwell® dissolution system. Directly 
after placing the insert 40 µl PBS buffer were added [61] (or not) onto each membrane and 
the lid was closed. The tests were performed with and without this additional 40 µl, respec-
tively. The dissolution tests were performed always with stirring. 
 
3.5.4.3. Stirring 
Furthermore, the influence of stirring of the dissolution medium in the acceptor chamber on 
the dissolution and diffusion process through the membrane was determined. Stirring should 
guarantee a homogeneous concentration and reduce concentration-based diffusion effects. 
Stirring speed was set to 140 rpm. 
After dose collection the inserts were placed into the Transwell® system. The dissolution 
tests were performed without dissolution layer and with or without stirring, respectively. 
 
The combination of dissolution layer and without stirring was not tested, because both setups 
for themselves turned out not to be beneficial. 
 
Table 3.9: Overview of experimental procedures, experiments performed are marked with an x 
 
 dose collection technique influencing factors 
aACI + 
cover 
aACI + SE mACI 
membrane 
permeation  
dissolution 
layer 
stirring 
yes no yes no 
Polyester x   x  x x x 
Polycarbonate x   x x x x  
Polycarbonate 
(Isopore™) 
 x  x  x x x 
reg. Cellulose 
  x x 
x  x  
 x x x 
 
3.5.4.4. Comparison of the two different polycarbonate membranes 
For supporting the diffusion results regarding the differences in permeation of Budesonide 
between the two types of polycarbonate membranes (PC & IPC), two additional tests were 
performed. After drug deposition on the Transwell® inserts the Transwell® polycarbonate 
membrane edge was perforated 32 times with a small needle (ø 0.5 mm). For the other test 
set up the membrane was cut out after drug deposition and placed onto the modified 
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Transwell® insert (as described above for RC and IPC). With the perforation a better access 
of dissolution medium between the upper side of membrane and acceptor medium should be 
possible. The test of the modified insert should show if there is a material or test set up de-
pending difference between the two membrane types. The two tests were performed in tripli-
cate for Budesonide with stirring and without dissolution layer. 
 
3.5.4.5. Surfactants 
For the Budesonide and Substances A dissolution tests with addition of each 0.02% DPPC 
and 0.02% Alveofact ®, respectively in the PBS buffer were performed to simulate the lung 
liquid composition. As membrane material IPC membrane was used and therefore the corre-
sponding dose collection method 3.3.1.3. The tests were performed in triplicate without dis-
solution layer and with stirring. 
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3.5.5. Paddle Apparatus 
The paddle apparatus is a pharmacopeia dissolution testing method since 1978 (USP, appa-
ratus 2) [46]. In addition to the rotating basket method (USP, apparatus 1), USP apparatus 2 
is the most widely used technique for in vitro dissolution testing. The handling is simple, the 
methods are standardized, robust [21], and there is a large experience over more than 30 
years for oral dosage forms. The scope of application is not limited to quality control of oral 
dosage forms but also on non - oral forms e.g., transdermal patches, implants, suppositories 
and so forth. The paddle apparatus is a valuable tool for formulation development, controlling 
of manufacturing processes and even for predicting in vivo performance of oral dosage forms 
[44] right up to bioequivalence tests in exactly defined cases [21,120]. The classic paddle 
apparatus consists of vessels placed into a temperate water bath, inside each vessel a pad-
dle for stirring is immersed [60]. Dissolution testing with the paddle apparatus is sophisticated 
and many impact factors are known and can be controlled [10,44,60]. The dissolution medi-
um for oral dosage forms varies from simple buffer solutions with or without surfactant up to 
biorelevant media, like fasted state simulated intestinal fluid or fed state simulated intestinal 
fluid. Some of the impact factors on dissolution are temperature, stirring speed, shaft center-
ing and wobbling, vibrations, air bubbles, hydrodynamic conditions and last but not least 
evaporation. The air bubbles could slow down the dissolution [44] due to adhering at the sur-
face of particles and acting as barrier or could hold particles on the vessel or shaft [44,65]. 
Therefore, the USP demands deaeration of dissolution medium for example with heat vacu-
um filtration [60] or other validated deaeration techniques like helium or ultrasonic treatment 
[44]. The hydrodynamic conditions could strongly influence the dissolution profiles and the 
reproducibility. Hence, the equipment used for solid dosage forms should be in accordance 
with the pharmacopeia to reduce irregularities and turbulences in the fluid flow [44].  
The use of the paddle apparatus with a membrane holder for dissolution testing of powders 
for inhalation was first described in 2009 [54]. The powder is not directly placed into the ap-
paratus but instead it is aerodynamically classified with the NGI onto a membrane. This 
membrane was than sandwiched with a second one and placed into a modified histology 
cassette, which was afterwards positioned in the paddle apparatus [54]. A more sophisticat-
ed approach used a special NGI dissolution cup which is covered with a membrane after 
dose collection. The cup with the membrane is fixed and then placed into the dissolution ap-
paratus [55]. 
In this PhD thesis instead of the NGI, ACI as dose collection method is used. Hence, instead 
of the special NGI cup as described above a membrane holder (Copley Scientific, Notting-
ham, UK) (Figure 3.26 A, page 50) is used. This “standard” membrane holder is normally 
used for transdermal patches [10,121] and consists of a watch glass and a polytetrafluoro-
ethylene mesh. The experiments were performed with two different dissolution testers. At the 
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beginning the experiments were performed with an apparatus consisting of one vessel with 
1 l dissolution medium which was immersed in a water bath (Erweka DT70, Erweka, Heu-
senstamm, Germany). Sampling was automated according to a defined time schedule (Table 
3.10) by a construction of the Zentrale Elektro Werkstatt, Boehringer Ingelheim (based on 
two Gilson Abimed syringe pumps and a Gilson Abimed 233 XL (Gilson, Middleton, United 
Kingdom)). The sleeves for sampling are placed in the shaft of the paddle. In the further pro-
gress of the thesis the equipment was changed to a dissolution tester with seven vessels 
(dissolution tester AT7 smart, piston pump CP7-35 and fraction collector C615 (Sotax, Lö-
rrach, Germany)) with automated sampling, too (Table 3.11). For sampling a stable sleeve is 
remaining in the vessel during dissolution testing, 40 mm next to the shaft and 20 mm next to 
the vessel wall. 
Dissolution tests were performed at 37°C with degassed PBS buffer pH 7.4 as dissolution 
medium. The solvent removed during sampling is refilled with fresh pre-warmed PBS buffer 
to maintain the volume of the dissolution medium at a constant level. 
 
 
Figure 3.25: The membrane is placed with the particles faced towards the watch glass. Afterwards the 
membrane holder is placed into the paddle apparatus. A sampling and refill unit is adapted to the dis-
solution tester. 
 
After dose collection the membrane with particles towards the watch glass is placed into the 
membrane holder. The membrane holder is then placed into temperature controlled paddle 
apparatus (37°C), release surface (membrane + mesh) sided up. The distance between bot-
tom edge of the paddle and surface of the membrane holder is 25 mm ± 2 mm due to hydro-
dynamic effects [60]. 
After dissolution testing residual amounts of drug in and on the membrane and on the watch 
glass are determined by rinsing both parts with each 50 ml solvent (Table 3.1). The total 
amount of drug initially loaded on the membrane is determined using the maximum of the 
cumulatively released amounts plus the remaining quantity of particles on the membrane 
(determined at the end of each trial). The percentages of released drug over time were calcu-
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lated by dividing the amount of drug released by the initial drug mass loaded on the mem-
brane. All experiments were performed in triplicate. 
 
Table 3.10: Erweka apparatus, time schedule for sampling 
 
interval [min] 3 5 15 60 
samples 20 11 17 7 
interval [min] 
for Fenoterol 
1 5 15 60 
 
Table 3.11: Sotax apparatus, time schedule for sampling 
 
interval [min] 4 6 60 120 
samples 1 9 7 2 
 
 
3.5.5.1. Dose collection and dissolution testing – Erweka tester 
As dose collection method aACI (chapter 3.3.1.2) was used. For dose collection 1 mg of 
Budesonide, modifications of Substance A, and Fenoterol HBr, and 10 mg Budesonide and 
Fenoterol HBr, respectively were filled into polyethylene capsules. The particles were col-
lected either on the regenerated cellulose (RC) or the Isopore™ polycarbonate (IPC) mem-
brane. 
At the beginning of the experiments stirring speeds of 50 rpm, 100 rpm and 140 rpm were 
compared. For the following experiments the stirring speed with fastest dissolution and 
smallest standard deviation was chosen (140 rpm). Furthermore, as dose collection method 
an airbrush system was used (chapter 3.3.2). 
 
3.5.5.2. Dose collection and dissolution testing – Sotax tester 
In the Sotax paddle apparatus the membrane holder showed irregular movement in the ves-
sel for a stirring speed of 140 rpm, hence stirring speed had to be reduced to 100 rpm. After 
changing the dissolution tester equipment, comparison between the two apparatus was per-
formed. As dose collection method aACI (chapter 3.3.1.2) was used.  
The following experiments were performed to evaluate the: 
a) best dose collection method  
First three different dose collection methods were compared (aACI ((chapter 3.3.1.2), 
aACI + SE, mACI (chapter 3.3.1.3), respectively). Second, experiments determining 
the effect of different mass on the dissolution profile were evaluated. These experi-
ments were performed for Budesonide only.  
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b) different membrane holder types 
As dose collection method the best method from a) was used. For dissolution of 
Budesonide the following three membrane holders were tested: 
 commercially available membrane holder from Copley (Figure 3.26 A) 
 blocked membrane holder (Figure 3.26 B) 
The blocked membrane holder should avoid diffusion along the edge of the 
membrane. Onto the watch glass of the commercial available membrane 
holder the membrane is placed and locked at the rim with a stainless steel 
ring utilizing an o-ring. 
 a membrane sandwich holder (Figure 3.26 C) 
This membrane holder consists of two stainless steel rings and a mesh. After 
dose collection the membrane is covered with a second empty membrane 
and placed on the mesh. The mesh and the membranes are clamped in-
between the two stainless steel rings.  
 
 
Figure 3.26. A) standard membrane holder adapted from [122], B) blocked membrane holder, and C) 
membrane sandwich holder adapted from [123] 
 
c) influence of temperature 
As dose collection method the best method from a) was used. The experiments at 
22°C and 37°C were performed for Budesonide only. 
d) influence of lactose 
As dose collection method aACI + SE was used. The experiments were performed 
with Budesonide – Lactose mixture 2 (Table 4.4) 
e) dissolution medium with surfactant 
Experiments were performed with the best method from a) as dose collection method 
and standard membrane holder.  
 For Budesonide with PBS buffer containing 0.02% DPPC, 0.2% SDS, 0.2% 
Tween® 20, and 0.2% Tween® 80, respectively. 
 For Substances A with PBS buffer with or without 0.02% DPPC, respectively.  
 In addition, for Substances A and Budesonide the membrane holder set up 
with blocking of the membrane and PBS buffer containing 0.02% DPPC was 
used. 
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3.5.6. Dissolution model 
From the very first the effects of experimental dissolution testing were tried to be explained 
theoretically [46]. There are several models especially for the dissolution of oral dosage 
forms described in literature. These models try to explain an existing profile or predict a dis-
solution profile, e.g. Nerns - Brunner, Noyes - Whitney, Hixon - Crowell, Niebergall or Higuchi 
[45,124-129]. In addition, these models are based on the hypothesis that the dissolution pro-
cess is divided into two steps [130]. First the solution of the solid to form a stagnant film or a 
diffusion layer and second the diffusion of the solute from this film to the bulk liquid [45,46]. 
Different mathematical expressions for describing this dissolution process are the laws of 
Noyes-Whitney, Brunner-Tolloczko, Nernst-Brunner and Hixson-Crowell.  
Yet for powders for inhalation authors used these models to fit their release profiles and draw 
conclusions from the correlation coefficient criterion R2 [3,54,104,131], but currently no publi-
cation determined influencing factors on or of the model. 
Here an equation based on a diffusion layer concept was chosen. The so-called Nernst -
Brunner equation, a modification of the Noyes - Whitney equation, combines the diffusion 
layer concept with Fick’s 2nd law [46]. 
For describing dissolution kinetics of monodisperse powders with the Nernst - Brunner equa-
tion several assumptions were made, e.g.: the surface area of particles changes during dis-
solution, the dissolution of all particles contributes to the total concentration of the solution, 
and the thickness of the diffusion layer depends on the particle size [125]. For the model in 
the thesis the following form of the Nernst - Brunner equation (Equation 3.4) was used. 
 
  
  
 
  
 
        
Equation 3.4: Nernst - Brunner equation 
Where m is the mass of solid material at time t, S is the surface area of the particles, D the diffusion 
coefficient of the substance in the solvent, h is the diffusion layer thickness, cs is the solubility of drug 
and ct is the concentration of the drug in the solution at time t 
 
The diffusion coefficient D was calculated by applying the Hayduk - Laudie equation 
(Equation 3.5) [129,132]. The van-der-Waals volume VM for each substance was theoretically 
determined in a two step procedure from the chemical structure of the molecule with CORI-
NA v3.46 (Molecular Networks (http://www.molecular-networks.com/products/corina)) and 
MOE v2011.10 (CCG (http://www.chemcomp.com/)). 
 
  
          
      
      
      
Equation 3.5: Hayduk - Laudie equation [129,132]. 
Where D is the diffusion coefficient, water  the dynamic viscosity of water at 37°C, and VM the molecu-
lar volume 
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The dissolution layer thickness h during dissolution process is a well described parameter in 
the literature. Classically the diffusion layer is defined as unstirred liquid layer adhering to the 
solid surface [45]. Bisrat and Nystrom suggested that the diffusion layer might be smaller for 
small particles than for large particles. In their dissolution tests they could not find an influ-
ence of agitation speed on the surface specific dissolution rate for the size fraction < 5 µm in 
contrast to the fraction of 25-35 µm [133]. 
However, in literature there is no clear opinion on the behavior of the diffusion layer during 
the dissolution process. On the one hand a time independent diffusion layer with a constant 
diffusion layer during particle shrinking [125] is postulated; on the other hand a time depend-
ent diffusion layer is assumed with a shrinking diffusion layer during particle shrinking 
[124,134] (Figure 3.27). 
In literature there is a consensus that below a certain particle size the diffusion layer is ap-
proximated by the particle radius [125,129,135]. The critical particle radius is assumed to be 
30 µm [134]. In the case of a critical particle radius for a spherical particle the diffusion layer 
thickness and the particle radius is given by Equation 3.6 [135]. 
 
          
Equation 3.6: Correlation of diffusion layer thickness h and particle radius r, for particles with a diame-
ter less than 30 µm 
 
Furthermore, the influence of hydrodynamic conditions on the diffusion layer is discussed. 
Sheng et al. showed, that the paddle speed primarily influences the diffusion layer of large 
particles while particles with a particle radius smaller than 13 µm showed no effects on the 
diffusion layer [129]. 
 
 
Figure 3.27: Time dependence of diffusion layer, modified from [124]. 
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The modeling of the dissolution layer of particles in this work is based on the following as-
sumptions: sink conditions (chapter 2.2.3) (but the concentration change is taken into ac-
count), spherical particles, well stirred medium, isotropic dissolution, concentration at the 
surface of the particle / interface is saturated, the diffusion coefficient is assumed to be con-
stant along the diffusion layer and no direct influence of stirring on the dissolution process 
due to the membrane.  
Because the fine particle fraction from an experiment is polydisperse, different fractions of 
the particle size distribution are taken into account by the model (Table 3.12). 
In order to model the particle size distribution, the sum of monodisperse particle fractions is 
applied [128,134] (Equation 3.7). Each group is represented by subscript e. 
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Equation 3.7: Sum of monodisperse particle fraction to take the assumption of polydisperse powder 
into consideration 
Xsum(t) is the total amount of undissolved drug at time t, Xe(t) the amount of undissolved drug in a par-
ticle size group e, Se the surface area of each particle size fraction, he the thickness of the diffusion 
layer which depends on the particle radius re.  
 
The number of particles in each fraction is assumed to be time independent as described by 
Hintz et al. [134].  
The particle size fractions are based on the cut off diameter of the ACI as described by Nich-
ols [90]. For spherical particles the surface area of a particle size group is calculated as de-
scribed in the Equation 3.8- Equation 3.10 [128,134].  
 
 
          
       
 
 
     
Equation 3.8: Calculation of particle number Ne in a particle size fraction  
Xe (0) is the amount of undissolved drug in a particle size group, r the radius and the ρ the density 
 
       
      
     
     
Equation 3.9: Calculation of radius of one particle size fraction re at time t 
 Xe is the amount of undissolved drug in a particle size group, Ne (t) is the particle number at any time 
 
               
  
Equation 3.10: Calculation of surface area Se(t) of one particle size group at time t 
Ne is the number of particles in a particle size fraction, re the radius 
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Figure 3.28: Dissolution of a polydisperse powder over time for e particle size fractions (schematic). 
 
In Table 3.12 (page 55) the used parameters are summarized. The particle mass for calcula-
tion corresponds to the mass on the membrane from experimental data. Furthermore, the 
particles of the substances used in this thesis are not spherical, thus influence of shape on 
the dissolution process needs to be taken into account. Consequently, the aerodynamic di-
ameters need to be converted into the geometric ones. For this calculation (Equation 3.11) 
shape is important and a shape factor has to be used, the shape factor for spherical particle 
is 1 and for cubic particles 1.08 [136]. The assumed particle density of Budesonide is 
1.27 gcm-3 [137].  
Starting particle sizes at time point t = 0 are the diameters listed in Table 3.12. The whole 
calculation is based on a stepwise procedure with dt = 0.01 min, till each particle fraction is 
dissolved.  
          √
 
 
 
Equation 3.11: Correlation between aerodynamic and geometric particle diameter 
ρ is particle density, k the shape factor 
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Table 3.12: Data for model calculation 
 
 
Budesonide 
Substance A 
crystalline 
base 
amorphous 
base 
Dibromide 
solubility 
[µg/ml]  
17 7 211 265 
van der Waals 
volume (A3) 
419 619 701 
drug diffusion 
coefficient 
[cm2/min]  
6.19x10-6 4.92x10-6 4.92x10-6 4.57x10-6 
Dissolution 
volume [ml] 
1000 
Diffusion layer 
thickness [µm] 
h(t) = r(t) 
dt [min] 0.01 
mass on 
membrane [µg] 
200 
Particle size distribution [%] for fine particle fractions [µm]: 
5.29 µm 18.8 % 10.4 % 15.4 % 14.2 % 
4.16 µm 29.7 % 25.0 % 25.7 % 22.9 % 
2.49 µm 27.4 % 37.2 % 27.5 % 52.1 % 
1.53 µm 18.1 % 21.8 % 21.9 %  60.8 % 
0.70 µm 3.2 % 3.7 % 5.2 % 8.2 % 
0.41 µm 1.3 % 1.1 % 2.5 % 3.6 % 
0.21 µm 1.5 % 1.1 % 1.8 % 1.1 % 
 
For evaluating possible influence factors for Budesonide, the fine particle fraction on the 
membrane, the particle shape, the solubility, the diffusion layer thickness, and the particle 
size distribution were varied individually. In each case the other parameters were kept con-
stant. Selected calculated graphs are compared with each other due to the use of the “fit fac-
tor” test as described in chapter 3.6.2.2. 
Model calculations were done with Excel 2007 (Microsoft Office, Windows). 
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3.6. Data Treatment 
3.6.1. Evaluation of Dissolution Tests 
After dissolution testing residual amounts of drug in and on the membrane and additional 
parts of the dissolution set up (the whole cell for the flow through cell, membrane holder at 
the paddle apparatus) were determined by rinsing the membrane and the parts with defined 
amounts of solvent (Table 3.1). Detailed information regarding the amount of solvent are 
mentioned in the corresponding dissolution technique chapter. The total amount of drug ini-
tially loaded on the membranes was measured using the maximum of the cumulatively re-
leased amounts plus the remaining quantity of particles on the membrane (determined at the 
end of each attempt). Percentages of drug released were calculated by dividing the amount 
of drug released by the drug mass loaded on the membrane after application with the ACI. 
Calculations were done with Excel 2007 (Microsoft Office, Windows). 
 
3.6.2. Comparison of dissolution profiles 
Dissolution profile comparison is divided into two different methods, either model dependent 
or model independent approaches.  
Model dependent approaches are distinguished whether they are used for modeling or com-
parison of dissolution profiles. In literature several approaches are described. The predomi-
nant rate of authors use existing models (e.g., zero order, first order (Noyes - Whitney), 
Hixson - Crowell, Weibull, Higuchi, Korsmeyer - Peppas) [45,124-129] and convert them for 
example into integral equations [138]. Nevertheless, in literature are also new approaches 
described [130]. As disadvantageous of the model dependent comparison could be seen that 
the chosen model does not fit over the complete dissolution curve and that the predicted as-
ymptotic value of the concentration is not with the necessary accuracy [139,140]. Further-
more the best function is often more shape than mechanism descriptive [139]. Additionally, 
for similarity test between experimental and modeled curves an extra similarity test could be 
performed [141]. Beside dissolution profile comparison model dependent approaches could 
give a mechanistic point of view. Sometimes two or more models are capable in this case the 
information that essentially describes the dominant mechanism is chosen [139].  
The model dependent approach is used for prediction of dissolution profiles and described in 
chapter 3.5.6. Focus in this PhD thesis for dissolution profile comparison are the model inde-
pendent methods, which could be ordered into ratio test procedure (e.g. mean dissolution 
time) and pair wise comparison [140]. 
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3.6.2.1. Mean Dissolution Time 
The Mean Dissolution Time (MDT) is a strict empirical model [35]. Advantageous is the ame-
nability to direct data treatment. Disadvantageous is the strong dependence on the upper 
limit of the dissolution profile [139]. 
In this PhD thesis comparison of profiles was not only done visually but also with calculation 
of the MDT. The MDT summarizes the whole profile into one number. It was calculated with 
Equation 3.12. Where t ¯I is the midpoint of time period during which the fraction ΔMi has 
been released from the dosage form [35,139]. Calculations were performed applying pro-
gram “R”. 
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Equation 3.12 For determining the mean dissolution time from the respective data set [35,139]. 
 
3.6.2.2. Difference and Similarity Test 
Comparison of the different dissolution profiles was performed with the difference and simi-
larity factor introduced by Moore and Flanner [142]. The European Medicines Agency (EMA) 
[120] as well as the Food and Drug Administration (FDA) [21] advice for the comparison of 
dissolution profiles the use of these “fit factors”. The difference (f1) (Equation 3.13) and the 
similarity (f2) (Equation 3.14) factor are model independent approaches that directly compare 
the difference between percent drug released per unit time for a test and a reference prod-
uct. Where n is the number of dissolution samples taken (number of samples), Rt and Tt are 
the mean percent drug released at each time point for reference and test product, respective-
ly. For two curves to be considered similar f1 needs to be smaller 15 (f1 < 15) and f2 needs to 
be larger than 50 (f2 > 50) [21,120]. 
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Equation 3.13: Formula to derive the difference factor 
 
         
[
 
 
 
 
√  
 
 
∑         
 
   
    
]
 
 
 
 
Equation 3.14: Formula to derive the similarity factor 
 
FDA and EMA require for the correct calculation of the similarity factor the following condi-
tions I) same test conditions for test and reference product, and especially same sampling 
points, II) only one more value after reaching 85% dissolved drug amount [21,120], III) using 
the mean values, the coefficient of variation should be less than 20% for the first point and 
less than 10% for following points [21] and IV) twelve individual values for every time point 
for each formulation [21,120]. 
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Advantageous is the reduction of complex dissolution profiles through an easy calculation 
into one number. Additionally, to the requirements of EMA and FDA for ensuring real similari-
ty between profiles are the shape and the maximum dissolved amount [143]. In literature 
several disadvantages of the two fit factors are discussed. The drawbacks listed are I) no 
indication of sense of the deviation (below, above), II) no consideration of the shape of the 
curve, III) no information about variability inside the batch [139,143], IV) the factors are sensi-
tive for measurements above 85% of the drug amount dissolved, V) sensitivity to the number 
of dissolution time points [143], VI) level of confidence for the f2 test is uncertain with low sta-
tistical power [143,144] and large difference between individual extremes are ignored due to 
usage of the arithmetic mean [144]. 
Calculations were performed applying Excel 2007 (Microsoft Office, Windows) 
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4. Results and Discussion 
 
4.1. Pre - test Results 
In this chapter the results of the pre - tests are summarized. A detailed discussion of the re-
sults follows according to the dissolution techniques. 
 
4.1.1. Determination of LoQ, solubility and micelle size 
Table 4.1: HPLC LoQ results 
 
 
Budesonide 
Substance A 
crystalline base amorphous base bromide 
concentration 
[µg/ml] 
0.052 0.099 0.044 0.046 
RSD [%] 4.45 5.99 2.29 4.54 
signal noise ratio < 10 < 10 < 10 <10 
 
Table 4.1 displays the LoQ concentrations for Budesonide and Substance A. The FPD 
masses on the membrane for dissolution tests should be above the LoQ of HPLC analysis 
but still allow sink conditions in the dissolution test set up. 
 
Table 4.2: Solubility of substances in PBS buffer with and without surfactant (22°C, 24h) 
Budesonide, Fenoterol and Substance A in PBS buffer, n = 3, for Substance A in PBS buffer with sur-
factant n = 1 
 
 Budesonide 
[µg/ml] 
Fenoterol HBr 
[µg/ml] 
Substance A [µg/ml] 
cryst. base amorp. base bromide 
PBS buffer 17 43000 7 211 265 
+ 0.02% DPPC 21 - 6 116 2505 
+ 0.2% SDS 406 - 847 504 2033 
+ 0.2% Tween® 20 40 - 22 663 3865 
+ 0.2% Tween® 80 53 - - - - 
 
 
The solubility of substances, expect of Substance A base using DPPC, is increased. Interest-
ingly the solubility increases for the poor soluble Substance A crystalline base and 
Budesonide is for SDS highest. For the amorphous base and the dibromide the increase of 
solubility using Tween® 20 is higher than using SDS (Table 4.2). 
The micelles of SDS, Tween® 20 and 80 can pass the pores of the used membranes with a 
pore diameter of 0.4 – 0.45 µm. DPPC forms large objects, which are too large for passing 
the membrane (Table 4.3). 
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Table 4.3: Micelle size of surfactants in PBS buffer (measured with dynamic light scattering)  
 
Peak 1 Mean 
[nm] 
Peak 2 Mean 
[nm] 
PBS buffer   
+ 0.02% DPPC 1106 0 
+ 0.2% SDS 7 222 
+ 0.2% Tween® 20 12 2473 
+ 0,2% Tween® 80 11 0 
 
4.1.2. Substance classification 
4.1.2.1. Budesonide – Respitose blend 
 
Table 4.4: Mixture homogeneities of Budesonide – Respitose blend  
content in % is referred to Budesonide weight 
samples mixture 1 
(20 minutes) 
mixture 2 
(20 minutes) 
1 1.5 % 1.5 % 
2 1.6 % 1.6 % 
3 2.0 % 1.7 % 
4 1.5 % 1.4 % 
5 1.9 % 3.7 % 
RSD 15.0 % 47.2 % 
RSD  
without outlier 
12.4 % 8.6 % 
 
Both mixtures show no optimum homogeneity (Table 4.4). However, without the outlier mix-
ture 2 is more homogeneous and therefore was used for further experiments. 
 
  
Figure 4.1: SEM picture: 2%Budesonide- Repsi-
tose blend 
Figure 4.2: SEM picture micronized Budesonide 
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In Figure 4.1 the smaller particles are probably Budesonide and the larger ones Lactose. If 
the SEM picture is compared to the micronized Budesonide (Figure 4.2) a definite differentia-
tion is not possible. 
 
4.1.2.2. Particle size 
 
Table 4.5: Geometric particle size (measured with laser diffraction)  
mean + SD, n = 3, x10, x50, x90 = 10%, 50%, 90% of particle diameter in µm 
Q5 = volume% of particles with a diameter < 5µm 
 
 
Budesonide 
Fenoterol 
HBr 
Substance A 
cryst. Base amorp. base bromide 
x10 [µm] 0.54 + 0.01 0.69 + 0.01 0.71 + 0.02 0.52 + 0.02 0.62 + 0.01 
x50 [µm] 1.53 + 0.02 1.90 + 0.01 1.64 + 0.00 1.24 + 0.03 1.67 + 0.07 
x90 [µm] 3.69 + 0.03 4.03 + 0.01 3.54 + 0.08 3.07 + 0.10 6.65 + 0.63 
Q5 [Vol%] 96.52 + 0.18 95.83 + 0.07 97.68 + 0.48 97.45 + 0.32 84.02 + 2.24 
 
Size distribution of Budesonide, Fenoterol HBr and modifications of Substance A particles 
measured by the laser diffraction technique is shown in Table 4.5. All substances except of 
Substance A dibromide showed a high amount of particles less than 5 μm. 
For determining the aerodynamic particle size distribution of Substance A, Budesonide and 
Fenoterol HBr ACI was used. Results are shown in Table 4.6. Percentages were calculated 
based on the capsule load (1 mg, Fenoterol 10 mg). As shown in Table 4.6 particle size dis-
tribution of Substance A dibromide and amorphous base is not significantly different to each 
other except stage 5. Furthermore, the amount of smallest particles (stage 6 - filter) of Sub-
stance A is increased versus Budesonide. Table 4.6 also shows only small difference be-
tween FPF calculated of data from particle size measurement of the whole ACI and directly 
determination of the FPF with the abbreviated ACI. 
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Table 4.6: Aerodynamic particle size distribution using the ACI, mean ± SD, n = 3 
 
 
Budesonide 
[%] 
Fenoterol 
HBr[%] 
Substance A 
cryst. base 
[%] 
amorp. base 
[%] 
Br2 
[%] 
HH + capsule 24.0 ± 1.8 11.2 ± 1.8 27.7 ± 3.0 10.6 ± 3.4 8.9 ± 2.6 
Adapter 
SIP  
High Top 
20.5 ± 7.2 20.8 ± 7.2 9.6 ± 1.1 24.9 ± 5.0 12.0 ± 7.5 
Presep 25.6 ± 3.8 48.7 ± 13.2 8.1 ± 1.9 41.3 ± 4.3 46.3 ± 8.2 
Stage 0 2.2 ± 0.1 1.2 ± 0.2 0.1 ± 0.2 0.4 ± 0.1 1.1 ± 0.2 
Stage 1 4.0 ± 0.2 2.0 ± 0.2 2.2 ± 0.3 0.8 ± 0.1 1.2 ± 0.2 
Stage 2 4.7 ± 0.3 3.3 ± 0.2 3.9 ± 0.5 1.3 ± 0.4 0.9 ± 0.1 
Stage 3 7.5 ± 0.6 4.6 ± 0.5 9.3 ± 1.1 2.2 ± 0.6 1.5 ± 0.5 
Stage 4 6.9 ± 0.8 3.3 ± 0.7 13.9 ± 1.9 2.3 ± 0.9 1.7 ± 0.5 
Stage 5 4.6 ± 0.4 1.3 ± 0.5 8.1 ± 1.4 1.9 ± 0.7 2.0 ± 0.5 
Stage 6 0.8 ± 0.1 0.2 ± 0.1 1.4 ± 0.2 0.4 ± 0.2 0.3 ± 0.2 
Stage 7 0.3 ± 0.1 0.1 ± 0.0 0.4 ± 0.1 0.2 ± 0.2 0.1 ± 0.1 
Filter 0.4 ± 0.1 0.1 ± 0.0 0.4 ± 0.1 0.2 ± 0.1 0.1 ± 0.0 
      
FPF (%) ACI 25.2 ± 1.9 12.9 ± 2.4 37.4 ± 4.6 8.5 ± 2.8 6.5 ± 1.8 
FPF (%) aACI 27.8 ± 2.7 17.6 ± 1.7 45.5 ± 2.7 17.8 ± 3.7 6.5 ± 4.0 
 
4.1.2.3. Wettability 
 
Table 4.7: Advanced contact angle for the different substances  
Substances were pressed to tablets, (3 drops, 15 measurements per drop). Due to small remaining 
amount of Substance A amorphous base the test was performed one time 
 
  
Budesonide 
Substance A 
crystalline base amorphous base dibromide 
water Θ[°] 72.7 ± 4.6 64.65 ± 30.21 83.5 78.9 ± 27.5 
+ 0,02% DPPC Θ[°] 52.2 ± 11.5 direct spreading 73.5 56.1 ± 20.1 
 
In Table 4.5 results of contact angle measurement of small substance pellets with water or 
water containing 0.02% is displayed. Contact angle of substances are near the 90° border, 
above 90° the wettability is poor and below 90° the wettability is good. Hence, the used sub-
stances have a still hydrophilic character but they are near the “border” which advises to a 
reduced wettability. Results for Substance A dibromide and crystalline base show a reduced 
reproducibility. By adding 0.02% DPPC to the water the contact angle decrease, indicating a 
better wettability. For Substance A crystalline base the wettability increasing is such as high, 
that the droplet could directly spread on the pellet surface. 
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4.1.3. Dose collection 
In the following dose collection pre – tests are summarized. Without the tests it is not possi-
ble to perform reliable dissolution tests because of possible unknown effects during dose 
collection. 
 
Table 4.8: ACI flow through cell pretests, FPD on membrane in membrane pattern, mean ± SD, n = 3 
 
Position Budesonide 
Substance A 
crystalline base amorphous base Br2 
0 o’clock [µg] 58.1 69.6 24.1 46.4 
3 o’clock [µg] 55.0 75.2 23.6 43.2 
6 o’clock [µg] 54.3 50.3 19.6 46.8 
9 o’clock [µg] 54.2 72.1 22.7 50.8 
Mean ± SD [µg] 55.4 ± 1.9 66.8 ± 11.3 22.5 ± 2.0 46.8 ± 3.1 
 
Table 4.8 displays no influence of membrane position in the pattern on FPD on each mem-
brane. Hence, each membrane could be used for dissolution test or as reference filter, re-
spectively. 
 
 
Figure 4.3: mACI pretest determination of waiting time, FPD of Budesonide on membrane, mean ± 
SD, n = 3. The tests were performed on two different days, black bars on the one, grey bars on the 
other day 
 
Figure 4.3 shows the impact of sedimentation or after pump stop waiting time on the FPD on 
membrane. Particles of the same substance have according to their size different sedimenta-
tion times. Therefore, with an increased sedimentation time up to 5 minutes the particle mass 
on the membrane is increased. Theoretically particles with an aerodynamic diameter of 1 µm 
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need for a distance of 10 cm approximately 55 minutes [145]. An increased sedimentation 
time up to 10 minutes or even 30 minutes shows no significant higher amount of particles on 
the membrane. Furthermore, an additional pump time of 0.4 s after 5 minutes waiting was 
performed for impaction of the smallest particles. It is obvious that the variability compared to 
5 minutes (grey bar) is highly increased and the amount of particles on the membrane was 
not increased. 
Due to no significant higher amount of particles on the membrane for a sedimentation time 
larger than 5 minutes and the low amount of particles with an aerodynamic diameter of less 
than 1 µm a waiting time of 5 minutes for all further experiments with the mACI set up was 
chosen. 
 
 
Figure 4.4: mACI determination of optimum powder weight into capsule, FPD: mean ± SD, 
Budesonide (blue square), Substance A crystalline base (open dark green triangle), Substance A 
amorphous base (light green triangle) and Substance A Br2 (green x), mean ± SD, n = 3  
 
In Figure 4.4 the determination of the required powder weight into capsule is shown. The 
FPD on the membrane is plotted against the amount of powder in the capsule before dose 
collection. Aim is to achieve a similar FPD on membrane for all the different substances. The 
limiting factors are time for emptying the capsule in the HH and LoQ of HPLC method. The 
pump time during dose collection and hence the time for capsule emptying is limited by the 
height of the used stage extension. As described in chapter 3.3.1.3 the aerosol should only 
reach the middle of the stage extension for allowing sedimentation of particles. Hence, the 
substance mass in the capsule should not be higher than 4 mg to 5 mg The LoQs of all sub-
stances are summarized in Table 4.1. The amount of dissolution medium used in Franz cell 
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and paddle apparatus is 1 l, thus the minimum FPD is 99 µg (LoQ crystalline base: 0.099 
µg/ml). Therefore, a FPD between 100 µg and 200 µg was chosen. 
 
 
Figure 4.5 Comparison of HH and aerosol generator with mACI  
FPD on membrane for Budesonide, mean ± SD, n = 3 
 
Table 4.9: Comparison of HH and aerosol generator with mACI, FPD on membrane, n = 1 
 
substance 
capsule 
[mg] 
FPD on membrane [µg] 
HandiHaler  
aerosol generator  
chamber volume 
300ml 600 ml 
Substance A  
crystalline base 
1 82.7 26.9 13.4  
3 294.5 65.3 38.0  
5 - 116.8 53.9 
Substance A 
amorphous base 
1 - 33.77 16.8 
3 - 82.75 77.6 
5 - 124.9 114.2 
Substance A di-
bromide 
1 28.1 3.3 8.1 
3 62.3 33.1 20.4 
5 - 75.5 39.9 
 
The results form Figure 4.5 and Table 4.9 show as expected a difference between the 300 ml 
and 600 ml aerosolisation chamber of the aerosol generator. Using the larger chamber the 
aerosol has more space for expansion without sticking at the walls and a higher amount 
reaches the membrane. Astonishingly, a comparison of aerosol generator and HH displays a 
higher amount of FPD for HH than for aerosol generator. Hence, the HH has the better de-
agglomeration properties and the usage is justified.  
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4.1.4. Membrane classification 
The SEM pictures (Figure 4.6) demonstrate the different structures and pore densities of the 
used membrane materials. Polycarbonate (PC) and polyester (PE) membrane are both 
tracked-etched filters having more or less straight pores crossing the membrane. However, 
the regenerated cellulose membrane has more spongy structure. 
 
Figure 4.6: a) Isopore® Polycarbonate, b) regenerated cellulose, c) Transwell®-Polyester, d) 
Transwell® Polycarbonate 
 
The Figure 4.7 - Figure 4.10 display the results of membrane permeation tests for the four 
used membrane materials and the substances. The figures show the diffused amount of 
substance through the membrane. It is obvious that there are substance depending differ-
ences but similar is a substance retraining effect of the Transwell® PE and PC membrane. 
For Budesonide (Figure 4.7) and Substance A dibromide (Figure 4.10) the Transwell® PE 
has the slowest diffusion process. For Budesonide the rank order of membrane permeability 
is IPC > RC > PC and PE membrane.  
 
Figure 4.7: Membrane permeation test for Budesonide 
Isopore™ polycarbonate (red square), regenerated cellulose (blue rhomb), Transwell® polycarbonate 
(green triangle) and Transwell® polyester (purple x), mean ± SD, n = 3. 
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For Substance A base (Figure 4.8 and Figure 4.9) the rank order of the mean of membrane 
permeability is RC > IPC > PE > PC. However, due to the large error bars the profiles of RC 
and IPC appear to be similar. 
The results are confirmed by the experiments of Bhagwat et al. who could demonstrate a 
reduced diffusion using the PC membrane [62]. 
 
Figure 4.8: Membrane permeation test for Substance A crystalline base 
Isopore™ polycarbonate (red square), regenerated cellulose (blue rhomb), Transwell® polycarbonate 
(green triangle) and Transwell® polyester (purple x), mean ± SD, n = 3. 
 
 
Figure 4.9: Membrane permeation test for Substance A amorphous base 
Isopore™ polycarbonate (red square), regenerated cellulose (blue rhomb), Transwell® polycarbonate 
(green triangle) and Transwell® polyester (purple x), mean ± SD, n = 3. 
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Figure 4.10: Membrane permeation test for Substance A dibromide 
Isopore™ polycarbonate (red square), regenerated cellulose (blue rhomb), Transwell® polycarbonate 
(green triangle) and Transwell® polyester (purple x), mean ± SD, n = 3. 
 
Table 4.10: Advanced contact angle for the different membranes (mean ± SD, n = 4, 15 measure-
ments per drop) 
 
  Isopore™ poly-
carbonate 
Transwell® poly-
carbonate 
Transwell® 
polyester 
water Θ[°] 57.4 ± 1.9 63.7 ± 9.3 43.5 ± 4.2 
+ 0,02% DPPC Θ[°] 36.3 ± 2.0 45.5 ± 15 35.7 ± 7.4 
 
Table 4.10 shows the results of contact angle measurements. For the regenerated cellulose 
a measurement was not possible due to spreading of the droplet because of the spongy 
structure and the high hydrophilicity (complete wetting). The contact angles for PC and PE 
membrane are less than 90° hence the chosen membranes have a more hydrophilic surface. 
Comparison of Isopore™ and Transwell® PC membrane displays a lower reproducibility for 
the Transwell® membrane. Hence, on the Transwell® membranes are areas with different 
hydrophobic or hydrophilic properties. 
As expected by adding DPPC the surface tension of the droplet is reduced and thus the wet-
tability of membrane increased. 
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4.2. µDiss Profiler™ 
 
In Figure 4.11 dissolution profiles for the tested substances are shown. The lag time from 
zero to one minute is the time needed for transferring the API suspension from the twin stage 
impinger to the µDiss vessels. It is obvious that for Substance A amorphous base and dibro-
mide 100 % were dissolved within the lag time and thus no discrimination is possible. For 
Budesonide the process starts from 28% and reaches in the first 10 minutes a plateau at 
around 85%. As expected from the solubility data Substance A crystalline base shows the 
slowest dissolution process, after 60 minutes only 10% are dissolved. 
 
Figure 4.11: Dissolution profiles µDiss profiler after dose collection with Twin Stage Impinger, Sub-
stance A amorphous base (light green), Substance A dibromide (green), Budesonide (blue), and Sub-
stance A crystalline base (dark green), mean ± SD, n = 3. 
 
Advantage of the µDiss is undoubtedly the real time measurement with short time intervals. 
Furthermore, there is the possibility to weight a small amount of the powder directly into the 
vessel without an aerodynamic classification and deagglomeration step. Without a deag-
glomeration step the possibility of increasing variability in dissolution profiles is given due to 
varying particle sizes or agglomerates. In addition, it is the only dissolution technique without 
membrane, therefore possible substance - membrane interactions are not existent. 
If there is an interest in dissolution of fine particle dose, first a dose collection method is nec-
essary. The twin stage impinger has been proved as beneficial compared to the ACI, due to 
the direct collection as suspension. For transferring the suspension into the dissolution ves-
sels a lag time is required. During this lag time the dissolution processes could already be 
started and when sample measurement starts for some substances 100% dissolved are al-
ready reached. A further disadvantage is the unknown particle mass in the sample because 
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for calculating and reporting the software needs the exact amount of substance. Hence, 
HPLC analysis must be used additionally  
Another drawback is the complicated and error - prone calibration, especially if there is a 
difference between solvent and dissolution media needed. This difference might be neces-
sary, if concentration in the dissolution medium is at the solubility limit. 
With a view to the used substances, Substance A amorphous base and Substance A dibro-
mide have already reached 100% dissolved at the starting point, resulting in an impossible 
discrimination. Hence, the dissolution is too fast, for this technique. 
Summarizing the µDiss dissolution technique is not useful for dissolution of inhalative pow-
ders, but a useful tool for determination of the solubility of substances in early stage of de-
velopment. 
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4.3. Flow Through Cell 
 
4.3.1. Diffusion pre-tests 
The diffusion test (Figure 4.12, left) demonstrates the applicability of the modified flow 
through cell. By pumping the substance – buffer - solution without the cell (background 
noise) directly into graduated flask 89.3 % ± 3 % of the dissolved amount are recovered. The 
amount is lower as expected. A value of almost 100% was expected. If the cell is used, inter-
estingly recovery rate of diffused substance increases. Hence, the question arises were the 
substance is lost.  
A possible interaction between substance and tube could be excluded, because PEEK tubes 
were used.  
 
Figure 4.12. Left side: diffusion test with background noise (white) and flow through cell (blue), right 
side: validity test with time schedule sampling (dark grey), all in one 24 h (light grey), all in one 50 min 
(light grey, dashed line), mean ± SD, n = 3 
 
The validity test (Figure 4.12 right) for time schedule sampling over 60 minutes and the “all in 
one” sampling over 50 minutes shows similar results. However, for the “all in one” sampling 
standard deviation is smaller. The validity test for all in one sampling over 24 h shows a high 
variability of data. Comparison of diffusion test and validity test indicates a larger variability of 
data for the validity test. Additionally, the standard deviation exceeds the background noise 
base line. One possible reason might be that the powder is directly weighed onto the mem-
brane, resulting in a less uniform particle distribution on membrane, due to the micronisation 
of Budesonide. In micronized powders, amongst others, triboelectric forces between particles 
might be high and the fine particles stick together [146]. Hence, the fine particles form ag-
glomerates, which are not splitted during the weighing process. The agglomerates have a 
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smaller surface compared to their volume than the fine particles, resulting in a different dis-
solving behavior, with decreasing surface solubility rate is increased [31,146]. 
 
4.3.2. Dissolution testing 
Due to possible influence of the sampling on the results (Figure 4.13), the two possible sam-
pling methods –“all” vs. “partial”- are compared. Drawing inferences from the dissolution pro-
files about similarity or differences is due to the high variability of dissolution profile data not 
possible. Calculation of the discarded amount in the partial set up was double checked with a 
different calculation attempt. In this different calculation approach the slope between single 
points was calculated. Both calculation attempts gave the same result. 
 
 
Figure 4.13: Influence of sampling type on Budesonide dissolution profile 
all (blue rhomb), partial (red square), mean ± SD, n = 3 
 
A further experiment determined the influence of flow rate (Figure 4.14) on the dissolution 
process and thus on the dissolution profile. The dissolution profiles show all a high variability, 
therefore only trends should be mentioned. Rank order expected was 0.5 ml/min as slowest 
and 5 ml/min as fastest dissolution profiles. With a slower dissolution rate the process in the 
cell should be more diffusion controlled. If the flow rate increases in addition pressure and 
hydrodynamic effects increases and they should be the controlling effects. This order is only 
in the first two minutes and the last ten minutes given: in between 1 ml/min dissolution profile 
is faster than the 5 ml/min. As previously described the high variability of the data reduces 
the interpretability. For this reason and for the more convenient handling for further experi-
ments a flow rate of 1 ml/min was used.  
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A reason for high variability might be pump depending. If the dissolution medium is not 
pumped continuously through the cell, already dissolved substances could be flow back in 
the inlet tubing. For avoiding these effects a HPLC pump with internal pulse damper was 
used, for ensuring an almost pulsating free dissolution medium flow. 
Concerning the MDT (Table 4.11) no significant difference between the profiles is shown.  
 
 
Figure 4.14: Influence of flow rate on Budesonide dissolution profile 
0.5 ml/min (turquoise rhomb), 1 ml/min (light blue square) and 5 ml/min (dark blue triangle) mean ± 
SD, n = 3 
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Table 4.11: Summary of substance, flow rate, FPD on reference filter, recalculated FPD on filter (mean 
± SD) and MDT (mean ± SD) 
 
substance Flow rate 
[ml min-1] 
sampling 
type 
powder 
weight 
[mg] 
reference 
filter 
[µg] 
filter flow through 
cell [µg] n = 3 
MDT [min] 
mean ± SD mean ± SD 
Budesonide 
0.5; all 
1 
25.9 12.5 ± 2.4 17.0 ± 6.9 
1; all 
1; partial 
7.5 11.0 ± 2.8 13.5 ± 3.1 
7.4 30.3 ± 9.9 16.6 ± 2.1 
5; all 15.4 31.3 ± 15.0 18.2 ± 4.1 
Fenoterol 1, partial 
5 10.9 15 ± 1.8 6.3 ± 0.2 
10 11.7 10.2 ± 2.1 11.1 ± 7.2 
15 42.5 32.6 ± 5.1 1.5 ± 0.3 
Substance A 
crystalline 
Base 
1, partial 
3 13.2 35.0 ± 5.4 44.5 ± 3.8 
10 32 44.6 ± 3.5 44.5 ± 0.3 
15 54.7 66.5 ± 18.0 41.2 ± 5.4 
Substance A 
amorphous 
base 
1, partial 
10 10.4 21.8 ± 3.6 9.2 ± 2.9 
30 120.6 158.0 ± 13.7 9.0 ± 1.7 
50 110.3 151 ± 17.3 11.5 ± 1.9 
Substance A 
Br2 
1, partial 
10 10.7 18.9 ± 4.8 12.2 ± 3.6 
25 56.1 87.1 ± 9.6 5.7 ± 0.6 
40 179.7 164.5 ± 22.5 4.9 ± 2.3 
 
In Figure 4.15 the dissolution profiles of Substance A amorphous base and in Table 4.11 the 
corresponding FPDs are shown. The dissolution profile 10 mg (light green rhomb) with a 
FPD of 10 µg is in the first few minutes similar to the profile 30 mg (green square) with a FPD 
of 120 µg. Over time the two profiles diverge. From the beginning the dissolution profile 
50 mg (dark green triangle, FPD 110 µg) shows a slower increase. It is obvious that variabil-
ity of data is high and interpretability is difficult. The expected rank order, 10 mg - fastest dis-
solution profile due to smallest mass on membrane and 50 mg -slowest dissolution profile, is 
not given. In contrast, the profile with the highest mass on the membrane shows the fastest 
progression. The results for the other substances are similar concerning the variability and 
the non linearity between mass on membrane and speed of the dissolution (Table 4.11, Fig-
ure 4.16, Figure 4.17 and Figure 4.18). 
Another very remarkable result is the relationship between reference filter amount and recal-
culated amount on experiment filter (Table 4.11), except for Fenoterol HBr. It is noticeable 
that there are often large differences between the results. The direction of divergence alter-
nate so that a systematic bias could be excluded.  
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Figure 4.15: Substance A amorphous base 
Influence of FPD on the membrane on dissolution profile. 
10 mg (light green rhomb, FPD: 21.8 µg ± 3.6 µg), 30 mg (green square, 158.0 µg ± 13.7 µg) and 
50 mg (dark green triangle, 151 µg ± 17.3 µg) mean ± SD, n = 3 
 
 
 
 
Figure 4.16: Fenoterol HBr  
Influence of FPD on the membrane on dissolution profile. 
5 mg (yellow triangle, 15 µg ± 1.8 µg), 10 mg (orange square, 10.2 µg ± 2.1 µg) and 15 mg (brown dot, 
32.6 µg ± 5.1 µg) mean ± SD, n = 3 
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Figure 4.17: Substance A crystalline base  
Influence of FPD on the membrane on dissolution profile. 
3 mg (light green rhomb, 35 µg ± 5.4 µg), 9 mg (green square, 44.6 µg ± 3.5 µg) and 15 mg (dark 
green triangle, 66.5 µg ± 18 µg) mean ± SD, n = 3 
 
 
 
 
Figure 4.18: Substance A dibromide  
Influence of FPD on the membrane on dissolution profile. 
10 mg (light mauve rhomb, 18.9 µg ± 4.8 µg), 25 mg (purple square, 87.1 µg ± 9.6 µg) and 40 mg 
(dark pruple triangle, 164.5 µg ± 22.5 µg) mean ± SD, n = 3 
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The newly developed flow through cell should combine the advantageous of standard flow 
through cell with usage for powders for inhalation. As described above the benefits of stand-
ard flow through cell are sink conditions due to infinite amount of dissolution medium in the 
open set up [82,105,106,108] and continuous sampling [82]. For testing of powders for inha-
lation, on detail the FPD, a particle size classification step is required. Therefore, aACI as 
dose collection method was used and the pre-test results (Table 4.8), concerning the ho-
mogenous mass on the four membranes, were promising. Furthermore, the diffusion pre-
tests (4.3.1) prove the functionality of the flow through cell. The validity tests with a direct 
weighing onto the membrane without deagglomeration step, resulted in a high variability of 
data with a limited validity. Langebucher et al. advised that dead edges inside the flow 
through cell has to be avoided, because undissolved particles could deposited outside the 
fluid stream [105]. The new developed “quench heads” allow a homogenous fluid stream 
over the whole membrane area, dead edges should be eliminated. Additionally, material of 
flow through cell was changed to PEEK, which is predominantly inert against the used sub-
stances and the solvent (ACN) used in the rinsing step. Consequently, adsorption and inter-
action is reduced to a minimum. As described above there are further aspects concerning the 
difference between the sampling methods, flow rate, mass depending dissolution and differ-
ence between recalculated amount on membrane and reference filter. 
Theoretically, the two profiles with the different time schedule based sampling methods are 
similar. Probably the suggested difference is not real, due to one possible outlier in each pro-
file, resulting in a mean based bias and higher standard deviations. Hence, both sampling 
methods might be similar. The expected influence of flow rate on dissolution profile rank or-
der (5 ml/min fastest, 0.5 ml/min slowest profile) was not detectable, due to the large stand-
ard deviation. One possible reason for the high variability might be the membrane material. 
The membrane has a small “pore” diameter for retaining undissolved particles. Hence, the 
small pores avoid a homogenous fluid stream in the cell and thus a homogenous wetting of 
the substance particles.  
As shown in literature for paddle apparatus, Franz cell, and Transwell® dissolution process 
depends on the particle mass deposited on the membrane [55,61,131]. With increasing parti-
cle mass, dissolution profiles become slower. Under this assumption the expected rank order 
is not reached for the flow through cell, which is seen individually not critical, but for flow 
through cell no other tendency is detectable. In contrast, once the dissolution profile with the 
smallest FPD is fastest, once the one with the highest FPD is fastest. 
The difference between recalculated FPD on experiment filter and reference filter is from 
dose collection point inexplicable, due to homogenous amounts on the membranes during 
pre-tests (Table 4.8). Conceivable might be a concentration processes or accumulation in-
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side the flow through cell during dissolution experiment [105]. However, the same effect has 
to be discoverable for the diffusion experiment, but this is not given. 
Furthermore, definition depending the open set up provides sink conditions [82,105,106,108] 
during the different experiments some samples showed even a higher concentration than 
solubility. Consequently, sink conditions weren’t given over the whole dissolution process 
and the dissolution process is affected. 
The last critical point is the data treatment. Due to the open set up, one sample represents 
the amount dissolved at a specific time interval. For a “traditional” dissolution profile these 
data has to be transformed into the cumulative form, with the consequence of mistake drag-
ging [108]. As already described above calculation was double checked with a different ap-
proach, hence mistakes concerning the calculation are avoided. 
 
Concerning the unexplainable problems with the new designed flow though cell for inhalation 
powders this technique is not advisable for dissolution testing of powders for inhalation. 
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4.4. Franz Cell 
 
4.4.1. Diffusion test 
As already shown in the general membrane permeation test (chapter 4.1.4) the permeability 
of the membrane depends on membrane material as well as on substance membrane inter-
actions. In Figure 4.19 the results of diffusion test for the IPC membrane, in Figure 4.20 the 
results for the regenerated cellulose membrane are displayed 
For Budesonide and Substance A amorphous base membrane permeation for IPC and RC is 
similar. For the crystalline base a trend is difficult to state because of large variability. For 
Fenoterol the diffusion through the IPC is faster and less variable compared to the regener-
ated cellulose membrane. The overall comparison of diffusion behavior through the IPC 
membrane is difficult due to large standard deviation for Substance A (Figure 4.19). Compar-
ison between substances beside Fenoterol show quite similar diffusion through the regener-
ated cellulose membrane for all substances (Figure 4.20). Diffusion of Fenoterol through the 
membranes is much faster than for all other APIs.  
 
 
Figure 4.19: Diffusion of substances through IPC membrane 
Fenoterol HBr (orange dot), Substance A amorphous base (light green triangle), Budesonide (blue 
square) and Substance A crystalline base (dark open triangle), mean ± SD, n = 3, error bars are in all 
cases existent but sometimes too small to be displayed 
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Figure 4.20: Diffusion of substances through RC membrane 
Fenoterol HBr (orange dot), Substance A amorphous base (light green triangle), Budesonide (blue 
square) and Substance A crystalline base (dark open triangle), mean ± SD, n = 3, error bars are in all 
cases existent but sometimes too small to be displayed 
 
4.4.2. Dose collection and dissolution testing 
In Figure 4.21 the influence of fine particle mass collected on the membrane (Table 4.12) on 
the dissolution profiles for Fenoterol and Budesonide is displayed. Fenoterol shows a faster 
dissolution process than Budesonide due to its higher solubility (43 mg/ml, Budesonide 
17 µg/ml) (Table 4.2). Furthermore, the dissolution profiles of Fenoterol for FPD of 
131.7 µg ± 16.6 µg and 1201.9 µg ± 260.2 µg on the membrane are not significant different. 
For Budesonide a FPD on membrane dependency of the dissolution profile could be shown. 
The dissolution process with 189.7 µg ± 15.5 µg membrane loading is much faster than the 
profile with a FPD of 1151.3 µg ± 7.8 µg. It is obvious that for Budesonide “1 mg” only a few 
particles are widespread on the membrane, whereas for Budesonide “10 mg” the suface is 
completely covered, and the particles are agglomerated. The influence of the agglomerates 
and therefore a reduced surface area is larger for Budesonide than for Fenoterol. Reason 
could be found in the high solubilty of Fenoterol. Due to the high wettability and solubility of 
Fenoterol the dissolution rate is almost independent of available surface area in this context.. 
In contrast, for Budesonide the wettability and solubility are poor and the dissolution rate 
depends strongly on the available surface. 
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Figure 4.21: Influence of FPD on membrane on the dissolution of Budesonide and Fenoterol HBr 
RC membrane, Fenoterol HBr 1 mg (open orange dot), Fenoterol HBr 10 mg (dark orange dot), 
Budesonide 1 mg (open blue square) and Budesonide 10 mg (dark blue square), mean ± SD, n = 3, 
error bars are in all cases existent but sometimes too small to be displayed, SEM picture for 
Budesonide 1 mg and Budesonide 10mg 
 
 
Table 4.12: Summary of substance, membrane material, powder weight into capsule, recalculated 
FPD on filter (mean ± SD) and MDT (mean ± SD). The amount on membrane is recalculated from the 
maximum dissolved amount and the remaining particles on the membrane as described in chapter 
3.6.1  
 
substance membrane 
material 
powder 
weight 
[mg] 
recalculated 
FPD on filter [µg] 
n = 3 
MDT [min] 
 mean ± SD mean ± SD 
Budesonide 
IPC 1 195.3 ± 29.2 78.3 ± 24.7 
RC 
1 189.7 ± 15.5 80.7 ± 19.5 
10 1151.3 ± 7.8 248.9 ± 40.1 
Fenoterol 
IPC 10 1286.4 ± 70.4 1.7 ± 0.3 
RC 1 131.7 ± 16.6 2.6 ± 0.1 
10 1201.9 ± 260.2 4.5 ± 1.0 
Substance A crys-
talline Base 
IPC 
1 
281.2 ± 63.6 488.0 ± 9.7 
RC 100.2 ± 15.5 467.6 ± 73.1 
Substance A 
amorphous base 
IPC 
1 
106.3 ± 16.8 67.9 ± 32.3 
RC 97.8 ± 9.5 42.8 ± 14.4 
Substance A Br2 
IPC 
1 
102.3 ± 49.8 48.7 ± 32.4 
RC 80.8 ± 30.2 10.7 ± 3.1 
 
In Figure 4.22 and Figure 4.23 the dissolution profiles and in Table 4.12 the MDT for the dif-
ferent substances using RC and IPC membrane are shown. The rank order of dissolution 
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profiles for both membrane types is identical: Fenoterol – Substance A dibromide and Sub-
stance A amorphous base - Budesonide – Substance A crystalline base. This rank order, 
except Substance A dibromide and Substance A amorphous base depends on the solubility 
(Table 4.2). Assuming same particle density, spherical shape and similar aerodynamic and 
geometric diameter the reason for similar dissolution profile despite different solubility for 
Substance A dibromide and Substance A amorphous base could be found in particle size 
distribution (Table 4.6). The aerodynamic particle size distribution for Substance A amor-
phous base shows a higher rate of fine particles than for Substance A dibromide. The solubil-
ity rate of the substance beside others depends also on particle size. With decreasing parti-
cle diameter the surface increases dramatically, resulting in a faster dissolution for small par-
ticles.  
Comparison between IPC and RC membrane type shows for Budesonide and Fenoterol for 
IPC a faster dissolution and for Substance A vice versa. The membrane permeation tests 
show a higher permeability for Fenoterol and Budesonide through the IPC than the through 
RC membrane (Figure 4.7, Figure 4.19, and Figure 4.20) due to smaller membrane-
substance interactions. For Substance A diffusion test through the IPC membrane (Figure 
4.19) displays a high standard deviation, because of larger interactions with the membrane 
material. 
 
 
Figure 4.22: Dissolution profiles using RC membrane 
Fenoterol HBr 10 mg (dark orange dot), Substance A Br2 (green x), Substance A amorphous base 
(light green triangle), Budesonide 1 mg (open blue square) and Substance A crystalline base (dark 
open triangle), mean ± SD, n = 3, error bars are in all cases existent but sometimes too small to be 
displayed 
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Figure 4.23: Dissolution profiles using IPC membrane 
Fenoterol HBr 10 mg (dark orange dot), Substance A Br2 (green x), Substance A amorphous base 
(light green triangle), Budesonide 1 mg (open blue square) and Substance A crystalline base (dark 
open triangle), mean ± SD, n = 3, error bars are in all cases existent but sometimes too small to be 
displayed 
 
A further step in data interpretation is the comparison of diffusion and dissolution profiles. 
First there are membranes depending differences.  
Regarding the IPC membrane (Figure 4.19 and Figure 4.23), as expected the diffusion profile 
of Budesonide and Substance A base is much faster than the dissolution profile, but for Fe-
noterol it is inverted. For the RC membrane (Figure 4.20 and Figure 4.22) as expected for 
Substance A crystalline base the diffusion process is faster than the dissolution plus diffusion 
through the membrane. For Budesonide both profiles are quite similar. As already described 
for the IPC membrane for Fenoterol and also for Substance A amorphous base the dissolu-
tion process is faster than the diffusion. 
This phenomenon could be explained with Fick’s First law [45]. For Fenoterol and Substance 
A, respectively the diffusion gradient across the membrane of solid particles is higher than 
the gradient of the substance-solution. Therefore, the dissolution profile is faster than the 
diffusion profile. 
 
It is noticeable that using the RC membrane the dissolved amount never exceeds 90 %. Fur-
thermore, the reproducibility is reduced using the RC membrane. In Figure 4.24 the mean 
relative standard deviations (RSD) of the two membrane types are plotted against each oth-
er. For the IPC a higher reproducibility could be found. Likely is the swelling of the regener-
ated cellulose membrane and therefore a wave or wrinkle formation of the membrane, due to 
the clamping in the membrane holder.  
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Figure 4.24: Comparison of reproducibility using IPC or RC membrane in Franz cell 
Budesonide 1 mg (open blue square), substance A crystalline base (open green triangle), substance A 
amorphous base (light green triangle), substance A Br2 (green x) Fenoterol (dark orange dot),  
relative standard deviation (RSD) [%], n = 3, less symbols in the respective part above or below the 
bisecting line means less variability and higher reproducibility. Therefore, the IPC is more suitable for 
dissolution testing in Franz Cell than the RC membrane. 
 
Particles on top of the wrinkles are less or even not wetted and hence have a reduced disso-
lution rate or do not dissolve compared to particles being wetted and being in contact with 
the dissolution medium. 
For visualization of the wetting problems methylene blue was placed onto the membrane. 
Also the substance is not homogenous distributed on the membrane Figure 4.25 demon-
strates the inhomogeneous wetting of methylene blue due to swelling of the regenerated cel-
lulose membrane. In areas with direct contact to the dissolution medium methylene blue is 
fast dissolved whereas on the peaks only low dissolution takes place. 
 
   
Figure 4.25: regenerated cellulose membrane in adapted Franz Cell membrane holder with methylene 
blue 
a) methylene blue powder on the clamped membrane, without dissolution medium contact 
b) after a few seconds dissolution medium contact 
c) after a few minutes dissolution medium contact 
a b c 
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Nevertheless, for Substance A dibromide and amorphous base using the IPC membrane the 
standard deviations are also quite large. One reason could be found in air bubbles beneath 
the membrane, which is described in literature as typically Franz Cell problem [112,114,116]. 
Due to the air bubbles no consistent wetting is possible. 
 
The use of MDT as reporting method is difficult. The trends displayed for MDT compared to 
the dissolution profiles are not in all cases consistent. For example the profiles of Substance 
A amorphous base and dibromide using the RC membrane are similar but the MDT suggests 
a difference. A detailed discussion on the MDT “problematic” is following in the chapter 5.1.1. 
Concerning the dissolution profiles Franz cell could discriminate between good and poor sol-
uble substances. For substances with low solubility the deposited mass on the membrane 
has a larger effect than for good soluble substances. A higher mass loading leads to almost 
complete coverage of the membrane with particles, forming heaps and agglomerates. These 
agglomerates compared to a single particle, have a smaller surface resulting in a slower sol-
ubility rate. Furthermore, a wetting of the inner particles in agglomerates is more difficult than 
the wetting of a single particle, resulting in a more decreasing of the solubility rate. 
 
The Franz cell for dissolution testing of inhalation powders has a limited applicability, due to 
complicated handling and the risk of air bubbles beneath the membrane.  
Therefore, further experiments especially concerning the mass on membrane were per-
formed with the paddle apparatus. 
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4.5. Transwell® Dissolution System 
 
4.5.1. Addition of a dissolution layer on the membrane 
The use of the additional diffusion layer was expected to be beneficial relating to the repro-
ducibility and acceleration of dissolution. A closed view on the profiles of the different sub-
stances shows substance depending differences.  
Using a regenerated cellulose membrane for Budesonide in the first 20 minutes the profiles 
show no difference (MDT Table 4.13). During further progress of dissolution the profile with-
out additional dissolution medium reaches almost 100 % with small error bars. In contrast the 
profile with additional dissolution medium reaches in middle 70 % with large error bars. The 
observed effect is not mass depending, because the FPDs on the membranes are quite simi-
lar (Table 4.13, page 89). The expected benefit of the additional dissolution layer is only visi-
ble for Substance A crystalline base at the beginning of the dissolution process (Figure 4.26). 
In the further progress of dissolution the two profiles converge. The expected acceleration of 
the dissolution process by adding an additional layer is not given. The plateau phase for 
Substance A crystalline base was not reached after 240 min, hence calculation of MDT is not 
meaningful.  
 
 
Figure 4.26: Influence of dissolution layer on the dissolution process using the RC membrane. 
Additional diffusion layer (full symbols), without additional diffusion layer (open symbols), Budesonide 
(blue squares), Substance A crystalline base (dark green rhombs), mean ± SD, n = 3  
 
For Substance A amorphous base and the dibromide dissolution profiles with and without 
dissolution layer appear to be similar. The results of MDT calculation (Table 4.13, page 89) 
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and the dissolution profiles for Substance A dibromide (Figure 4.27) show not the same re-
sults. Whereas the profiles show a similarity (f1 = 9.9, f2 = 61.7) the MDT does not. For the 
amorphous base MDT with dissolution layer is shorter than without layer. 
 
 
Figure 4.27: Influence of dissolution layer on the dissolution process using the RC membrane. 
Additional diffusion layer (full symbols), without additional diffusion layer (open symbols), Substance A 
amorphous base (light green triangles), Substance A Br2 (green X), mean ± SD, n = 3  
 
In Figure 4.28 the data variability indicates that dissolution profiles with dissolution layer 
show a similar to even smaller reproducibility than without dissolution layer, with the excep-
tion of the amorphous base. 
 
Figure 4.28: Comparison of reproducibility with and without dissolution layer using the RC membrane 
Budesonide (blue square), Substance A amorphous base (light green triangle), Substance A crystal-
line base (dark green rhomb) and Substance A Br2 (green X). 
Relative standard deviation (RSD) [%], n = 3, symbols in the respective part above or below the bi-
secting line mean less variability and higher reproducibility. Therefore, performance without dissolution 
layer is more suitable for dissolution testing in Transwell® system than with dissolution layer. 
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Table 4.13: Summary of used substances and membrane material with corresponding dissolution set  
up, recalculated FPD on filter (mean ± SD) and MDT (mean ± SD), dl = dissolution layer, + = with, - = 
without, rpm = stirring, n.p. = calculation not possible, because profile “plateau” was too low 
 
substance mem-
brane 
material 
additional information recalculated 
FPD on filter 
[µg] n = 3 
MDT [min] 
 mean ± SD mean ± SD 
Budesonide 
PC 
+ dl, + rpm 5.5 ± 0.7 
n.p. 
- dl, + rpm 5.9 ± 1.5 
RC 
+ dl, + rpm 3.9 ± 1.5 12.8 ± 2.6 
- dl, + rpm 4.2 ± 0.2 16.6 ± 0.7 
- dl, - rpm 5.2 ± 0.6 40.6 ± 13.3 
PE 
- dl, + rpm 4.4 ± 0.5 21.6 ± 8.9 
- dl, - rpm 4.4 ± 0.5 40.5 ± 15.8 
IPC 
- dl, + rpm 15.2 ± 1.0 40.4 ± 6.3 
- dl, - rpm 17.7 ± 0.5 94.6 ± 4.6 
-dl, + rpm, 0.02%DPPC 16.5 ± 0.8 54.5 ± 1.7 
-dl, + rpm, 0.02%Alveof 18.8 ± 1.9 41.9 ± 2.6 
Substance A 
crystalline 
base 
PC 
+ dl, + rpm 
- dl, + rpm 
5.6 ±1.7  
n.p. 
6.7 ± 5.0 
RC 
+ dl, + rpm 3.8 ± 0.5 n.p. 
- dl, + rpm 3.8 ± 0.6 103.0 ± 3.0 
- dl, - rpm 2.3 ± 0.1 112.4 ± 3.8 
PE 
- dl, + rpm 5.2 ± 0.5 
n.p. 
- dl, - rpm 3.5 ± 0.7 
IPC 
- dl, + rpm 15.8 ± 1.3 
n.p 
- dl, - rpm 16.9 ± 1.5 
-dl, + rpm, 0.02%DPPC 17.9 ± 1.2 112.4 ± 0.7 
-dl, + rpm, 0.02%Alveof 15.4 ± 1.4 109.7 ± 1.4 
Substance A 
amorphous 
base 
PC 
+ dl, + rpm 
- dl, + rpm 
26.2 ± 5.4 
n.p. 
37.8 ± 5.6 
RC 
+ dl, + rpm 9.0 ± 0.5 6.9 ± 1.5 
- dl, + rpm 8.6 ± 0.9 13.6 ± 10.1 
 - dl, - rpm 1.8 ± 0.1 29.7 ± 6.9 
PE 
- dl, + rpm 6.5 ± 1.0 
n.p. 
- dl, - rpm 10.4 ± 3.3 
IPC 
- dl, + rpm 17.6 ± 4.3 16.9 ± 3.9 
- dl, - rpm 33.1 ± 7.6 27.9 ± 4.7 
-dl, +rpm, 0.02%DPPC 27.3 ± 3.7 18.4 ± 1.4 
-dl, +rpm, 0.02%Alveof 28.8 ± 6.9 15.9 ± 1.8 
Substance A 
Br2 
PC 
+ dl, + rpm 
- dl, + rpm 
7.1 ± 1.5 
n.p. 
12.0 ± 1.2 
RC 
+ dl, + rpm 2.2 ± 0.2 14.6 ± 3.0 
- dl, + rpm 3.2 ± 0.5 6.5 ± 2.8 
- dl, - rpm 1.6 ± 1.0 36.4 ± 9.7 
PE 
- dl, + rpm 3.5 ± 1.6 n.p. 
- dl, - rpm 1.6 ± 0.5 
IPC 
- dl, + rpm 19.6 ± 2.5 4.4 ± 0.5 
- dl, - rpm 4.9 ± 0.3 24.7 ± 7.0 
-dl, +rpm, 0.02%DPPC 25.3 ± 2.1 10.1 ± 4.9 
-dl, +rpm, 0.02%Alveof 17.1 ± 0.4 15.3 ± 3.6 
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Furthermore, the impact of the dissolution layer was tested for the PC membrane (Figure 
4.29). The membrane permeation tests (Chapter 4.1.4) provide only for Substance A base a 
low diffusibility. It appears that for Substance A base the additional dissolution layer increas-
es the dissolution process in the first 50 minutes, later the profiles converge. For Budesonide 
and Substance A dibromide data variability is too high, so a conclusion is not possible 
 
 
Figure 4.29: Influence of dissolution layer on the dissolution process using the PC membrane. 
Additional diffusion layer (full symbols), without additional diffusion layer (open symbols), Budesonide 
(blue square) Substance A amorphous base (light green triangles), Substance A Br2 (green X) and 
Substance A crystalline base (dark green rhomb) mean ± SD, n =3 
 
The impact of the dissolution layer is substance dependent but in most cases leads to higher 
variability of the dissolution profiles and is consequently not advantageous. Under the as-
sumption that the 40 µl are uniformly distributed on the membrane, PBS buffer has a height 
of 88 µm; so particles with diameters of less than 5 µm are covered. As already described 
the contact angle measurement provides a hydrophilic character of the membranes (RC con-
tact angle < 20°) (Table 4.10). Hence, the buffer spreads over the membrane and a uniform 
layer could be assumed. This uniform layer was confirmed by an optical inspection during the 
test. Nevertheless, the substance particles on the membrane showed still a poor dissolution 
rate. 
 
4.5.2. Stirring 
Due to the poor solubility for Substance A crystalline base (cs = 7 µg/ml) stirring has the 
smallest effect (RC, Figure 4.32) or even no effect (IPC Figure 4.30 and PE Figure 4.34). 
The profiles for the crystalline base are similar as well as for the PE and IPC membrane. As 
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expected due to a better homogenization of the dissolution medium, using the IPC and the 
RC membranes stirring leads to faster dissolution and higher dissolved amounts for all other 
tested substances (Figure 4.30 - Figure 4.35).  
 
 
Figure 4.30: Dissolution profiles by the use of IPC membrane with (full symbols) and without (open 
symbols) stirring  
Budesonide (blue squares), Substance A crystalline base (dark green rhombs), mean ± SD, n = 3, 
error bars are in all cases existent but too small to be displayed 
 
 
Figure 4.31: Dissolution profiles by the use of IPC membrane with (full symbols) and without (empty 
symbols) stirring 
Substance A amorphous base (light green triangle), Substance A Br2 (green X), mean ± SD, n = 3, 
error bars are in all cases existent but sometimes too small to be displayed 
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Figure 4.32: Dissolution profiles by the use of RC membrane with (full symbols) and without (open 
symbols) stirring  
Budesonide (blue squares), Substance A crystalline base (dark green rhombs), mean ± SD, n = 3, 
error bars are in all cases existent but sometimes too small to be displayed 
 
 
 
Figure 4.33: Dissolution profiles by the use of RC membrane with (full symbols) and without (open 
symbols) stirring 
Substance A amorphous base (light green triangle), Substance A Br2 (green X), mean ± SD, n = 3, 
error bars are in all cases existent but sometimes too small to be displayed 
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As expected from the membrane permeation test chapter 4.1.4 the dissolution profile plat-
eaus using the PE membrane (Figure 4.34 and Figure 4.35) are on a low level (< 40% dis-
solved amount). Due to the hindered diffusion process using the PE membrane, the dissolu-
tion process is probably also slowed down. For Budesonide the dissolution profile plateau in 
the unstirred set up for the PE membrane reaches in contrast to the other membrane types a 
higher plateau (30%), than the stirred one (<20%) (Figure 4.34).  
 
 
Figure 4.34: Dissolution profiles by the use of PE membrane with (full symbols) and without (open 
symbols) stirring  
Budesonide (blue squares), Substance A crystalline base (dark green rhombs), mean ± SD, n = 3, 
error bars are in all cases existent but sometimes too small to be displayed 
 
The corresponding MDT and FPD are summarized in Table 4.13 (page 89). As already de-
scribed above again MDT is not in all cases consistent with the corresponding dissolution 
profiles. For Substance A amorphous base (IPC, with and without stirring) the dissolution 
profiles are similar whereas the MDT is different.  
For comparison of dissolution profiles it is mandatory that particle size distribution and drug 
loading are almost identical [55,61,131]. In Table 4.13 (page 89) FPD of the different sub-
stances on the membrane for dissolution tests are summarized. The membrane loading is 
found to be very similar for PE and PC membrane. Hence, differences in the dissolution pro-
files are not mass effects but caused by the method used. A FPD-based comparison of IPC 
and RC for stirred / non stirred has to be done carefully, due to significant different masses 
on the membrane. For RC although at the non stirred experiments a lower mass is on the 
membrane, the dissolution process for the stirred experiments is faster. For experiments in-
cluding the IPC membrane on the substances has to be looked individually. For Substance A 
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crystalline base the absence of any effect of stirring is most likely based on the poor solubili-
ty. This is supported by the equal mass and homogeneous mass distribution on the mem-
brane thus not influencing the dissolution profile. For Budesonide the large difference be-
tween the dissolution profiles could be definitely explained by the positive effect of stirring, as 
the particle mass on the membrane is similar and hence has no effect. 
 
 
Figure 4.35: Dissolution profiles by the use of PE membrane with (full symbols) and without (open 
symbols) stirring 
Substance A amorphous base (light green triangle), Substance A Br2 (green X), mean ± SD, n = 3, 
error bars are in all cases existent but sometimes too small to be displayed 
 
In Figure 4.36 RSD of substances for the different membrane types and substances are 
compared. The use of stirring during dissolution test is beneficial due to faster distribution of 
the dissolved substance in the acceptor chamber [114] and hence an increased reproducibil-
ity. These positive aspects of stirring in the Transwell® dissolution system were underlined 
by the results of Bhagwat et al. [62]. Mechanistically the advantageous effect of stirring is 
based on acceleration of diffusion phenomena [147]. Directly under the membrane in accep-
tor medium the concentration of API is highest, without stirring the dissolution is limited be-
cause of the high surrounding concentration. Hence, diffusion of API to areas with lower con-
centration in the acceptor medium is the rate determining step. With stirring a concentration 
gradient through the membrane is established and the rate determining step is the dissolu-
tion of the particles.  
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Figure 4.36: Comparison of reproducibility with and without stirring for different membrane types 
a) RC, b) IPC and c) PE membrane 
Budesonide (blue square), Substance A amorphous base (light green triangle), Substance A crystal-
line base (dark green rhomb) and Substance A Br2 (green X) 
Relative standard deviation (RSD) [%], n = 3, less symbols in one triangle divided through the bisect-
ing line means less variability and higher reproducibility. Therefore, stirring is more suitable for dissolu-
tion testing in Transwell® system than without. 
 
4.5.3. Comparison of the two different polycarbonate membranes 
As already mentioned above, from the membrane permeation tests the low dissolved / dif-
fused amounts of Budesonide and Substance A dibromide using the PC membrane was un-
expected. The dissolution profiles of all substances never reach more than 20% of drug in 
the receptor compartment (Figure 4.37 and Figure 4.38). 
 
 
Figure 4.37: Dissolution profiles with the use of PC (open symbols) and IPC (full symbols) membrane, 
respectively. Set up was with stirring of the dissolution medium and without dissolution layer, Sub-
stance A amorphous base (light green triangles), Substance A Br2 (green X), mean ± SD, n = 3. Error 
bars are in all cases existent but sometimes too small to be displayed 
 
a b c 
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Figure 4.38: Dissolution profiles with the use of PC (open symbols) and IPC (full symbols) membrane, 
respectively. Set up was with stirring of the dissolution medium and without dissolution layer, 
Budesonide (blue squares), Substance A crystalline base (dark green rhombs), mean ± SD, n = 3. 
Error bars are in all cases existent but sometimes too small to be displayed 
 
Remarkable are the large differences between the polycarbonate membranes. But neverthe-
less, interestingly is also the high reproducibility of each dissolution profile for PC and IPC. 
IPC membranes show a higher permeability of dissolved substance than PC membranes for 
all used APIs. Bhagwat et al. also described problems with the PC membrane. They cut the 
membrane out and used instead a glass micro fiber filter [62]. Therefore, the differences be-
tween the membranes need to be identified. Both have a comparable pore number per cm2 
(PC: 1 x 108 pores / cm2, IPC: 1.5 x 108 pores / cm2) and SEM pictures show a similar ap-
pearance (Figure 4.39). Due to the substance specific differences in membrane permeation 
tests (chapter 4.1.4) and a larger difference in the dissolution profiles for all substances 
(Figure 4.37 and Figure 4.38), a direct comparison of the set ups between the two mem-
branes for Budesonide (Figure 4.39) and contact angle measurements were performed. The 
results in Figure 4.39 support the already found differences in permeability and demonstrate 
that the results are not depending on the Transwell® set ups. For the IPC the modified insert 
with a sieve is used where the membrane is placed on, consequently there is a small gap 
between membrane and insert wall. This gap does not exist in the unmodified insert. For this 
reason, the PC membrane was cut out after dose collection and placed into the modified in-
sert. A direct comparison of the profiles demonstrates again the large difference in between 
PC and IPC membrane (Figure 4.39) indicating the crucial role of the material. Additionally, 
an edge perforation of the Transwell® PC membrane was tested to avoid cutting but allow for 
an easier access of buffer onto the membrane. But with this set up no effect could be shown, 
too. The advanced contact angle measurement with water showed for PC membrane a con-
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tact angle of 63° ± 9° and for IPC of 57° ± 2° (Table 4.10). These contact angles underline 
the hydrophilic character of both membranes, as described in the manufacturer information. 
But the higher variability for the PC membrane indicates that there might be hydrophilic and 
hydrophobic hot spots. The hot spots could be explained with the “tissue culture treatment” of 
PC membrane by the manufacturer. Due to this process the membrane surface becomes 
hydrophilic and especially negatively charged when medium is added [148]. Furthermore, the 
tissues culture treating agent might interact with the substances. Hence, substance dissolu-
tion through the PC membrane is hindered. 
 
 
Figure 4.39: Budesonide dissolution profiles by the use of PC membrane and IPC membrane: IPC 
(blue line), PC Transwell® membrane cutted with modified Transwell® insert (red line), PC Transwell® 
insert (red square). PC Transwell® Insert perforated edge (open red square), mean ± SD, n = 3 
SEM pictures of IPC (up) and PC (down) membrane 
 
 
4.5.4. Surfactants 
Figure 4.40 displays the influence of surfactants added to the dissolution medium in the 
Transwell® system on the dissolution using the IPC membrane. Table 4.13 (page 89) sum-
marizes the MDTs and Table 4.14 (page 99) the results of dissolution profile comparison 
regarding fit factors. The IPC membrane was chosen due to the best results in the aforemen-
tioned dissolution tests.  
For Substance A base the dissolution process is not significantly accelerated by the addition 
of DPPC to the dissolution medium. For Substance A dibromide and Budesonide the dissolu-
tion profiles indicate a slower dissolution process. For the dibromide this trend is not signifi-
cant. The results of the visual comparison of the profiles are supported by test of similarity 
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with the fit factors. For the crystalline base there is a small increase of dissolution by the use 
of DPPC, but fit factors provide contradictory results. 
 
 
Figure 4.40: Comparison of dissolution profiles using surfactants 
0.02% DPPC (symbol), 0.02% Alveofact (dashed line), buffer (no symbol), Substance A Br2 (green X), 
Substance A amorphous base (light green triangle), Budesonide (blue square) and Substance A crys-
talline base (open dark green triangle), mean ± SD, n = 3, error bars are in all cases existent but 
sometimes too small to be displayed  
 
DPPC is a surface active substance and was used to improve the wettability of the used 
substances. Solubility tests show (Table 4.2) for Budesonide and Substance A crystalline 
base no or low improvement of the solubility, for Substance A amorphous base a decreased 
and for Substance A dibromide an increased solubility. The effect of wettability / solubility 
improvement depends strongly on the hydrophobic structures in the API molecules. Further-
more, the measurement of the micelle size for DPPC with dynamic light scattering showed a 
large micelle / object size (Table 4.3). As already shown by Son et al., these objects are too 
large for traveling through the pores with a diameter of 0.4 µm [55]. But the micelles are only 
a reservoir for the remaining DPPC, in addition there are also free DPPC molecules [31] 
which could pass the membrane pores and increase wettability or solubility on the donor site. 
Alveofact® a medicine with 50.76 - 60.00 mg phospholipids (66 µmol) should show similar 
results to DPPC. 
As displayed in Figure 4.40 addition of Alveofact® to the dissolution medium results in sub-
stance depending different dissolution profiles compared to PBS buffer. But the trends shown 
for DPPC, besides Budesonide, are similar. Therefore, the hypothesis of similar results for 
dissolution medium with DPPC and Alveofact® was achieved. With 0.02% addition of Alve-
ofact® to the dissolution medium, for Substance A base dissolution is accelerated, for the 
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dibromide the dissolution process is slower. The effect of Alveofact® on the dissolution pro-
file of Budesonide is contradictory to DPPC. The profile with Alveofact® and of pure buffer 
show similar dissolution profiles.  
 
Table 4.14: f1 and f2 test results 
 
 f1 f2 
similarity? 
profiles similar < 15 50-100 
Substanz A Br2    
normal vs. DPPC 7.0 64.3 yes 
DPPC vs. Alveofact 7.7 61.3 yes 
Alveofact vs. normal 18.0 47.5 no 
Substanz A amorphous base    
normal vs. DPPC 9.4 61.0 yes 
DPPC vs. Alveofact 5.7 65.5 yes 
Alveofact vs. normal 13.4 50.1 yes 
Substanz A crystalline base    
normal vs. DPPC 61.6 69.3 inconsistent 
DPPC vs. Alveofact 66.1 58.0 inconsistent 
Alveofact vs. normal 41.1 51.2 inconsistent 
Budesonide    
normal vs. DPPC 13.5 54.5 yes 
DPPC vs. Alveofact 18.7 53.9 inconsistent 
Alveofact vs. normal 3.8 8.2 yes 
 
Summarizing, adding of 0.02% DPPC or Alveofact® to the dissolution medium show a slight 
acceleration of dissolution process for Substance A base, although there is no effect on sol-
ubility, which provides the hypothesis of a better wettability. The wettability improvement for 
DPPC is underlined by the results of contact angle measurements of substance pellets 
(Table 4.7). For Substance A dibromide although solubility is increased, the dissolution rate 
decreases using these surfactants. These results are confirmed by the contact angle meas-
urements. They show by the use of DPPC a better wettability of the substances, but are due 
to the high variability not meaningful. 
 
The results for Budesonide are contradictory to those of Arora et al.. They showed for 
Budesonide a dissolved amount of 50 - 80% within 5 hours using the PE membrane with an 
additional dissolution layer [61]. In this thesis it was demonstrated that the PE membrane 
itself is hindering permeation of already dissolved Budesonide and therefore, the effect ob-
served by Arora et al. is membrane and not substance depending. 
It should be noted that before dissolution tests are started first a suitable membrane has to 
be chosen. Therefore, membrane permeation tests are mandatory. If this is considered, the 
modified Transwell® is a suitable dissolution test for powders of inhalation.  
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The usage of an additional dissolution layer is not beneficial but stirring of the acceptor me-
dium is advantageous.  
In future this in vitro test might be advanced for performing cell- and tissue based in vitro 
models as next step. As dose collection method for depositing the fine particles directly on 
the cell layer for example the PADDOCC system [149] could be used. A further step could be 
an in vitro in vivo correlation, as tried by Bhagwat et al. [62]. They used 0.5% SDS in the dis-
solution medium for improving solubility and therefore getting comparable results to pharma-
cokinetic studies. But the usage of SDS can be critical, due to a large improvement of solubil-
ity and therefore discrimination power between different substances could vanish.  
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4.6. Paddle Apparatus 
 
4.6.1. Stirring speed 
Figure 4.41 shows the dissolved amount of Budesonide in the paddle apparatus with mem-
brane holder at different stirring speeds. MDT is summarized in Table 4.15. The profiles of 
100 rpm and 140 rpm are similar (Table 4.16, page 118) but at 140 rpm the SD was smaller. 
50 rpm showed as expected compared to 140 rpm the slowest dissolution profile due to an 
assumed correlation between stirring speed and dissolution rate [46]. With increasing stirring 
speed the diffused amount at the membrane is faster reduced and hence more dissolved 
substance could diffuse through the membrane. A stirring speed of more than 140 rpm was, 
however, not possible because the membrane holder was irregularly moving at higher 
speeds. Son et al. mentioned already a dead volume between membrane holder and bottom 
of the vessel and that circulation of dissolution medium is hindered between the holder and 
the vessel wall around the holder [55]. The lag time for reaching the dead volume of dis-
solved substance at a stirring speed of 100 rpm is approximately 3 minutes, for 140 rpm ap-
proximately 2 minutes. Hence, a higher stirring speed ensures a faster circulation in the dead 
volume. Therefore, 140 rpm was chosen for all other experiments with the Erweka paddle 
apparatus.  
 
 
 
Figure 4.41: Influence of stirring speed on the dissolution profile of Budesonide 
RC membrane, aACI 140 rpm (blue rhomb), 100 rpm (black open square) and 50 rpm (green triangle), 
mean ± SD, n = 3, error bars are in all cases existent, but sometimes too small to be displayed 
 
 
Chapter 4.6 Paddle Apparatus 
 
102 
4.6.2. Influence of FPD on the dissolution process of Budesonide and Fenoterol 
In Figure 4.42 the influence of fine particle mass on the membrane (Table 4.15, page 117) on 
the dissolution process in the paddle apparatus for Fenoterol and Budesonide is displayed. 
The MDTs are summarized in Table 4.15. As it can be seen in Figure 4.42 the dissolution for 
Fenoterol is much faster than for Budesonide due to the higher solubility (Table 4.2). For 
Budesonide it could be shown that the dissolution process depends on the fine particle dose 
on the membrane. The dissolution process for 353 µg ± 114 µg deposited mass is much 
faster than the process with a FPD of 1892 µg ± 126 µg. For Fenoterol the mass dependency 
(272.4 µg ± 65.8 µg vs. 1582 µg ± 124 µg) (Table 4.15, page 117) is not significant and the 
two profiles appear to be similar. Both Fenoterol dissolution profiles reach the 85% limit with-
in 2 minutes. Hence, for fit factor tests the number of data points (n = 3) is too small [120].  
 
 
Figure 4.42: Influence of FPD on membrane for Budesonide and Fenoterol HBr 
RC membrane, aACI, Fenoterol HBr 1 mg (open orange dot), Fenoterol HBr 10 mg (dark orange dot), 
Budesonide 1 mg (open blue square) and Budesonide 10 mg (dark blue square), mean ± SD, n = 3, 
error bars are in all cases existent but sometimes too small to be displayed 
 
 
4.6.3. Comparison of different membrane materials 
In Figure 4.43 and Figure 4.44 the dissolution profiles and in Table 4.15 (page 117) the MDT 
for substances using RC and IPC membrane are shown. The rank order of dissolution pro-
files, due to solubility data, should be: Fenoterol – Substance A dibromide, Substance A 
amorphous base - Budesonide – Substance A crystalline base. In contrast to the Franz cell 
set up (Figure 4.22) for the RC membrane the rank order is as predicted by the solubility data 
and no similarity for the dissolution profiles could be shown (Table 4.16, page 118). Thus 
discrimination between all tested substances is possible.  
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Figure 4.43: Dissolution profiles using the RC membrane 
aACI, Fenoterol HBr 10 mg (dark orange dot), Substance A Br2 (green x), Substance A amorphous 
base (light green triangle), Budesonide 1 mg (open blue square) and Substance A crystalline base 
(open dark green triangle), mean ± SD, n = 3, error bars are in all cases existent but sometimes too 
small to be displayed 
 
 
Figure 4.44: Dissolution profiles using the IPC membrane 
aACI, Fenoterol HBr 10 mg (dark orange dot), Substance A Br2 (green x), Substance A amorphous 
base (light green triangle), Budesonide 1 mg (open blue square) and Substance A crystalline base 
(open dark green triangle), mean ± SD, n = 3, error bars are in all cases existent but sometimes too 
small to be displayed 
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For the IPC membrane as described for Franz cell there is no difference in dissolution pro-
files for Substance A dibromide and Substance A amorphous base (f1 = 7.6; f2 = 61.8 (Table 
4.16, page 118)). This could be explained by the different structure of the membrane. The 
IPC membrane has, due to the defined pores a stronger retention effect than the RC mem-
brane with the more spongy structure. Therefore, the particle size depending dissolution rate 
influence as already described for the Franz Cell (Figure 4.22) is stronger. The influence of 
particle size on the dissolution profile is supported by the results of the model calculation 
(chapter 4.7.5). 
 
 
 
Figure 4.45: Comparison of reproducibility using IPC or RC membrane in paddle apparatus 
Budesonide 1 mg (blue square), substance A crystalline base (green, white triangle), substance A 
amorphous base (light green triangle), substance A Br2 (green x), Fenoterol (dark orange dot),  
relative standard deviation (RSD) [%], n = 3, less symbols in the respective part above or below the 
bisecting line means less variability and higher reproducibility. Therefore, the RC is more suitable for 
dissolution testing in paddle apparatus than the IPC membrane. 
 
In Figure 4.45 the mean relative standard deviations (RSD) of the two membrane types are 
plotted against each other. The reproducibility of data for the both membrane types are com-
parable except for Substance A crystalline base. In contrast to the Franz cell (Figure 4.24) 
the RC membrane is the most suitable membrane in the paddle apparatus. Beside the higher 
reproducibility, it has the better discrimination power and the more convenient handling and 
therefore was chosen for the following experiments. 
The higher reproducibility using the RC membrane in paddle apparatus underlines the hy-
pothesis of inhomogeneous wetting in the Franz cell due to the swelling dependent defor-
mation of the clamped membrane (Figure 4.25). In contrast to the Franz cell in the mem-
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brane holder of the paddle apparatus the membrane has the chance to stretch during the 
swelling process, because it is not clamped rigidly. 
 
4.6.4. Equipment change 
Due to equipment change of dissolution apparatus from the Erweka to the Sotax apparatus 
comparison of the respective dissolution profiles was necessary. In the Sotax apparatus it is 
unfortunately not possible to use a higher stirring speed than 100 rpm. When the stirring 
speed is increased the membrane holder is moving irregularly. Therefore, a comparison of 
100 rpm and 140 rpm stirring speed in the Sotax paddle apparatus was not possible. As al-
ready described above for the Erweka apparatus the dissolution profiles using either 140 rpm 
or 100 rpm are similar. But with the decreased stirring speed the SD increases and the lag 
time for circulation in the dead volume under the membrane holder is increased. To prevent 
this irregular movement a stirring speed of 100 rpm was used in the further experiments with 
the Sotax paddle apparatus.  
Figure 4.46 and Table 4.18 show as expected similar profiles for the two dissolution tester. 
Remarkable are the different variability of the dissolution profiles. Astonishingly profiles of 
Budesonide in the Sotax apparatus show a higher reproducibility, probably due to different 
hydrodynamic conditions. The vessels have a deviating form and sampling in both apparatus 
is different as described above. In the Erweka apparatus sampling is performed through the 
shaft of the paddle. In the Sotax apparatus an additional small stable sleeve for sampling is 
placed in the vessel. 
 
 
Figure 4.46: Comparison of Erweka paddle apparatus and Sotax paddle apparatus 
RC membrane, Budesonide, mean ± SD, n = 3 
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4.6.5. Best dose collection method 
To overcome the problem of agglomerates on the membrane and therefore hindered dissolu-
tion the dose collection method had to be improved. The agglomerates are generated during 
dose collection with the aACI because the deagglomerated particles are impacted in line with 
the holes of the filter stage on the membrane. Hence, areas with a high amount of agglomer-
ated particles occur. 
As new approach spraying of substance on the membrane was tested as described in (chap-
ter 3.3.2, 3.5.5.1). With similar masses on the membrane the SEM pictures (Figure 4.47) 
underline a more homogenous distribution with fewer agglomerates resulting similar dissolu-
tion profiles (Figure 4.47; f1 = 9.2; f2 = 58.3 (Table 4.16, page 118)). Beneficial is the ability of 
using not only micronized powders and to be independent of the aACI. But for reaching the 
same amount on the membrane, a higher amount of powder has to be weighed into the anti-
solvent (chapter 3.3.2) which could be problematic if there is only a small amount of sub-
stance available. In addition, it is arguable if dichloromethane has any effect on substance 
properties.  
 
 
 
 
Figure 4.47: Comparison of dissolution profiles of Budesonide using the aACI or the airbrush for depo-
sition. IPC membrane, aACI (red cube), airbrush (blue rhomb), mean ± SD, n = 3, SEM pictures of 
Budesonide on IPC membrane above: after airbrush, down:aACI 
 
Therefore, the dose collection method with the aACI was adapted and a stage extension is 
inserted to allow sedimentation of the particles instead of impaction.  
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Figure 4.48 demonstrates the impact of the dose collection method on the dissolution profile. 
The dissolution process is slower by using the aACI than by the use of mACI having the 
same particle mass on the filter. The SEM pictures (Figure 4.49) illustrate that using the 
mACI a more homogenous particle distribution on the filter is obtained compared to the aACI 
were dark areas are visible. These areas are in line with the holes of the filter stage and con-
tain a high number of agglomerated particles. For the set up aACI + SE the dissolution profile 
is similar to the one with modified filter stage (mACI) (f1 = 1.2, f2 = 92.1 (Table 4.16, page 
118)). For getting better SEM pictures the amount of FPD on membrane is increased (ap-
proximately 1 mg). Therefore, for the aACI + SE set up are also the holes of the filter stage in 
form of darker areas visible as for the aACI set up. Nevertheless, the shape is not as clearly 
defined as for the aACI SEM pictures. For that reason it could be supposed that with increas-
ing FPD using the SE with normal filter stage the dissolution profile will approximate with the 
profiles of aACI. 
 
 
 
Figure 4.48: Dose collecting depending dissolution profiles of Budesonide 
mACI (red dot), aACI (blue squares) and aACI + SE (black triangle) mean ± SD, n = 3 with FPD on 
membrane mean ± min/max with SEM pictures (for details see Figure 4.49) 
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mACI aACI + SE aACI 
Figure 4.49: SEM pictures of regenerated cellulose with Budesonide after use of different dose collec-
tion methods (FPD on SEM picture membrane 1000 µg) 
 
The impact of particle mass on the dissolution process is shown in Figure 4.50, the higher 
the mass of particles on the membrane, the slower the dissolution. Although mass differ-
ences for aACI are the same compared to mACI the differences in dissolution profiles for 
aACI are much larger than for the mACI. Fit factors (f1 = 9.4; f2 = 59.1 (Table 4.16, page 
118)) confirm similarity of dissolution profiles for the mACI with different masses on the 
membrane. The fit factors show no similarity for the aACI profiles (f1 = 34.9; f2 = 30.8 (Table 
4.16)). Additionally, MDT was calculated, but the trends displayed in the profile could not 
been shown clearly with the MDT (Table 4.15, page 117). In contrast to the dissolution pro-
files the MDT displays similarity of aACI set ups.  
 
 
Figure 4.50: Mass dependent dissolution profile of Budesonide 
200 µg FPF on membrane (open bright symbols), 400 µg on membrane (closed dark symbols), mACI 
(red dots), a ACI (blue squares) mean ± SD, n = 3 with FPD on membrane mean ± min/max 
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Above with the Erweka apparatus an influence of particle mass (100 µg vs. 1000 µg) on 
membrane onto the dissolution process and therefore on the dissolution profile was already 
demonstrated. In the modelling section (Figure 4.58) it could be demonstrated, that the FPD 
on the membrane has only a negligible influence on the dissolution profile assuming optimal 
conditions, especially no agglomerates and therefore no dissolution interaction between the 
particle and its neighbors. Figure 4.50 demonstrates for areas with a high amount of particles 
even changes of less than 200µg mass on the membrane strongly influence the dissolution 
process. The mACI guarantees a homogenous particle distribution on membrane, resulting in 
smaller mass dependency of the dissolution process. 
In conclusion, a less mass depending dissolution profile is beneficial due to a reduced varia-
bility which indicates a higher robustness of the method. Although a higher weight of sub-
stance is necessary for mACI than for aACI, the amount is smaller than for the airbrush set 
up, furthermore the benefits of the new dose collection set up predominate this drawback. 
Consequently, mACI is a step to achieve optimum in vitro dissolution conditions. 
 
4.6.6. Comparison of different membrane holder types 
Figure 4.51 shows no significant difference between the different membrane holder setups 
and the fit factors (Table 4.16, page 118) indicate similarity.  
 
 
Figure 4.51: Dissolution profiles of Budesonide for different membrane holders 
mACI, membrane sandwich holder (light blue dots), membrane holder (blue squares), blocked mem-
brane holder (blue open squares), mean ± SD, n = 3 
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The blocked membrane holder was used to reduce the effect of diffusion over the edge of the 
membrane instead of diffusion direct through the membrane. Interestingly, with this set up an 
air liquid interface was created, too. 
Due to the reduced diffusion pathways for the blocking set up slower dissolution profiles than 
without blocking were expected. This could not be shown for Budesonide (Figure 4.51). 
Hence, most of the dissolved amount diffuses through the membrane and not over the edge 
between membrane and membrane holder. 
The idea behind the membrane sandwich holder was to reduce possible effects of the watch 
glass on the diffusion and therefore on the dissolution process. Comparison of the mem-
brane holder set up and the membrane sandwich holder shows no difference between the 
dissolution profiles (Figure 4.51, f1 = 5.8, f2 = 65.3 (Table 4.16, page 118)). Hence, most of 
the solution diffuses through the upper membrane. The reason could be found in the con-
stant movement of the paddle and thus low concentration of dissolved substance directly at 
the membrane. Consequently, the diffusion gradient is high and the dissolved substance 
moves faster through the upper membrane.  
Beneath the watch glass the dissolution medium is almost unstirred and convection is rela-
tively slow [55]. Changing the watch glass to another membrane like at the membrane sand-
wich holder, dissolution medium hydrodynamics on the lower part of the holder are the same. 
At the lower membrane the concentration of dissolved substance directly at the membrane is 
very high, but due to the low convection the diffusion gradient is small and substance pass 
the membrane at the upper sight. 
Overall the “standard” membrane holder adapted form the transdermal patches is beneficial 
compared to other tested membrane holders (blocked and sandwich) and the system devel-
oped by Son et al. [55]. By the membrane holders used in this study the substance particles 
are directly placed on the membrane and the diffused dissolution medium has direct access 
to the particles for dissolving, possible air bubbles between watch glass and membrane have 
no impact on the dissolution process. Using the NGI dissolution cup the powder is on the 
plate, then a membrane is placed on top and the cassette is sealed. Hence, there is trapped 
air under the membrane, which could slow down or even hinder the access of dissolution 
medium to the API particles resulting in a reduced dissolution [17]. 
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4.6.7. Influence of temperature on the dissolution process 
In Figure 4.52 the influence of temperature on dissolution profile is shown. As expected due 
to a better solubility of Budesonide at 37°C (21 µg/ml vs. 17 µg/ml at 22°C) the dissolution 
profile at 37°C is faster and standard deviation is smaller.  
 
Figure 4.52: Dissolution profiles of Budesonide at different temperatures 
mACI, 37°C (blue rhomb), 22°C (red squares), mean ± SD, n = 3, error bars are in all cases existent, 
but sometimes too small to be displayed 
 
Therefore, temperature control during a dissolution test and between different dissolution 
tests is important. Furthermore, the temperature should be within a defined range, for avoid-
ing any temperature influence on the solubility and hence on the dissolution process. The 
temperature for dissolution testing of powders for inhalation should be the same like the hu-
man body temperature, 37°C. This would be in accordance to the pharmacopoeias claims for 
dissolution testing of oral dosage forms (37°C ± 0.5°C [10,60]). 
 
4.6.8. Influence of lactose 
As expected there is no difference in the dissolution process (Figure 4.53, MDT: Table 4.15, 
page 117) of micronized Budesonide and micronized Budesonide from a Respitose blend 
(f1 = 4.9, f2 = 71.9 (Table 4.16, page 118)). 
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Figure 4.53: Dissolution profiles of Budesonide and Budesonide-Respitose blend 
mACI, bend (blue rhomb), micronized Budesonide (red squares), mean ± SD, n = 3, error bars are in 
all cases existent, but sometimes too small to be displayed 
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4.6.9. Dissolution medium containing surfactants 
In Figure 4.54 influence of different surfactant on the dissolution process of Budesonide is 
shown. Due to the small micelle size (Table 4.3) the micelles of SDS and Tween® can pass 
the membrane and increase the wettability of Budesonide. The objects of DPPC are too 
large for passing the membrane [55], but as described above free DPPC molecules [31] can 
pass the membrane and increase the wettability. Due to the solubility data (Table 4.2) the 
rank order of dissolution profiles using surfactants expected is: SDS (fastest), Tween® 80, 
Tween® 20, DPPC, without surfactant (slowest).  
 
 
Figure 4.54: Dissolution profiles of Budesonide with use of different surfactants in the dissolution me-
dium, mACI, 0.2% SDS (purple rhomb), 0.2% Tween® 20 (open red squares), 0.2% Tween® 80 (red 
squares), 0.02% DPPC (green triangle) and without surfactant (no symbol), mean ± SD, n =3, error 
bars are in all cases existent, but sometimes too small to be displayed 
 
This expected rank order is not in all cases given. It is obvious that the dissolution profile of 
Budesonide using PBS buffer containing SDS has the fastest dissolution process, but at the 
beginning the profiles using Tween® 80 and 20 in dissolution medium show the same slope. 
In the further progress of dissolution Tween® 80 data variability highly increases and dissolu-
tion process slows compared to Tween® 20. The cause for this behavior might be found in 
HPLC handling problems if Tween® 80 is used. The profile by using DPPC is similar to the 
profile without surfactant (Table 4.18), but shows a more smooth behavior with higher repro-
ducibility. Besides the SDS set up, MDT (Table 4.15) calculation provides contradictory re-
sults compared to the profiles. In chapter 5.1.1 a discussion of the MDT “problematic” will 
follow. 
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In Table 4.2 the solubility data of substances in PBS buffer with and without surfactants are 
compared to each other. In this thesis a comparison of dissolution profiles of different sub-
stance is aimed. Therefore, the use of the surfactant should increase the wettability of the 
substances but not increase the solubility, because a solubility increase might reduce the 
discrimination power. It is obvious that SDS and Tween® 20 strongly increase the solubility 
of Budesonide and Substance A base. Hence, these surfactants (SDS, Tween®) are not 
suitable and DPPC was chosen for further experiments. 
 
 
Figure 4.55: Dissolution profiles using the RC membrane 
mACI, Substance A Br2 (green x), Substance A amorphous base (light green triangle), Budesonide 
(blue square) and Substance A crystalline base (open dark green triangle), mean ± SD, n = 3, error 
bars are in all cases existent but sometimes too small to be displayed 
 
Due to the low solubility of substance A crystalline base, the substance shows as expected 
the slowest dissolution process independent of dissolution medium or membrane holder 
(Figure 4.55 - Figure 4.57). In the following results description for Substance A crystalline 
base is not extra mentioned, because the dissolution process is always the slowest. From 
solubility results the rank order of dissolution profiles in buffer expected was Substance A 
dibromide, Substance A amorphous base, and Budesonide. The FPD on membrane for all 
substances is similar (Table 4.15). As Figure 4.55 displays the dissolution profiles are similar 
especially in the first 20 minutes and discrimination between the substances is not possible. 
Fit factor test (Table 4.16, page 118) underlines these results. The fit factors for comparison 
of dissolution profiles of the dibromide and Budesonide are not definite.  
If PBS buffer with 0.02% DPPC as dissolution medium is used discrimination between all 
tested substances is possible (Figure 4.56, Table 4.16). Furthermore, for the tested sub-
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stances except for the crystalline base the standard deviation of the dissolution profiles de-
creases with the use of 0.02% DPPC in the dissolution medium. 
 
 
Figure 4.56: Dissolution medium containing 0.02% DPPC 
mACI, Substance A Br2 (green x), Substance A amorphous base (light green triangle), Budesonide 
(blue square) and Substance A crystalline base (open dark green triangle), mean ± SD, n = 3, error 
bars are in all cases existent but sometimes too small to be displayed 
 
Amazingly in Figure 4.57, Budesonide shows a faster dissolution than Substances A dibro-
mide and amorphous base.  
However, discrimination between these two substances (amorphous base and dibromide) is 
not possible. The fit factors confirm these results (Table 4.16). As already described above 
blocking has no influence on the dissolution profiles of Budesonide. For Substance A dibro-
mide and Substance A amorphous base the dissolution profile in the blocking set up is much 
slower, due to a reduced diffusion (Figure 4.56 compared to Figure 4.57). Substance A di-
bromide (cs = 265 µg/ml) and amorphous base (cs = 211 µg/ml) have both a more than 10 
fold higher solubility than Budesonide (cs = 17µg/ml), so the diffusion rate might be the rate 
limiting step and not the solubility. With hindering the diffusion over the membrane border, 
the rate-limiting step is more underlined. 
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Figure 4.57: Dissolution medium containing 0.02% DPPC and blocked membrane holder 
mACI, Substance A Br2 (green x), Substance A amorphous base (light green triangle), Budesonide 
(blue square) and Substance A crystalline base (open dark green triangle), mean ± SD, n = 3, error 
bars are in all cases existent but sometimes too small to be displayed 
 
Compared to the results with Erweka paddle apparatus it could be shown that by controlling 
the major influence factors, especially mass and distribution on membrane, Substance A 
amorphous base, Substance A dibromide and Budesonide show no discrimination (Figure 
4.43 vs. Figure 4.55). By adding 0.02% DPPC to the dissolution medium, discrimination be-
tween the used substances (Figure 4.56) is possible. 
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Table 4.15. Summary of used substances and membrane material with corresponding dissolution set  
up, recalculated FPD on filter (mean ± SD) and MDT (mean ± SD), E = Erweka paddle apparatus, S = 
Sotax stirring speed always 100 rpm, Tw = Tween® 
 
substance 
mem-
brane 
ma-
terial 
additional information 
recalculated 
FPD on filter 
[µg] n = 3 
MDT [min] 
mean ± SD mean ± SD 
Budesonide 
RC 
E, aACI, 50rpm 1805.0 ± 264 204.6 ± 29.1 
E, aACI, 100rpm 1917.0 ± 442 174.9 ± 43.2 
E, aACI, 140rpm 1892.0 ± 126 160.3 ± 8.0 
E, aACI, 140rpm 353.0 ± 114 25.6 ± 1.3 
IPC 
E, aACI, 140rpm 314.4 ± 22.7 21.6 ± 9.0 
E, Airbrush, 140rpm 211.8 ± 28.5 29.4 ± 5.6 
RC 
S, mACI 194.8 ± 30.7 39.7 ± 11.1 
S, aACI, ,1 157.7 ± 34.5 49.7 ± 8.5 
S, aACI, 2 387.7 ± 63.4 45.9 ± 8.8 
S, aACI + SE, 2 350.2 ± 29.1 34.6 ± 5.1 
S, mACI, 1 194.7 ± 30.7 27.9 ± 1.6 
S, mACI, 2 331.9 ± 24.4 35.2 ± 9.7 
S, mACI, sandwich hold-
er 
78.2 ± 19.0 32.0 ± 4.6 
S, mACI, blocked holder 84.6 ± 8.7 23.1 ± 6.9 
S, mACI, 22°C 187.2 ± 15.6 45.0 ± 7.6 
S, mACI, 0.02% DPPC 129.5 ± 14.8 26.2 ± 2.8 
S, mACI, 0.2% Tw 20 176.2 ± 11.2 15.9 ± 2.3 
S, mACI, 0.2% Tw 80 157.1 ± 27.8 20.1 ± 12.5 
S, mACI, 0.2% SDS 184.4 ± 31.2 6.2 ± 1.4 
S, mACI, 0.02% DPPC, 
blocked holder 
81.2 ± 16.2 27.7 ± 8.4 
Budesonide-
Respitose 
RC S, mACI, 37°C 216.0 ± 2 25.0 ± 6.1 
Substance A 
crystalline 
base 
RC E, aACI, 140rpm 447.0 ± 124 315.3 ± 7.6 
IPC E, aACI, 140rpm 431.5 ± 42.0 243.9 ± 28.0 
S, mACI 103.2 ± 6.9 91.7 ± 1.3 
RC 
S, mACI, 0.02% DPPC 110.4 ± 11.3 81.1 ± 8.2 
S, mACI, 0.02% DPPC, 
blocked holder 
59.3 ± 9.2 97.8 ± 10.3 
Substance A 
amorphous 
base 
RC E, aACI, 140rpm 187.5 ± 14.3 9.8 ± 3.6 
IPC E, aACI, 140rpm 153.7 ± 63.4 3.2 ± 1.0 
S, mACI 98.9 ± 10.6 23.9 ± 9.0 
RC 
S, mACI, 0.02% DPPC 98.6 ± 20.4 16.7 ± 7.5 
S, mACI, 0.02% DPPC, 
blocked holder 
62.7 ± 12.9 55.9 ± 12.7 
Substance A 
dibromide 
RC E, aACI, 140rpm 156.3 ± 64.4 4.6 ± 0.7 
IPC E, aACI, 140rpm 167.4 ± 61.6 6.6 ± 5.7 
S, mACI 98.0 ± 16.9 21.7 ± 3.0 
RC 
S, mACI, 0.02% DPPC 77.2 ± 15.9 17.0 ± 0.8 
S, mACI, 0.02% DPPC, 
blocked holder 
59.8 ± 10.4 59.4 ± 1.5 
Fenoterol RC E, aACI, 140rpm 272.4 ± 65.8 0.8 ± 0.1 
E, aACI, 140rpm 1582.0 ± 124 0.9 ± 0.3 
IPC E, aACI, 140rpm 2067.0 ± 447 0.7 ± 0.1 
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Table 4.16: Results of fit factor calculation 
 
 f1 f2 Similar? 
similar profiles < 15 50-100 
stirring speed    
50 rpm vs. 100 rpm 7.8 63.3 yes 
100 rpm vs. 140 rpm 3.1 85.4 yes 
PBS buffer aACI, RC membrane   
Fenoterol vs. Substance A Br2 57.0 32.0 no 
Substance A Br2 vs. Substance A amorphous base 30.8 36.3 no 
Substance A amorphous base vs. Budesonide 25.4 42.5 no 
PBS buffer aACI, IPC membrane   
Fenoterol vs. Substance A Br2 37.2 24.4 no 
Substance A Br2 vs. Substance A amorphous base 7.6 61.8 yes 
Substance A amorphous base vs. Budesonide 5.7 30.0 no 
Airbrush vs. aACI 3.3 77.1 yes 
Erweka vs. Sotax 9.2 58.3 yes 
dose collection method depending    
aACI vs. aACI +SE 19.1 47,7 no 
aACI vs. mACI 17.9 48.2 no 
mACI vs. aACI +SE 1.2 92.1 yes 
mass and dose collection method depending    
aACI 200µg vs. aACI 400µg 34.9 30.8 no 
mACI 200µg vs. mACI 400µg 9.4 59.1 yes 
aACI 200µg vs. mACI 200µg 7.2 63.2 yes 
aACI 400µg vs. mACI 400µg 17.9 48.2 no 
different membrane holders    
normal vs. blocked 5.6 64.8 yes 
normal vs. sandwich 5.8 65.3 yes 
blocked vs. sandwich 11.5 53.6 yes 
Budesonid: without surfactant vs. 0.02% DPPC 4.6 71.4 yes 
Budesonid: 22°C vs. 27°C 19.9 42.0 no 
Budesonid vs Budesonid- Respitose blen 4.9 71.9 yes 
PBS buffer    
Substance A Br2 vs. Budesonide 14.7 47.6 inconsistent 
Budesonide vs. Substance A amorphous base  8.4 55.4 yes 
Substance A Br2 vs. substance  A amorphous base 11.6 52.0 yes 
Substance A amorphous base vs. Substance A crystalline 
base 
64.1 16.4 no 
PBS buffer with 0.02% DPPC    
Substance A Br2 vs. Budesonide 20.8 44.1 no 
Budesonide vs. Substance A amorphous base  32.3 39.0 no 
Substance A Br2 vs. Substance A amorphous base 48.2 34.6 no 
Substance A amorphous base vs Substance A crystalline 
base 
89.0 12.8 no 
PBS buffer with 0.02% DPPC, blocking    
Substance A Br2 vs. Budesonide 28.9 39.4 no 
Budesonide vs. Substance A amorphous base 25.6 37.0 no 
Substance A Br2 vs. Substance A amorphous base 6.4 65.1 yes 
Substance A amorphous base vs Substance A crystalline 
base 
44.1 29.3 no 
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4.7. Dissolution Model 
4.7.1. Influence of particle mass on the membrane 
For the model in Figure 4.58 FPD on the membrane was varied (10 µg, 100 µg, 250 µg, 
500 µg, 750 µg, and 1000 µg). The calculated models in Figure 4.58 show a minimal de-
pendence of dissolution profile on the deposited mass on the membrane. In the first twenty 
minutes the profiles are identical. With increasing time the dissolution profiles diverge de-
pending on particles on the membrane. The “fastest” dissolution is as expectable for the 
smallest amount (10 µg) the slowest for the highest deposited mass (1000 µg). Comparison 
of the profiles 10 µg and 1000 µg with fit factor test shows similar almost identical profiles 
(f1 = 1.1, f2 = 95.7 (Table 4.18, page 125)). The model is based on the assumption of optimal 
conditions, which means no agglomerates; no dissolution interaction between the particles, 
therefore the model is probably not sensitive on different masses, resulting in similar dissolu-
tion profiles. 
The SEM pictures display a chronological order of the decrease of substance on the mem-
brane associated with an increasing dissolution profile. 
 
 
 
 
 
Figure 4.58: Graphs for calculated model for Budesonide with a different mass on the membrane 
(10 µg (dotted line), 100 µg (blue), 250 µg (red), 500 µg (purple) 750 µg (green), 1000 µg dashed line) 
with SEM pictures of a membrane with Budesonide at the time points 0 min, 5 min, 20 min, and 120 
min. The SEM pictures display a more and more brighter “circle”. This illustrates the more and more 
decreasing particle mass on the membrane, shown by an increasing slope of dissolved amount 
 
 0 min   5 min   20 min   120 min 
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4.7.2. Influence of particle shape 
The aerodynamic particle diameter was converted with Equation 3.11 in the geometric diam-
eter using either the shape factor for spherical particles or for cubic ones. 
In Figure 4.59 the dissolution profile by assumption of spherical particles is a little bit faster 
than for the cubic particles. However, the two profiles are similar (f1 = 4.1, f2 = 79.7 (Table 
4.18, page 125)). 
 
 
Figure 4.59: Graphs for calculated model of Budesonide with spherical (blue line) or cubic (red dashed 
line) particles 
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4.7.3. Influence of solubility 
As expected dissolution profiles strongly depend on the solubility of the substance in the dis-
solution medium (Figure 4.60), the higher the solubility the faster the dissolution. 
 
Figure 4.60: Graphs for calculated model of Budesonide with different solubility. The solubility data are 
based on the solubility measurement for budesonide in PBS buffer pH 7.4 with different surfactants 
(table 2). 
 
4.7.4. Influence of diffusion layer thickness 
Figure 4.61 demonstrates the influence of the diffusion layer thickness h on the dissolution 
profiles. The models A and D are based on the assumption that the diffusion layer thickness 
is directly depending on the radius of each particle size group. In model D the diffusion layer 
is shrinking with the particle, in model A the diffusion layer is staying constant while the parti-
cle is dissolving. At the beginning the models A and D are similar due to the same starting 
diffusion layer thickness, later the models diverge. At model A, the constant h results in a 
slower dissolution process, than for model D where h decreases with the particle size. The 
dissolution curves of the models B and C differ strongly from A and D. B and C are both 
models with a time independent diffusion layer and for the different particle size classes the 
diffusion layer thickness is equal. Model B is based on the assumption that the diffusion layer 
thickness for all groups correlates with the radius of the largest particles; in model C with the 
smallest. It is obvious that a too small diffusion layer thickness results in a very fast dissolu-
tion profile and an overall to large h in a too slow profile. 
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Figure 4.61: Graphs for calculated model of Budesonide with several assumptions for diffusion layer 
thickness h  
A: h(0) = h(t) = const. = d(0)/2particle size group (blue dashed line) 
B: h(0) = h(t) = const. = 2.65x10
-4
 (dark green dashed dotted line) 
C: h(0) = h(t) = const. = 1.05x10
-5
 (green line) 
D: h: 2.65x10
-4 
µm, 2.08 x10
-4
 µm, 1.25 x10
-4
 µm, 7.65x10
-5
 µm,
 
3.50 x10
-5
 µm, 2.05 x10
-5
 µm, 1.05 
x10
-5
 µm and h(t) = d(t)/2particle size group (red dotted line) 
 
4.7.5. Influence of particle size distribution 
In Figure 4.62 the models for different particle sizes and particle size distributions on the 
membrane are compared with experimental data from Figure 4.50. Table 4.17 summarizes 
the different particle sizes for the model. As expected, with a higher percentage of smaller 
particles the dissolution results in faster dissolution profiles (b and a). The dissolution profiles 
of c and d are identical in the first 50 minutes, later the profiles diverge. The model with the 
largest particles (d) has the slowest dissolution profile. As already described, mACI shows a 
faster dissolution as aACI because of a more homogeneous distribution of particles on the 
membrane. The next step is comparison of the models with experimental data. The slower 
profile of aACI fits in the first 20 minutes with the model a, c and d. After approximate 50 
minutes model d don’t describe the experimental set up any longer and model a fits best. 
The results of fit factor test underlines the similarity, the rank order starting with the best fit-
ting model is a, c, d, and b (Table 4.18, page 125). The models a, c and d have a higher 
amount of particles larger than 4.16 µm. In contrast, the dissolution profile of mACI fits with 
model b, which haves a higher amount of small particles and has no similarity with model d 
(Table 4.18). 
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Figure 4.62: Comparison of various modeled profiles for Budesonide with different particle size distri-
butions on the membrane compared to experimental data. mACI: square; aACI: triangle, for a- d see 
table 5 
 
Table 4.17: Data for Figure 4.62 
a) experimental data, b) and c) permutation of percentages (b) more small particle, c) more large par-
ticles), d) randomly chosen diameters for assumption of agglomerates 
 
particle diame-
ter [µm] 
a [%] 
(red) 
 
 
b [%] 
(blue) 
 
 
c [%] 
(light 
green) 
 
d 
(dark green) 
diameter 
[µm] 
 
[%] 
5.29 18.8 18.8 29.7 8 18.8 
4.16 29.7 18.1 27.4 5 29.7 
2.49 27.4 27.4 18.8 2.49 27.4 
1.53 18.1 29.7 18.1 1.53 18.1 
0.70 3.2 % 
1.3 % 
1.5 % 
0.41 
0.21 
 
4.7.6. Comparison of experimental and modeled data 
Figure 4.63 compares experimental dissolution profiles with the associated model, in Table 
4.18 results of fit factor test are summarized. For the model calculation solubility of sub-
stances in PBS buffer containing 0.02% DPPC (Table 4.2) and the data summarized in Table 
3.12 were used. Furthermore, a time-dependent diffusion layer thickness was assumed. The 
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model for Substance A base and Budesonide describes the experimental data quite well. But 
the model for Substance A dibromide is really different form the experimental data.  
In addition the model using solubility of substances in PBS buffer (dotted line) is inserted. 
Comparison of the two models show as expected for Budesonide and Substance A dibro-
mide a slower dissolution profile, for Substance A amorphous base a faster profile and for 
Substance A crystalline base no difference. 
It is obvious that the model with buffer data for Substance A dibromide also does not de-
scribe the experimental data well, but it is closer to the experimental data. The case of the 
dibromide demonstrates that there are further impact factors which are not fully considered 
through the model.  
Nevertheless, this model is useful for the description of dissolution profiles for powders for 
inhalation, because trends of experimental data could be shown by the model. 
 
 
Figure 4.63: Comparison of model data (no symbols) with experimental data (symbols) of the tested 
substances (Substance A Dibromide green X; Substance A amorphous base light green triangle, 
Budesonide blue square, Substance A crystalline base open dark green triangle) set up: mACI and 
0.02% DPPC in PBS buffer, mean ± SD, n = 3, in addition dotted lines: model of substance in PBS 
buffer 
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Table 4.18: Results of fit factor calculation 
 f1 f2 Similar? 
similar profiles < 15 50-100 
10 µg vs. 1000 µg (Figure 4.58) 1.1 95.7 yes 
spherical vs. cubic (Figure 4.59) 4.1 79.7 yes 
particle size (Figure 4.62)    
b vs. a 8.7 62.1 yes 
b vs. c 15.7 50.2 inconsistent 
b vs. d 17.7 47.8 no 
a vs. c 7.7 66.5 yes 
a vs. d 9.9 59.7 yes 
c vs. d 3.0 78.7 yes 
b vs. mACI 5.9 68.7 yes 
d vs. mACI 28.7 42,1 no 
c vs. aACI 6.1 71.7 yes 
a vs. aACI 2.9 63.7 yes 
b vs. aACI 11.3 56.5 yes 
d vs. aACI 9.0 62.7 yes 
model vs. experimental data (Figure 4.63)    
Substance A crystalline base 13.8 63.9 yes 
Substance A amorphous base 11.1 48.1 inconsistent 
Substance A Br2 - - no 
Budesonide 13.6 50.1 yes 
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5. General Discussion 
This chapter focuses on general points and discusses and compares the different dissolution 
techniques. 
5.1. General Points 
5.1.1. Comparison of dissolution profiles with MDT and “fit factors” 
The calculation of MDT itself is consistent. However, the results of MDT and the findings of 
the dissolution profiles are not in all cases concurrently. An important pre - requisite for cal-
culation is reaching of a plateau phase where almost the whole substance is dissolved and 
the profile should not show any further increase [35,139] or variation. Due to the strong de-
pendence of the MDT on this upper limit for each profile plateau phase deviations have to be 
averaged to one value introducing errors. Furthermore, for the crystalline base a MDT calcu-
lation could not be always performed, although the dissolution time was > 240 minutes, be-
cause the profile often does not reaches a plateau phase. Calculation of MDT without reach-
ing plateau results in not significant values.  
 
For getting a high statistical power of difference (f1) and similarity (f2) test EMA and FDA 
claim several requirements (chapter 3.6.2.2) e.g. strict borders for coefficient of variation 
(less than 20% for the first point and less than 10% for following points [21]) and 12 individual 
values for each time point [21,120]. 
In this thesis f1 and f2 test were used as additional factors for evaluating if two profiles are 
similar or not. Due to the limited amount of individual values (n = 3) and in some cases a 
higher coefficient of variation than 20% the statistical power of the “fit factor” test is reduced. 
Especially if the variability of data is high and a low number of values is given the variance is 
increased. This could be shown at “border cases” where f1 test provides similarity and f2 test 
no similarity or vice versa.  
 
5.1.2. Wettability and Dissolution 
For increasing the dissolution rate of a substance the particle size could be decreased [31]. 
However, in the case of powders for inhalation this process has a reduced applicability be-
cause the micronized substances particles have already an aerodynamically particle size 
around or below 5 µm. 
In literature the use of surfactants is described for overcoming wetting problems [20]. For 
performing a dissolution test it is necessary to consider what the aim of the performed disso-
lution test is e.g. discrimination between different substances, in vivo in vitro correlation or 
dissolution test of one substance. As consequence of this consideration it needs to be decid-
ed which surfactant in which concentration is useful. Surfactants increase or decrease the 
wettability and / or solubility of one substance. In this thesis the focus lies more on discrimi-
nation between substances. Therefore, a large increase of solubility for example with SDS 
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was not suitable because the discrimination power between the substances was decreased. 
Hence, DPPC with a small effect on the solubility of substance (beside Substance A dibro-
mide) was used. 
 
Another very important point is the duration of the experiment, especially if an amorphous 
substance is used. An amorphous modification might recrystallize during the dissolution test 
in a more stable crystalline modification with a different solubility. Furthermore, the salt form 
of substances could change due to the amount of salts in the dissolution medium. Different 
salt forms of substance have a different solubility. Hence, the dissolution process could be 
influenced.  
 
5.2. Is a comparison of the dissolution techniques possible? 
The used dissolution techniques have different advantages and disadvantages. For a com-
parison between the techniques first criteria need to be established. The criteria for compari-
son could be similarities, handling, duration of experiment, amount of dissolution medium, 
reproducibility, discrimination power, and validity on which the next subchapter will focus 
 
5.2.1. Similarities 
According to the dissolution profiles all techniques can be used to differentiate between good 
(Fenoterol) and poorly soluble substances (Budesonide).  
Furthermore, a large influence of the deposited mass of the substance on the membrane on 
the dissolution process was shown. A higher mass on the membrane results in a thicker 
powder layer. In a thicker powder layer the possibility of agglomerates is increased resulting 
in a released dissolution [55] due to a reduced wettability of all particles, especially in the 
“middle” or upper site of the agglomerates. Hence, a mono particle layer has to be preferred 
[55]. As the model calculation shows under ideal conditions – monolayer, no dissolution in-
teraction between the particle and its neighbors - the dissolution profile in the tested range 
(10 µg -1000 µg) is almost independent of particle mass. By use of the newly developed 
modified Andersen cascade impactor a less mass dependent dissolution process could be 
shown. As the SEM pictures reveal (Figure 4.49) the new set up achieves an evenly distrib-
uted and almost a mono layer of particles on the membrane.  
In addition, an influence of particle size classes might be expected [61] and the model de-
scribes the influence of particle size on the dissolution quite well (chapter 4.7.5). However, a 
more detailed focus on individual particle size classes in this thesis was not performed, be-
cause only the whole particle fraction with an aerodynamic diameter < 5 µm was of interest. 
Additionally, the membrane associated processes are based on a combined dissolution-
diffusion process [59]. First the dissolution medium has to pass the membrane through the 
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pores, and then it dissolves the dispersed API. Second, after the dissolution the solution dif-
fuses through the membrane into the bulk of dissolution medium. Consequently, the mem-
brane material, its properties and possible membrane substance interactions play an im-
portant role for the dissolution process. If sink conditions are given the dissolution process 
depends stronger on membrane material and stirring speed, than on the amount of dissolu-
tion medium [54]. Important membrane properties listed in literature are: membrane thick-
ness, pore size and pore tortuosity [59]. In this thesis it could be demonstrated, that mem-
brane material has to be added to the list above. The membrane permeation tests show im-
pressively large differences between the different materials. Interestingly, the test also dis-
plays a difference between two comparable membranes with comparable thickness, pore 
size and tortuosity from two different manufacturers (chapter 4.1.4).This indicates a possible 
impact of pre treatment that should be taken into account.  
 
5.2.2. Handling 
The µDiss® dissolution technique is very different from the other used set ups. Besides a 
different dose collection method, no membrane is used and the concentration measurements 
were performed online. Disadvantageous is the need of dose collection method which col-
lects the FPD in a liquid. Due to a lag time for transferring the suspension the dissolution 
process starts before the measurement is started. 
Regarding handling aspects the main problem by using the flow through cell is to achieve a 
fully closed system without leakage. In addition, in the set up used in thesis it is difficult to 
harmonize first droplet from the cell and starting of the auto sampler. 
For the Franz cell and the paddle apparatus with membrane holder sampling is automated. 
The main difficulty by use of the Franz cell, is to avoid the already in literature described 
problem of air bubbles beneath the membrane [112,114,116]. Interestingly, the problem of air 
bubbles seems not existent in the Transwell® system. The handling at the Transwell® disso-
lution system is not as easy as at the paddle apparatus, because sampling must be done 
manually, but nevertheless the Transwell®s dissolution system is quite suitable. It is possible 
to use different membrane materials due to inserting a small mesh and compared to the 
Franz cell also regenerated cellulose membrane can be used. A further advantage of the 
Transwell® system is the possibility to use cells as in vivo model for dissolution testing in the 
future. An additional advantaged of the paddle apparatus is the possibility of seven simulta-
neously experiments and the easy handling of the membrane holder. The membrane is 
placed in the membrane holder and than in the vessel of the paddle apparatus. 
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5.2.3. Duration of experiment 
Overall the duration of the experiment depends on the solubility of the used substances. 
Nevertheless, the duration of the experiments in the µDiss® and flow through cell is approx-
imately 1 to 2h, in Franz Cell, Transwell® and paddle apparatus approximately 4 h. Further-
more, currently in the Transwell® dissolution system in the µDiss® six, and in the paddle 
apparatus with membrane holder seven experiments could be performed simultaneously. 
 
5.2.4. Amount of dissolution medium 
The amount of dissolution medium varies from a few milliliters in the Transwell® dissolution 
system and the µDiss® to 60 ml depending on duration (60 min) and flow rate (1ml/min) in 
the flow through cell up to 1l in the modified Franz Cell and paddle apparatus.  
Additionally, the amount of dissolution medium depends on solubility of the substances. For 
ensuring sink conditions for extreme poorly water soluble substances larger amounts of dis-
solution medium are mandatory. If large amounts of dissolution medium are necessary of 
course costs for expensive buffers or surfactants increase.  
 
5.2.5. Reproducibility, discrimination power and validity 
The µDiss® might be useful at the beginning of substance and / or product development, 
when only small amounts of API are produced, especially for intrinsic dissolution tests. As 
dissolution test for powders for inhalation it is not useful, due the small discrimination power. 
Furthermore, the dissolution process can be influenced by using a suspension because par-
ticles could stick on the vessel wall, the optrode, float or sediment. However, no membrane is 
needed and thus no interaction between membrane material and substance can influence 
the dissolution and diffusion. 
Mechanistically, compared to the other membrane based systems in the flow through cell 
besides diffusion the dissolution process is also influenced by the constant flow of the disso-
lution medium. In literature for flow through cell sink conditions are stated [20], but that is 
only true if an adequate flow rate depending on the solubility of the substance is used. Is the 
flow rate to low and the substance good soluble more substance could be dissolved and sink 
conditions are exceeded. The custom made flow through cell used in this thesis could not 
guarantee sink conditions over the whole experiment. The reason can be found in the 
“quench heads” which distribute the dissolution medium ideally. Therefore, the membrane is 
fully and homogeneous wetted. Thus, a lot of substance is initially dissolved and sink condi-
tions are exceeded. However, for the non – sink conditions as well as for the sink conditions 
reproducibility and validity are poor. Hence, the flow through cell is not useful for dissolution 
testing of powders for inhalation. 
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In the Franz cell wetting of the particles on the membrane has a high experiment to experi-
ment inconsistency resulting in an increased variability of data. An explanation can be found 
on the one side in the air bubbles beneath the membrane and on the other side in the mem-
brane material. If regenerated cellulose as membrane material is used the clamped mem-
brane is fluted due to the swelling of the cellulose. Thus, the wetting of the particles is inho-
mogeneous. 
Comparing to the Franz Cell one could argue that reaching sink conditions in the strict defini-
tion (10% of saturation solubility) in the Transwell® dissolution system especially for poorly 
soluble substances like Budesonide (cs = 17 µg/ml) or Substance A crystalline base 
(cs = 7 µg/ml ) (Table 4.2), respectively is not possible. However, due to sampling of 0.2 ml 
(8% of 2.5 ml dissolution medium, 5% of 3.85 ml, respectively), for the used FPD on mem-
brane sink conditions are given over the whole experiment. A direct comparison of dissolu-
tion data for Transwell® and Franz cell for the IPC membrane shows similar dissolution pro-
files for Budesonide and Substance A crystalline base. In contrast to the Franz cell the 
Transwell® system can discriminate between Substances A amorphous base and dibromide. 
In the PhD thesis it could be shown that for better soluble substance the rate determining 
step of dissolved substance is diffusion through the membrane (chapter 4.4). Therefore, the 
different hydrodynamics in Franz cell and Transwell® influence the dissolution process. In 
the Transwell® as well as in the paddle apparatus the stirring hydrodynamics enforces the 
diffusion process through the membrane. In the paddle apparatus / Transwell® the diffusion 
layer at the membrane is quite small, because convection of the dissolution medium is high. 
Hence, concentration gradient is higher and more dissolved substance can pass the mem-
brane. In the Franz cell stirring is performed on the bottom of the vessel, hence difference 
between this movement and membrane is high, and the convection at the membrane low 
(compared to Transwell® system the dissolution medium amount is 260 fold increased the 
membrane surface only 6 folds). Consequently, diffusion layer of diffused substance is larger 
and concentration difference between the two membrane sides low. Thus, diffusion through 
the membrane is slower compared to paddle apparatus / Transwell® and the rate determin-
ing step in the Franz cell for good soluble substances. 
As already described the paddle apparatus is a widely used dissolution technique for solid 
and semi solid dosage forms and found suitable for dissolution testing of powders for inhala-
tion in this thesis. 
Compared to the Transwell® system, in the paddle apparatus a large volume of dissolution 
medium is used. But the focus of the thesis is on a useful in vitro dissolution test and not on 
mimicking in vivo conditions. Therefore, the paddle apparatus is suitable because of good 
reproducibility and validity. 
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Table 5.1 summarizes the results of the comparison between the different used dissolution 
techniques depending on different criteria. 
 
Table 5.1 In this table for each technique the most suitable set up is taken into account 
+ good, 0 middle, - poor 
Dissolution medium without addition of surfactants, dissolution medium is stirred 
Franz cell and Transwell® dissolution system: IPC membrane, paddle apparatus: RC membrane, 
mACI 
 
 µDiss® modified 
flow through 
cell 
modified 
Franz cell 
Transwell® 
dissolution 
system 
paddle apparatus 
with membrane  
holder 
handling 
 
0 0 0 0 + 
duration of 
experiment 
 
+ + 0 0 + 
amount of 
dissolution 
medium 
 
+ + - + - 
reproducibility 
 
+ - + + + 
discrimination 
power 
 
0 - 0 + 0 
validity 0 - 0 + + 
 
Consequently, referred to the above mentioned reasons for dissolution testing of inhalation 
powders flow through cell is not appropriate, Franz cell and µDiss with limitations, and 
Transwell® and paddle apparatus should be used. 
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6. Summary and Outlook 
In vitro dissolution testing of solid and semi-solid dosage forms is a reliable tool for quality 
control testing and prediction of in vivo drug release [20]. Currently, for the Ad hoc advisory 
panel of the USP there is no need for dissolution testing of powders for inhalation [13] but the 
development of new APIs tend to poorly soluble substances [15]. For bioavailability of sub-
stances it is necessary that the APIs dissolve in the limited volume of aqueous fluid in the 
lung [13,14]. For understanding of the in vivo processes in vitro tests are not necessary, but 
the in vitro dissolution tests could be used as a selection tool for drug substances and formu-
lations and as quality test. Currently, some work was already done but the research results in 
this field have not progressed far enough yet. 
The aims of the presented work were to evaluate the most suitable dissolution technique for 
aerodynamic classified powders, to point out important impact factors and to evaluate a theo-
retical model for predicting dissolution profiles of powders for inhalation. Therefore, five dif-
ferent dissolution systems were tested. 
In this thesis, it could be demonstrated that dose collection method as well as the used 
membrane material plays an important role on the dissolution tests. The modified Andersen 
cascade impactor emerged as the only dose collection technique which ensures an almost 
mono layer and homogeneous particle distribution on the membrane. As dissolution tech-
niques paddle apparatus with membrane holder and modified Transwell system were most 
suitable. Both set ups have advantages and disadvantages and a decision which technique 
should be used depends on the specific aim of the user. Furthermore, a suitable theoretical 
model was developed. 
 
However, it should be emphasized that the here presented findings are just the beginning to 
a standardized dissolution technique for powders for inhalation. Nevertheless, this thesis 
reveled important impact factors on the dissolution process of inhalation powders. Yet, there 
are still open questions which need to be answered in the future: 
 
 In the dissolution testing of solid and semi solid dosage forms biorelevant dissolu-
tion media are used. A further step in dissolution testing of powders for inhalation 
could be the use of broncho alveolar lining fluid (BALF) or simulated lung fluid es-
pecially in the Tranwell® system  
 The in vitro measured data should be compared to in vivo data and an in vitro in 
vivo correlation should be performed. 
 Currently, the dissolution tests focus on in vitro tests. In the future there might be 
an advanced in vitro dissolution model with lung cell lines. 
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7. Appendix 
HPLC Methods 
 
eluent A 
buffer pH3 / acetonitrile (90/10 Vol%) degased 
4,9g KH2PO4 + 1800ml Wasser,pH3 mit H3PO4 (16%) +180ml ACN,  
eluent B acetonitrile, degased 
column LiChrosphor 60 RP select B, 60x4 mm  
column temperature 40°C 
sample temperature 37°C 
injection volume 10 µl 
needle wash acetonirile/water (50/50) 
  
Budesonide  
Gradient 60% A 40% B 
flow rate  1,7 ml min-1 
UV detection 280 nm 
 
Fenoterol HBr 
Gradient 90% A 10% B 
flow rate  1 ml min-1 
UV detection 280 nm 
  
Substance A 
Gradient 65% A 35%B 
flow rate  1 ml min-1 
UV detection 226 nm 
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